Treatment of metastatic breast cancer

ABSTRACT

The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.12/484,440, filed Jun. 15, 2009, which claims priority under 35 U.S.C.Section 119(e) and the benefit of U.S. Provisional Application Ser. No.61/061,962, filed Jun. 16, 2008, the entire disclosures of which areincorporated herein by reference.

INCORPORATION OF SEQUENCE LISTING

This application includes a Sequence Listing submitted via EFS-Web onAug. 25, 2009, as a computer-readable form file entitled“GNE-0318USrevised.txt” (32 KB) dated Aug. 12, 2009. Which is herebyincorporated herein by reference it its entirety.

FIELD OF THE INVENTION

The present invention concerns treatment of previously untreatedHER2-positive metastatic breast cancer with a combination of a growthinhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and ataxane. In particular, the invention concerns the treatment ofHER2-positive metastatic breast cancer in patients who did not receiveprior chemotherapy or biologic therapy with a HER2 antibody bindingessentially to epitope 2C4, a HER2 antibody binding essentially toepitope 4D5, and a taxane. The invention further comprises extendingsurvival of such patients by the combination therapy of the presentinvention. In a preferred embodiment, the treatment involvesadministration of trastuzumab, pertuzumab and docetaxel.

BACKGROUND OF THE INVENTION HER Receptors and Antibodies Thereagainst

Members of the HER family of receptor tyrosine kinases are importantmediators of cell growth, differentiation and survival. The receptorfamily includes four distinct members including epidermal growth factorreceptor (EGFR, ErbB1, or HER1), HER2 (ErbB2 or p185′), HER3 (ErbB3) andHER4 (ErbB4 or tyro2).

EGFR, encoded by the erbB 1 gene, has been causally implicated in humanmalignancy. In particular, increased expression of EGFR has beenobserved in breast, bladder, lung, head, neck and stomach cancer as wellas glioblastomas. Increased EGFR receptor expression is often associatedwith increased production of the EGFR ligand, transforming growth factoralpha (TGF-α), by the same tumor cells resulting in receptor activationby an autocrine stimulatory pathway. Baselga and Mendelsohn Pharmac.Ther. 64:127-154 (1994). Monoclonal antibodies directed against the EGFRor its ligands, TGF-α and EGF, have been evaluated as therapeutic agentsin the treatment of such malignancies. See, e.g., Baselga andMendelsohn., supra; Masui et al. Cancer Research 44:1002-1007 (1984);and Wu et al. J. Clin. Invest. 95:1897-1905 (1995).

The second member of the HER family, p185^(neu), was originallyidentified as the product of the transforming gene from neuroblastomasof chemically treated rats. The activated form of the neu proto-oncogeneresults from a point mutation (valine to glutamic acid) in thetransmembrane region of the encoded protein. Amplification of the humanhomolog of neu is observed in breast and ovarian cancers and correlateswith a poor prognosis (Slamon et al., Science, 235:177-182 (1987);Slamon et al., Science, 244:707-712 (1989); and U.S. Pat. No.4,968,603). To date, no point mutation analogous to that in the neuproto-oncogene has been reported for human tumors. Overexpression ofHER2 (frequently but not uniformly due to gene amplification) has alsobeen observed in other carcinomas including carcinomas of the stomach,endometrium, salivary gland, lung, kidney, colon, thyroid, pancreas andbladder. See, among others, King et al., Science, 229:974 (1985); Yokotaet al., Lancet: 1:765-767 (1986); Fukushige et al., Mol Cell Biol.,6:955-958 (1986); Guerin et al., Oncogene Res., 3:21-31 (1988); Cohen etal., Oncogene, 4:81-88 (1989); Yonemura et al., Cancer Res., 51:1034(1991); Borst et al., Gynecol. Oncol., 38:364 (1990); Weiner et al.,Cancer Res., 50:421-425 (1990); Kern et al., Cancer Res., 50:5184(1990); Park et al., Cancer Res., 49:6605 (1989); Zhau et al., Mol.Carcinog., 3:254-257 (1990); Aasland et al. Br. J. Cancer 57:358-363(1988); Williams et al. Pathobiology 59:46-52 (1991); and McCann et al.,Cancer, 65:88-92 (1990). HER2 may be overexpressed in prostate cancer(Gu et al. Cancer Lett. 99:185-9 (1996); Ross et al. Hum. Pathol.28:827-33 (1997); Ross et al. Cancer 79:2162-70 (1997); and Sadasivan etal. J. Urol. 150:126-31 (1993)).

Antibodies directed against the rat p185^(neu) and human HER2 proteinproducts have been described.

Drebin and colleagues have raised antibodies against the rat neu geneproduct, p185neu See, for example, Drebin et al., Cell 41:695-706(1985); Myers et al., Meth. Enzym. 198:277-290 (1991); and WO94/22478.Drebin et al. Oncogene 2:273-277 (1988) report that mixtures ofantibodies reactive with two distinct regions of p185^(neu) result insynergistic anti-tumor effects on neu-transformed NIH-3T3 cellsimplanted into nude mice. See also U.S. Pat. No. 5,824,311 issued Oct.20, 1998.

Hudziak et al., Mol. Cell. Biol. 9(3):1165-1172 (1989) describe thegeneration of a panel of HER2 antibodies which were characterized usingthe human breast tumor cell line SK-BR-3. Relative cell proliferation ofthe SK-BR-3 cells following exposure to the antibodies was determined bycrystal violet staining of the monolayers after 72 hours. Using thisassay, maximum inhibition was obtained with the antibody called 4D5which inhibited cellular proliferation by 56%. Other antibodies in thepanel reduced cellular proliferation to a lesser extent in this assay.The antibody 4D5 was further found to sensitize HER2-overexpressingbreast tumor cell lines to the cytotoxic effects of TNF-α. See also U.S.Pat. No. 5,677,171 issued Oct. 14, 1997. The HER2 antibodies discussedin Hudziak et al. are further characterized in Fendly et al. CancerResearch 50:1550-1558 (1990); Kotts et al. In Vitro 26(3):59A (1990);Sarup et al. Growth Regulation 1:72-82 (1991); Shepard et al. J. Clin.Immunol. 11(3):117-127 (1991); Kumar et al. Mol. Cell. Biol.11(2):979-986 (1991); Lewis et al. Cancer Immunol. Immunother.37:255-263 (1993); Pietras et al. Oncogene 9:1829-1838 (1994); Vitettaet al. Cancer Research 54:5301-5309 (1994); Sliwkowski et al. J. Biol.Chem. 269(20):14661-14665 (1994); Scott et al. J. Biol. Chem.266:14300-5 (1991); D'souza et al. Proc. Natl. Acad. Sci. 91:7202-7206(1994); Lewis et al. Cancer Research 56:1457-1465 (1996); and Schaeferet al. Oncogene 15:1385-1394 (1997).

A recombinant humanized version of the murine HER2 antibody 4D5(huMAb4D5-8, rhuMAb HER2, trastuzumab or HERCEPTIN®; U.S. Pat. No.5,821,337) is clinically active in patients with HER2-overexpressingmetastatic breast cancers that have received extensive prior anti-cancertherapy (Baselga et al., J. Clin. Oncol. 14:737-744 (1996)). Trastuzumabreceived marketing approval from the Food and Drug Administration Sep.25, 1998 for the treatment of patients with metastatic breast cancerwhose tumors overexpress the HER2 protein. While the administration oftrastuzumab has led to excellent results in the treatment of breastcancer, recent data from a clinical trial of lapirinib appear to suggestthat even with administration of trastuzumab, HER2 plays an active rolein tumor biology (Geyer et al., N Engl J Med 2006; 355:2733-2743).

Other HER2 antibodies with various properties have been described inTagliabue et al. Int. J. Cancer 47:933-937 (1991); McKenzie et al.Oncogene 4:543-548 (1989); Maier et al. Cancer Res. 51:5361-5369 (1991);Bacus et al. Molecular Carcinogenesis 3:350-362 (1990); Stancovski etal. PNAS (USA) 88:8691-8695 (1991); Bacus et al. Cancer Research52:2580-2589 (1992); Xu et al. Int. J. Cancer 53:401-408 (1993);WO94/00136; Kasprzyk et al. Cancer Research 52:2771-2776 (1992); Hancocket al. Cancer Res. 51:4575-4580 (1991); Shawver et al. Cancer Res.54:1367-1373 (1994); Arteaga et al. Cancer Res. 54:3758-3765 (1994);Harwerth et al. J. Biol. Chem. 267:15160-15167 (1992); U.S. Pat. No.5,783,186; and Klapper et al. Oncogene 14:2099-2109 (1997).

Homology screening has resulted in the identification of two other HERreceptor family members; HER3 (U.S. Pat. Nos. 5,183,884 and 5,480,968 aswell as Kraus et al. PNAS (USA) 86:9193-9197 (1989)) and HER4 (EP PatAppln No 599,274; Plowman et al., Proc. Natl. Acad. Sci. USA,90:1746-1750 (1993); and Plowman et al., Nature, 366:473-475 (1993)).Both of these receptors display increased expression on at least somebreast cancer cell lines.

The HER receptors are generally found in various combinations in cellsand heterodimerization is thought to increase the diversity of cellularresponses to a variety of HER ligands (Earp et al. Breast CancerResearch and Treatment 35: 115-132 (1995)). EGFR is bound by sixdifferent ligands; epidermal growth factor (EGF), transforming growthfactor alpha (TGF-α), amphiregulin, heparin binding epidermal growthfactor (HB-EGF), betacellulin and epiregulin (Groenen et al. GrowthFactors 11:235-257 (1994)). A family of heregulin proteins resultingfrom alternative splicing of a single gene are ligands for HER3 andHER4. The heregulin family includes alpha, beta and gamma heregulins(Holmes et al., Science, 256:1205-1210 (1992); U.S. Pat. No. 5,641,869;and Schaefer et al. Oncogene 15:1385-1394 (1997)); neu differentiationfactors (NDFs), glial growth factors (GGFs); acetylcholine receptorinducing activity (ARIA); and sensory and motor neuron derived factor(SMDF). For a review, see Groenen et al. Growth Factors 11:235-257(1994); Lemke, G. Molec. & Cell. Neurosci. 7:247-262 (1996) and Lee etal. Pharm. Rev. 47:51-85 (1995). Recently three additional HER ligandswere identified; neuregulin-2 (NRG-2) which is reported to bind eitherHER3 or HER4 (Chang et al. Nature 387 509-512 (1997); and Carraway et alNature 387:512-516 (1997)); neuregulin-3 which binds HER4 (Zhang et al.PNAS (USA) 94(18):9562-7 (1997)); and neuregulin-4 which binds HER4(Harari et al. Oncogene 18:2681-89 (1999)) HB-EGF, betacellulin andepiregulin also bind to HER4.

While EGF and TGFα do not bind HER2, EGF stimulates EGFR and HER2 toform a heterodimer, which activates EGFR and results intransphosphorylation of HER2 in the heterodimer. Dimerization and/ortransphosphorylation appears to activate the HER2 tyrosine kinase. SeeEarp et al., supra. Likewise, when HER3 is co-expressed with HER2, anactive signaling complex is formed and antibodies directed against HER2are capable of disrupting this complex (Sliwkowski et al., J. Biol.Chem., 269(20):14661-14665 (1994)). Additionally, the affinity of HER3for heregulin (HRG) is increased to a higher affinity state whenco-expressed with HER2. See also, Levi et al., Journal of Neuroscience15: 1329-1340 (1995); Morrissey et al., Proc. Natl. Acad. Sci. USA 92:1431-1435 (1995); and Lewis et al., Cancer Res., 56:1457-1465 (1996)with respect to the HER2-HER3 protein complex. HER4, like HER3, forms anactive signaling complex with HER2 (Carraway and Cantley, Cell 78:5-8(1994)).

Patent publications related to HER antibodies include: U.S. Pat. No.5,677,171, U.S. Pat. No. 5,720,937, U.S. Pat. No. 5,720,954, U.S. Pat.No. 5,725,856, U.S. Pat. No. 5,770,195, U.S. Pat. No. 5,772,997, U.S.Pat. No. 6,165,464, U.S. Pat. No. 6,387,371, U.S. Pat. No. 6,399,063,US2002/0192211A1, U.S. Pat. No. 6,015,567, U.S. Pat. No. 6,333,169, U.S.Pat. No. 4,968,603, U.S. Pat. No. 5,821,337, U.S. Pat. No. 6,054,297,U.S. Pat. No. 6,407,213, U.S. Pat. No. 6,719,971, U.S. Pat. No.6,800,738, US2004/0236078A1, U.S. Pat. No. 5,648,237, U.S. Pat. No.6,267,958, U.S. Pat. No. 6,685,940, U.S. Pat. No. 6,821,515, WO98/17797,U.S. Pat. No. 6,127,526, U.S. Pat. No. 6,333,398, U.S. Pat. No.6,797,814, U.S. Pat. No. 6,339,142, U.S. Pat. No. 6,417,335, U.S. Pat.No. 6,489,447, WO99/31140, US2003/0147884A1, US2003/0170234A1,US2004/0037823A1, US2005/0002928A1, U.S. Pat. No. 6,573,043, U.S. Pat.No. 6,905,830, US2003/0152987A1, WO99/48527, US2002/0141993A1,US2005/0244417A1, U.S. Pat. No. 6,949,245, US2003/0086924,US2004/0013667A1, WO00/69460, US2003/0170235A1, U.S. Pat. No. 7,041,292,WO01/00238, US2006/0083739, WO01/15730, U.S. Pat. No. 6,627,196B1, U.S.Pat. No. 6,632,979B1, WO01/00244, US2002/0001587A1, US2002/0090662A1,U.S. Pat. No. 6,984,494B2, WO01/89566, US2002/0064785, US2003/0134344,WO 2005/099756, US2006/0013819, WO2006/07398A1, US2006/0018899, WO2006/33700, US2006/0088523, US 2006/0034840, WO 04/24866,US2004/0082047, US2003/0175845A1, WO03/087131, US2003/0228663,WO2004/008099A2, US2004/0106161, WO2004/048525, US2004/0258685A1, WO2005/16968, US2005/0038231A1 U.S. Pat. No. 5,985,553, U.S. Pat. No.5,747,261, U.S. Pat. No. 4,935,341, U.S. Pat. No. 5,401,638, U.S. Pat.No. 5,604,107, WO 87/07646, WO 89/10412, WO 91/05264, EP 412,116 B1, EP494,135 B1, U.S. Pat. No. 5,824,311, EP 444,181 B1, EP 1,006,194 A2, US2002/0155527A1, WO 91/02062, U.S. Pat. No. 5,571,894, U.S. Pat. No.5,939,531, EP 502,812 B1, WO 93/03741, EP 554,441 B1, EP 656,367 A1,U.S. Pat. No. 5,288,477, U.S. Pat. No. 5,514,554, U.S. Pat. No.5,587,458, WO 93/12220, WO 93/16185, U.S. Pat. No. 5,877,305, WO93/21319, WO 93/21232, U.S. Pat. No. 5,856,089, WO 94/22478, U.S. Pat.No. 5,910,486, U.S. Pat. No. 6,028,059, WO 96/07321, U.S. Pat. No.5,804,396, U.S. Pat. No. 5,846,749, EP 711,565, WO 96/16673, U.S. Pat.No. 5,783,404, U.S. Pat. No. 5,977,322, U.S. Pat. No. 6,512,097, WO97/00271, U.S. Pat. No. 6,270,765, U.S. Pat. No. 6,395,272, U.S. Pat.No. 5,837,243, WO 96/40789, U.S. Pat. No. 5,783,186, U.S. Pat. No.6,458,356, WO 97/20858, WO 97/38731, U.S. Pat. No. 6,214,388, U.S. Pat.No. 5,925,519, WO 98/02463, U.S. Pat. No. 5,922,845, WO 98/18489, WO98/33914, U.S. Pat. No. 5,994,071, WO 98/45479, U.S. Pat. No. 6,358,682B1, US 2003/0059790, WO 99/55367, WO 01/20033, US 2002/0076695 A1, WO00/78347, WO 01/09187, WO 01/21192, WO 01/32155, WO 01/53354, WO01/56604, WO 01/76630, WO02/05791, WO 02/11677, U.S. Pat. No. 6,582,919,US2002/0192652A1, US 2003/0211530A1, WO 02/44413, US 2002/0142328, U.S.Pat. No. 6,602,670 B2, WO 02/45653, WO 02/055106, US 2003/0152572, US2003/0165840, WO 02/087619, WO 03/006509, WO03/012072, WO 03/028638, US2003/0068318, WO 03/041736, EP 1,357,132, US 2003/0202973, US2004/0138160, U.S. Pat. No. 5,705,157, U.S. Pat. No. 6,123,939, EP616,812 B1, US 2003/0103973, US 2003/0108545, U.S. Pat. No. 6,403,630B1, WO 00/61145, WO 00/61185, U.S. Pat. No. 6,333,348 B1, WO 01/05425,WO 01/64246, US 2003/0022918, US 2002/0051785 A1, U.S. Pat. No.6,767,541, WO 01/76586, US 2003/0144252, WO 01/87336, US 2002/0031515A1, WO 01/87334, WO 02/05791, WO 02/09754, US 2003/0157097, US2002/0076408, WO 02/055106, WO 02/070008, WO 02/089842, and WO 03/86467.

Patients treated with the HER2 antibody trastuzumab are selected fortherapy based on HER2 overexpression/amplification. See, for example,WO99/31140 (Paton et al.), US2003/0170234A1 (Hellmann, S.), andUS2003/0147884 (Paton et al.); as well as WO01/89566, US2002/0064785,and US2003/0134344 (Mass et al.). See, also, U.S. Pat. No. 6,573,043,U.S. Pat. No. 6,905,830, and US2003/0152987, Cohen et al., concerningimmunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)for detecting HER2 overexpression and amplification.

WO2004/053497 and US2004/024815A1 (Bacus et al.), as well as US2003/0190689 (Crosby and Smith), refer to determining or predictingresponse to trastuzumab therapy. US2004/013297A1 (Bacus et al.) concernsdetermining or predicting response to ABX0303 EGFR antibody therapy.WO2004/000094 (Bacus et al.) is directed to determining response toGW572016, a small molecule, EGFR-HER2 tyrosine kinase inhibitor.WO2004/063709, Amler et al., refers to biomarkers and methods fordetermining sensitivity to EGFR inhibitor, erlotinib HCl. US2004/0209290and WO04/065583, Cobleigh et al., concern gene expression markers forbreast cancer prognosis. See, also, WO03/078662 (Baker et al.), andWO03/040404 (Bevilacqua et al.). WO02/44413 (Danenberg, K.) refers todetermining EGFR and HER2 gene expression for determining achemotherapeutic regimen.

Patients treated with pertuzumab can be selected for therapy based onHER activation or dimerization. Patent publications concerningpertuzumab and selection of patients for therapy therewith include: U.S.Pat. No. 6,949,245, WO01/00245, US2005/0208043, US2005/0238640,US2006/0034842, and US2006/0073143 (Adams et al.); US2003/0086924(Sliwkowski, M.); US2004/0013667A1 (Sliwkowski, M.); as well asWO2004/008099A2, and US2004/0106161 (Bossenmaier et al.).

Cronin et al. Am. J. Path. 164(1): 35-42 (2004) describes measurement ofgene expression in archival paraffin-embedded tissues. Ma et al. CancerCell 5:607-616 (2004) describes gene profiling by gene oliogonucleotidemicroarray using isolated RNA from tumor-tissue sections taken fromarchived primary biopsies.

Pertuzumab (also known as recombinant human monoclonal antibody 2C4;OMNITARG™, Genentech, Inc, South San Francisco) represents the first ina new class of agents known as HER dimerization inhibitors (HDI) andfunctions to inhibit the ability of HER2 to form active heterodimerswith other HER receptors (such as EGFR/HER1, HER3 and HER4) and isactive irrespective of HER2 expression levels. See, for example, Harariand Yarden Oncogene 19:6102-14 (2000); Yarden and Sliwkowski. Nat. RevMol Cell Biol 2:127-37 (2001); Sliwkowski Nat Struct Biol 10:158-9(2003); Cho et al. Nature 421:756-60 (2003); and Malik et al. Pro Am SocCancer Res 44:176-7 (2003).

Pertuzumab blockade of the formation of HER2-HER3 heterodimers in tumorcells has been demonstrated to inhibit critical cell signaling, whichresults in reduced tumor proliferation and survival (Agus et al. CancerCell 2:127-37 (2002)).

Pertuzumab has undergone testing as a single agent in the clinic with aphase Ia trial in patients with advanced cancers and phase II trials inpatients with ovarian cancer and breast cancer as well as lung andprostate cancer. In a Phase I study, patients with incurable, locallyadvanced, recurrent or metastatic solid tumors that had progressedduring or after standard therapy were treated with pertuzumab givenintravenously every 3 weeks. Pertuzumab was generally well tolerated.Tumor regression was achieved in 3 of 20 patients evaluable forresponse. Two patients had confirmed partial responses. Stable diseaselasting for more than 2.5 months was observed in 6 of 21 patients (Aguset al. Pro Am Soc Clin Oncol 22:192 (2003)). At doses of 2.0-15 mg/kg,the pharmacokinetics of pertuzumab was linear, and mean clearance rangedfrom 2.69 to 3.74 mL/day/kg and the mean terminal elimination half-liferanged from 15.3 to 27.6 days. Antibodies to pertuzumab were notdetected (Allison et al. Pro Am Soc Clin Oncol 22:197 (2003)).

US 2006/0034842 describes methods for treating ErbB-expressing cancerwith anti-ErbB2 antibody combinations. WO 08/031,531 describes the useof trastuzumab and pertuzumab in the treatment of HER2-positivemetastatic cancer, such as breast cancer. Baselga et al., J Clin Oncol,2007 ASCO Annual Meeting Proccedings Part I, Col. 25, No. 18S (June 20Supplement), 2007: 1004 report the treatment of patients withpre-treated HER2 positive breast cancer, which has progressed duringtreatment with trastuzumab, with a combination of trastuzumab andpertuzumab. Portera et al., J Clin Oncol, 2007 ASCO Annual MeetingProceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007:1028evaluated the efficacy and safety of trastuzumab+pertuzumab combinationtherapy in HER2-positive breast cancer patients, who had progressivedisease on trastuzumab-based therapy. The authors concluded that furtherevaluation of the efficacy of combination treatment was required todefine the overall risk and benefit of this treatment regimen.

Pertuzumab has been evaluated in Phase II studies in combination withtrastuzumab in patients with HER2-positive metastatic breast cancer whohave previously received trastuzumab for metastatic disease. One study,conducted by the National cancer Institute (NCI), enrolled 11 patientswith previously treated HER2-positive metastatic breast cancer. Two outof the 11 patients exhibited a partial response (PR) (Baselga et al., JClin Oncol 2007 ASCO Annual Meeting Proceedings; 25:18 S (June 20Supplement): 1004.

Breast cancer is the most common cancer in women, with a globalprevalence of more than 1 million patients and a mortality rate ofapproximately 400,000 deaths per year (International Agency for Researchon Cancer; http://www-dep.iarc.fr; Globocan 2002). While improved earlydetection and advances in systemic therapy for early stage disease haveresulted in a decline in breast cancer mortality since 1989, metastaticbreast cancer (MBC) remains largely incurable with a median survival ofapproximately 24 months. Factors associated with poor survival includeage ≧50 years, visceral disease, shorter disease-free interval (DFI),aneuploid tumors, tumors with a high S-phase fraction, p53 accumulation,low bcl-2 expression, negative hormone receptor status, and positivehuman epidermal growth factor receptor 2 (HER2) status (Chang J, et al.,Cancer 2003; 97:545-53).

Although chemotherapy agents, such as anthracyclines, taxanes,alkylating agents, and/or vinca alkaloids, used as single agents, haveproduced important results in extending the survival of patients withmetastatic breast cancer, the rare complete responses are short-lived,and usually the disease continues to progress. (Chung C, Carlson R. TheOncologist 2003; 8:514-20; Bernard-Marty C, et al., The Oncologist 2003;9:617-32).

The HER2-antibody trastuzumab is approved for use as monotherapy or incombination with chemotherapy in the metastatic setting, and incombination with chemotherapy as adjuvant treatment for HER2-positivebreast cancer. The optimal management of metastatic breast cancer nowtakes into account not only a patient's general condition, medicalhistory, tumor burden, and receptor status, but also the HER2 status.

A randomized Phase II study evaluated trastuzumab and docetaxel vs.docetaxel alone as a first-line treatment for HER2-positive metastaticbreast cancer (Marty et al., J Clin Oncol 2005; 23:4265-4274).

Improvement in survival is an important goal in the treatment ofpatients diagnosed with HER2-positive metastatic breast cancer. Despiteadvances in cancer therapy, there is significant medical need for newtreatment regimens in order to achieve this goal.

SUMMARY OF THE INVENTION

The present invention provides clinical data from human breast cancerpatients treated with a combination of trastuzumab, pertuzumab anddocetaxel.

In one aspect, the invention concerns a method for the treatment ofbreast cancer, comprising administering to a HER2 positive metastaticbreast cancer patient an effective amount of a growth inhibitory HER2antibody, a HER2 dimerization inhibitor antibody, and a taxane, whereinthe patient did not receive prior chemotherapy or biologic therapy.

In one embodiment, the growth inhibitory HER2 antibody binds to anepitope within Domain IV (SEQ ID NO: 17) of the HER2 amino acidsequence.

In another embodiment, the growth inhibitory HER2 antibody bindsessentially to epitope 4D5 of HER2.

In yet another embodiment, the HER2 dimerization inhibitor antibodybinds HER2 at the junction of domains I, II and III (SEQ ID NOs: 14, 15,and 16).

In a further embodiment, the HER2 dimerization inhibitor antibody bindsessentially to epitope 2C4.

In a still further embodiment, the growth inhibitory and/or the HER2dimerization inhibitor antibody is an antibody fragment.

In an additional embodiment, the growth inhibitory and/or the HER2dimerization inhibitor antibody is chimeric, humanized, or human.

In a particular embodiment, the growth inhibitory antibody istrastuzumab, or a fragrement thereof, the HER2 dimerization antibody ispertuzumab, or a fragment thereof, and the taxane is docetaxel.

In another aspect, the invention concerns a method for the treatment ofbreast cancer, comprising administering to a HER2 positive metastaticbreast cancer patient an effective amount of a first HER2 antibodybinding essentially to epitope 2C4, a second HER2 antibody bindingessentially to epitope 4D5, and a taxane, wherein the patient did notreceive prior chemotherapy or biologic therapy.

In one embodiment, the patient is a human patient.

In another embodiment, the first and second antibodies are monoclonalantibodies.

In yet another embodiment, at least one of the first and the secondantibodies is an antibody fragment.

In a different embodiment, at least one of the first and the secondantibodies is chimeric humanized, or human.

In a particular embodiment, the first antibody is pertuzumab.

In another particular embodiment, the second antibody is trastuzumab.

In yet another particular embodiment, the taxane is docetaxel.

In a further embodiment, the first and second antibodies and said taxaneare administered concurrently.

In a still further embodiment, the first and second antibodies and thetaxane are administered consecutively, in any order.

In another embodiment, administration of the first antibody precedesadministration of the second antibody and the taxane.

In yet another embodiment, at least one of the pertuzumab and thetranstuzumab is a naked antibody.

In a different embodiment, at least one of the pertuzumab and thetranstuzumab is an intact antibody.

In a further embodiment, administration of the pertuzumab, trastuzumaband docetaxel results in a synergistic effect.

In a still further embodiment, administration of the pertuzumab,trastuzumab and docetaxel extends survival of the human patient relativeto treatment in the absence of at least one of pertuzumab, trastuzumaband docetaxel. In a particular embodiment, progression free survival(PFS) or overall survival (OS) is extended.

Although the methods of the present invention may be performed in theabsence of any other means of cancer therapy, e.g. in the absence of afurther therapeutic agent, including chemotherapeutic agents andbiologics, the methods may optionally comprise the administration of afurther therapeutic agent selected from the group consisting ofchemotherapeutic agent, a different HER antibody, antibody directedagainst a tumor associated antigen, anti-hormonal compound,cardioprotectant, cytokine, EGFR-targeted drug, anti-angiogenic agent,tyrosine kinase inhibitor, COX inhibitor, non-steroidalanti-inflammatory drug, farnesyl transferase inhibitor, antibody thatbinds oncofetal protein CA 125, HER2 vaccine, HER targeting therapy, Rafor ras inhibitor, liposomal doxorubicin, topotecan, taxane, dualtyrosine kinase inhibitor, TLK286, EMD-7200, a medicament that treatsnausea, a medicament that prevents or treats skin rash or standard acnetherapy, a medicament that treats or prevents diarrhea, a bodytemperature-reducing medicament, and a hematopoietic growth factor.

In another aspect, the invention concerns a kit comprising a first HER2antibody binding essentially to epitope 2C4, a second HER2 antibodybinding essentially to epitope 4D5, and a taxane, and a package insertor label with directions to treat a HER2 positive metastatic breastcancer patient, who did not receive prior chemotherapy or biologictherapy.

In yet another aspect, the invention concerns a method of promotingpertuzumab for the treatment of a HER2 positive metastatic breast cancerpatient who did not receive prior chemotherapy or biologic therapy, incombination with trastuzumab and a taxane. Just as before the taxanemay, for example, be docetaxel.

In a further aspect, the invention concerns a method of promotingtrastuzumab for the treatment of a HER2 positive metastatic breastcancer patient who did not receive prior chemotherapy or biologictherapy, in combination with pertuzumab and a taxane, such as docetaxel.

In a still further aspect, the invention concerns a method for promotinga taxane for the treatment of a HER2 positive metastatic breast cancerpatient who did not receive prior chemotherapy or biologic therapy, incombination with pertuzumab and trastuzumab, wherein the taxane may, forexample, be docetaxel. Without limitation, the promotion may be in theform of a written material, or a package insert.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides a schematic of the HER2 protein structure, and aminoacid sequences for Domains I-IV (SEQ ID Nos.14-17, respectively) of theextracellular domain thereof.

FIGS. 2A and 2B depict alignments of the amino acid sequences of thevariable light (V_(L)) (FIG. 2A) and variable heavy (V_(H)) (FIG. 2B)domains of murine monoclonal antibody 2C4 (SEQ ID Nos. 1 and 2,respectively); V_(L) and V_(H) domains of variant 574/pertuzumab (SEQ IDNos. 3 and 4, respectively), and human V_(L) and V_(H) consensusframeworks (hum id, light kappa subgroup I; humIII, heavy subgroup III)(SEQ ID Nos. 5 and 6, respectively). Asterisks identify differencesbetween variable domains of pertuzumab and murine monoclonal antibody2C4 or between variable domains of pertuzumab and the human framework.Complementarity Determining Regions (CDRs) are in brackets.

FIGS. 3A and 3B show the amino acid sequences of pertuzumab light chain(FIG. 3A; SEQ ID NO. 7) and heavy chain (FIG. 3B; SEQ ID No. 8). CDRsare shown in bold. Calculated molecular mass of the light chain andheavy chain are 23,526.22 Da and 49,216.56 Da (cysteines in reducedform). The carbohydrate moiety is attached to Asn 299 of the heavychain.

FIGS. 4A and 4B show the amino acid sequences of trastuzumab light chain(FIG. 4A; SEQ ID NO. 9) and heavy chain (FIG. 4B; SEQ ID NO. 10),respectively.

FIGS. 5A and 5B depict a variant pertuzumab light chain sequence (FIG.5A; SEQ ID NO. 11) and a variant pertuzumab heavy chain sequence (FIG.5B; SEQ ID NO. 12), respectively.

FIG. 6. Serum Pertuzumab Concentrations (μg/mL) for the First 84 Days(through Study Day 85) for Studies TOC2689g and B016934.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS I. Definitions

The terms “biologic therapy” “immunotherapy” are used hereininterchangeably, and refer to cancer treatments utilizing the body'simmune system to fight cancer, regardless of their mechanism of action.Biologic therapy specifically includes antibody treatment.

The term “chemotherapy” as used herein refers to treatment comprisingthe administration of a chemotherapeutic agent, as defined hereinbelow.

“Survival” refers to the patient remaining alive, and includes overallsurvival as well as progression free survival.

“Overall survival” or “OS” refers to the patient remaining alive for adefined period of time, such as 1 year, 5 years, etc from the time ofdiagnosis or treatment. For the purposes of the clinical trial describedin the examples, overall survival (OS) is defined as the time from thedate of randomization of patient population to the date of death fromany cause.

“Progression-free survival” or “PFS” refers to the patient remainingalive, without the cancer progressing or getting worse. For the purposeof the clinical trial described in the examples, progression-freesurvival (PFS) is defined as the time from randomization of studypopulation to the first documented progressive disease, or death fromany cause, whichever occurs first. Disease progression can be documentedby any clinically accepted methods, such as, for example, radiographicalprogressive disease, as determined by Response Evaluation Criteria inSolid Tumors (RECIST) (Therasse et al., J Natl Ca Inst 2000;92(3):205-216), carcinomatous meningitis diagnosed by cytologicevaluation of cerebral spinal fluid, and/or medical photography tomonitor chest wall recurrences of subcutaneous lesions.

By “extending survival” is meant increasing overall or progression freesurvival in a patient treated in accordance with the present inventionrelative to an untreated patient and/or relative to a patient treatedwith one or more approved anti-tumor agents, but not receiving treatmentin accordance with the present invention. In a particular example,“extending survival” means extending progression-free survival (PFS)and/or overall survival (OS) of breast cancer patients receiving thecombination therapy of the present invention (e.g. treatment with acombination of a HER2 antibody binding essentially to epitope 2C4, aHER2 antibody binding essentially to epitope 4D5, and a taxane, e.g.pertuzumab+trastuzumab+docetaxel) relative to patients treated with aHER2 antibody binding essentially to epitope 4D5, and a taxane, e.g.trastuzumab+docetaxel, in the absence of a HER2 antibody bindingessentially to epitope 2C4, i.e. pertuzumab.

Herein “time to disease progression” or “TTP” refer to the time,generally measured in weeks or months, from the time of initialtreatment until the cancer progresses or worsens. Such progression canbe evaluated by the skilled clinician. Disease progression can beevaluated and documented by any clinically accepted methods, such as,for example, radiographical progressive disease, as determined byResponse Evaluation Criteria in Solid Tumors (RECIST) (Therasse et al.,J Natl Ca Inst 2000; 92(3):205-216), carcinomatous meningitis diagnosedby cytologic evaluation of cerebral spinal fluid, and/or medicalphotography to monitor chest wall recurrences of subcutaneous lesions.

By “extending TTP” is meant increasing the time to disease progressionin a patient treated in accordance with the present invention relativeto an untreated patient and/or relative to a patient treated with one ormore approved anti-tumor agents, but not receiving treatment inaccordance with the present invention. In a particular example,“extending TTP” means extending time to disease progression (TTP) ofbreast cancer patients receiving the combination therapy of the presentinvention (treatment with a combination of a HER2 antibody bindingessentially to epitope 2C4, a HER2 antibody binding essentially toepitope 4D5, and a taxane, e.g. pertuzumab+trastuzumab+docetaxel)relative to patients treated with a HER2 antibody binding essentially toepitope 4D5, and a taxane, e.g. trastuzumab+docetaxel, in the absence ofa HER2 antibody binding essentially to epitope 2C4, i.e. pertuzumab.

An “objective response” refers to a measurable response, includingcomplete response (CR) or partial response (PR).

By “complete response” or “CR” is intended the disappearance of allsigns of cancer in response to treatment. This does not always mean thecancer has been cured.

“Partial response” or “PR” refers to a decrease in the size of one ormore tumors or lesions, or in the extent of cancer in the body, inresponse to treatment.

A “HER receptor” is a receptor protein tyrosine kinase which belongs tothe HER receptor family and includes EGFR, HER2, HER3 and HER4receptors. The HER receptor will generally comprise an extracellulardomain, which may bind an HER ligand and/or dimerize with another HERreceptor molecule; a lipophilic transmembrane domain; a conservedintracellular tyrosine kinase domain; and a carboxyl-terminal signalingdomain harboring several tyrosine residues which can be phosphorylated.The HER receptor may be a “native sequence” HER receptor or an “aminoacid sequence variant” thereof. Preferably the HER receptor is nativesequence human HER receptor.

The terms “ErbB1,” “HER1”, “epidermal growth factor receptor” and “EGFR”are used interchangeably herein and refer to EGFR as disclosed, forexample, in Carpenter et al. Ann. Rev. Biochem. 56:881-914 (1987),including naturally occurring mutant forms thereof (e.g. a deletionmutant EGFR as in Humphrey et al. PNAS (USA) 87:4207-4211 (1990)). erbB1refers to the gene encoding the EGFR protein product.

The expressions “ErbB2” and “HER2” are used interchangeably herein andrefer to human HER2 protein described, for example, in Semba et al.,PNAS (USA) 82:6497-6501 (1985) and Yamamoto et al. Nature 319:230-234(1986) (Genebank accession number X03363). The term “erbB2” refers tothe gene encoding human ErbB2 and “neu@ refers to the gene encoding ratp185^(neu). Preferred HER2 is native sequence human HER2.

Herein, “HER2 extracellular domain” or “HER2ECD” refers to a domain ofHER2 that is outside of a cell, either anchored to a cell membrane, orin circulation, including fragments thereof. The amino acid sequence ofHER2 is shown in FIG. 1. In one embodiment, the extracellular domain ofHER2 may comprise four domains: “Domain I” (amino acid residues fromabout 1-195; SEQ ID NO:14), “Domain II” (amino acid residues from about196-319; SEQ ID NO:15), “Domain III” (amino acid residues from about320-488: SEQ ID NO:16), and “Domain IV” (amino acid residues from about489-630; SEQ ID NO:17) (residue numbering without signal peptide). SeeGarrett et al. Mol. Cell. 11: 495-505 (2003), Cho et al. Nature 421:756-760 (2003), Franklin et al. Cancer Cell 5:317-328 (2004), andPlowman et al. Proc. Natl. Acad. Sci. 90:1746-1750 (1993), as well asFIG. 6 herein.

“ErbB3” and “HER3” refer to the receptor polypeptide as disclosed, forexample, in U.S. Pat. Nos. 5,183,884 and 5,480,968 as well as Kraus etal. PNAS (USA) 86:9193-9197 (1989).

The terms “ErbB4” and “HER4” herein refer to the receptor polypeptide asdisclosed, for example, in EP Pat Appln No 599,274; Plowman et al.,Proc. Natl. Acad. Sci. USA, 90:1746-1750 (1993); and Plowman et al.,Nature, 366:473-475 (1993), including isoforms thereof, e.g., asdisclosed in WO99/19488, published Apr. 22, 1999.

By “HER ligand” is meant a polypeptide which binds to and/or activates aHER receptor. The HER ligand of particular interest herein is a nativesequence human HER ligand such as epidermal growth factor (EGF) (Savageet al., J. Biol. Chem. 247:7612-7621 (1972)); transforming growth factoralpha (TGF-α) (Marquardt et al., Science 223:1079-1082 (1984));amphiregulin also known as schwanoma or keratinocyte autocrine growthfactor (Shoyab et al. Science 243:1074-1076 (1989); Kimura et al. Nature348:257-260 (1990); and Cook et al. Mol. Cell. Biol. 11:2547-2557(1991)); betacellulin (Shing et al., Science 259:1604-1607 (1993); andSasada et al. Biochem. Biophys. Res. Commun. 190:1173 (1993));heparin-binding epidermal growth factor (HB-EGF) (Higashiyama et al.,Science 251:936-939 (1991)); epiregulin (Toyoda et al., J. Biol. Chem.270:7495-7500 (1995); and Komurasaki et al. Oncogene 15:2841-2848(1997)); a heregulin (see below); neuregulin-2 (NRG-2) (Carraway et al.,Nature 387:512-516 (1997)); neuregulin-3 (NRG-3) (Zhang et al., Proc.Natl. Acad. Sci. 94:9562-9567 (1997)); neuregulin-4 (NRG-4) (Harari etal. Oncogene 18:2681-89 (1999)); and cripto (CR-1) (Kannan et al. J.Biol. Chem. 272(6):3330-3335 (1997)). HER ligands which bind EGFRinclude EGF, TGF-α, amphiregulin, betacellulin, HB-EGF and epiregulin.HER ligands which bind HER3 include heregulins. HER ligands capable ofbinding HER4 include betacellulin, epiregulin, HB-EGF, NRG-2, NRG-3,NRG-4, and heregulins.

“Heregulin” (HRG) when used herein refers to a polypeptide encoded bythe heregulin gene product as disclosed in U.S. Pat. No. 5,641,869, orMarchionni et al., Nature, 362:312-318 (1993). Examples of heregulinsinclude heregulin-α, heregulin-β1, heregulin-β2 and heregulin-β3 (Holmeset al., Science, 256:1205-1210 (1992); and U.S. Pat. No. 5,641,869); neudifferentiation factor (NDF) (Peles et al. Cell 69: 205-216 (1992));acetylcholine receptor-inducing activity (ARIA) (Falls et al. Cell72:801-815 (1993)); glial growth factors (GGFs) (Marchionni et al.,Nature, 362:312-318 (1993)); sensory and motor neuron derived factor(SMDF) (Ho et al. J. Biol. Chem. 270:14523-14532 (1995)); γ-heregulin(Schaefer et al. Oncogene 15:1385-1394 (1997)).

A “HER dimer” herein is a noncovalently associated dimer comprising atleast two HER receptors. Such complexes may form when a cell expressingtwo or more HER receptors is exposed to an HER ligand and can beisolated by immunoprecipitation and analyzed by SDS-PAGE as described inSliwkowski et al., J. Biol. Chem., 269(20):14661-14665 (1994), forexample. Other proteins, such as a cytokine receptor subunit (e.g.gp130) may be associated with the dimer. Preferably, the HER dimercomprises HER2.

A “HER heterodimer” herein is a noncovalently associated heterodimercomprising at least two different HER receptors, such as EGFR-HER2,HER2-HER3 or HER2-HER4 heterodimers.

A “HER antibody” is an antibody that binds to a HER receptor.Optionally, the HER antibody further interferes with HER activation orfunction. Preferably, the HER antibody binds to the HER2 receptor. HER2antibodies of interest herein are pertuzumab and trastuzumab.

“HER activation” refers to activation, or phosphorylation, of any one ormore HER receptors. Generally, HER activation results in signaltransduction (e.g. that caused by an intracellular kinase domain of aHER receptor phosphorylating tyrosine residues in the HER receptor or asubstrate polypeptide). HER activation may be mediated by HER ligandbinding to a HER dimer comprising the HER receptor of interest. HERligand binding to a HER dimer may activate a kinase domain of one ormore of the HER receptors in the dimer and thereby results inphosphorylation of tyrosine residues in one or more of the HER receptorsand/or phosphorylation of tyrosine residues in additional substratepolypeptides(s), such as Akt or MAPK intracellular kinases.

“Phosphorylation” refers to the addition of one or more phosphategroup(s) to a protein, such as a HER receptor, or substrate thereof.

An antibody which “inhibits HER dimerization” is an antibody whichinhibits, or interferes with, formation of a HER dimer. Preferably, suchan antibody binds to HER2 at the heterodimeric binding site thereof. Themost preferred dimerization inhibiting antibody herein is pertuzumab orMAb 2C4. Other examples of antibodies which inhibit HER dimerizationinclude antibodies which bind to EGFR and inhibit dimerization thereofwith one or more other HER receptors (for example EGFR monoclonalantibody 806, MAb 806, which binds to activated or “untethered” EGFR;see Johns et al., J. Biol. Chem. 279(29):30375-30384 (2004)); antibodieswhich bind to HER3 and inhibit dimerization thereof with one or moreother HER receptors; and antibodies which bind to HER4 and inhibitdimerization thereof with one or more other HER receptors.

A “HER2 dimerization inhibitor” is an agent that inhibits formation of adimer or heterodimer comprising HER2.

A “heterodimeric binding site” on HER2, refers to a region in theextracellular domain of HER2 that contacts, or interfaces with, a regionin the extracellular domain of EGFR, HER3 or HER4 upon formation of adimer therewith. The region is found in Domain II of HER2 (SEQ ID NO:15). Franklin et al. Cancer Cell 5:317-328 (2004).

A HER2 antibody that “binds to a heterodimeric binding site” of HER2,binds to residues in Domain II (SEQ ID NO: 15) and optionally also bindsto residues in other of the domains of the HER2 extracellular domain,such as domains I and III, SEQ ID NOs: 14 and 16), and can stericallyhinder, at least to some extent, formation of a HER2-EGFR, HER2-HER3, orHER2-HER4 heterodimer. Franklin et al. Cancer Cell 5:317-328 (2004)characterize the HER2-pertuzumab crystal structure, deposited with theRCSB Protein Data Bank (ID Code IS78), illustrating an exemplaryantibody that binds to the heterodimeric binding site of HER2.

An antibody that “binds to domain II” of HER2 binds to residues indomain II (SEQ ID NO: 15) and optionally residues in other domain(s) ofHER2, such as domains I and III (SEQ ID NOs: 14 and 16, respectively).Preferably the antibody that binds to domain II binds to the junctionbetween domains I, II and III of HER2.

Protein “expression” refers to conversion of the information encoded ina gene into messenger RNA (mRNA) and then to the protein.

Herein, a sample or cell that “expresses” a protein of interest (such asa HER receptor or HER ligand) is one in which mRNA encoding the protein,or the protein, including fragments thereof, is determined to be presentin the sample or cell.

The technique of “polymerase chain reaction” or “PCR” as used hereingenerally refers to a procedure wherein minute amounts of a specificpiece of nucleic acid, RNA and/or DNA, are amplified as described inU.S. Pat. No. 4,683,195 issued 28 Jul. 1987. Generally, sequenceinformation from the ends of the region of interest or beyond needs tobe available, such that oligonucleotide primers can be designed; theseprimers will be identical or similar in sequence to opposite strands ofthe template to be amplified. The 5′ terminal nucleotides of the twoprimers may coincide with the ends of the amplified material. PCR can beused to amplify specific RNA sequences, specific DNA sequences fromtotal genomic DNA, and cDNA transcribed from total cellular RNA,bacteriophage or plasmid sequences, etc. See generally Mullis et al.,Cold Spring Harbor Symp. Quant. Biol., 51: 263 (1987); Erlich, ed., PCRTechnology, (Stockton Press, NY, 1989). As used herein, PCR isconsidered to be one, but not the only, example of a nucleic acidpolymerase reaction method for amplifying a nucleic acid test sample,comprising the use of a known nucleic acid (DNA or RNA) as a primer andutilizes a nucleic acid polymerase to amplify or generate a specificpiece of nucleic acid or to amplify or generate a specific piece ofnucleic acid which is complementary to a particular nucleic acid.

“Quantitative real time polymerase chain reaction” or “qRT-PCR” refersto a form of PCR wherein the amount of PCR product is measured at eachstep in a PCR reaction. This technique has been described in variouspublications including Cronin et al., Am. J. Pathol. 164(1):35-42(2004); and Ma et al., Cancer Cell 5:607-616 (2004).

The term “microarray” refers to an ordered arrangement of hybridizablearray elements, preferably polynucleotide probes, on a substrate.

The term “polynucleotide,” when used in singular or plural, generallyrefers to any polyribonucleotide or polydeoxyribonucleotide, which maybe unmodified RNA or DNA or modified RNA or DNA. Thus, for instance,polynucleotides as defined herein include, without limitation, single-and double-stranded DNA, DNA including single- and double-strandedregions, single- and double-stranded RNA, and RNA including single- anddouble-stranded regions, hybrid molecules comprising DNA and RNA thatmay be single-stranded or, more typically, double-stranded or includesingle- and double-stranded regions. In addition, the term“polynucleotide” as used herein refers to triple-stranded regionscomprising RNA or DNA or both RNA and DNA. The strands in such regionsmay be from the same molecule or from different molecules. The regionsmay include all of one or more of the molecules, but more typicallyinvolve only a region of some of the molecules. One of the molecules ofa triple-helical region often is an oligonucleotide. The term“polynucleotide” specifically includes cDNAs. The term includes DNAs(including cDNAs) and RNAs that contain one or more modified bases.Thus, DNAs or RNAs with backbones modified for stability or for otherreasons are “polynucleotides” as that term is intended herein. Moreover,DNAs or RNAs comprising unusual bases, such as inosine, or modifiedbases, such as tritiated bases, are included within the term“polynucleotides” as defined herein. In general, the term“polynucleotide” embraces all chemically, enzymatically and/ormetabolically modified forms of unmodified polynucleotides, as well asthe chemical forms of DNA and RNA characteristic of viruses and cells,including simple and complex cells.

The term “oligonucleotide” refers to a relatively short polynucleotide,including, without limitation, single-stranded deoxyribonucleotides,single- or double-stranded ribonucleotides, RNA:DNA hybrids anddouble-stranded DNAs. Oligonucleotides, such as single-stranded DNAprobe oligonucleotides, are often synthesized by chemical methods, forexample using automated oligonucleotide synthesizers that arecommercially available. However, oligonucleotides can be made by avariety of other methods, including in vitro recombinant DNA-mediatedtechniques and by expression of DNAs in cells and organisms.

The phrase “gene amplification” refers to a process by which multiplecopies of a gene or gene fragment are formed in a particular cell orcell line. The duplicated region (a stretch of amplified DNA) is oftenreferred to as “amplicon.” Usually, the amount of the messenger RNA(mRNA) produced also increases in the proportion of the number of copiesmade of the particular gene expressed.

“Stringency” of hybridization reactions is readily determinable by oneof ordinary skill in the art, and generally is an empirical calculationdependent upon probe length, washing temperature, and saltconcentration. In general, longer probes require higher temperatures forproper annealing, while shorter probes need lower temperatures.Hybridization generally depends on the ability of denatured DNA toreanneal when complementary strands are present in an environment belowtheir melting temperature. The higher the degree of desired homologybetween the probe and hybridizable sequence, the higher the relativetemperature which can be used. As a result, it follows that higherrelative temperatures would tend to make the reaction conditions morestringent, while lower temperatures less so. For additional details andexplanation of stringency of hybridization reactions, see Ausubel etal., Current Protocols in Molecular Biology, Wiley IntersciencePublishers, (1995).

“Stringent conditions” or “high stringency conditions”, as definedherein, typically: (1) employ low ionic strength and high temperaturefor washing, for example 0.015 M sodium chloride/0.0015 M sodiumcitrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ duringhybridization a denaturing agent, such as formamide, for example, 50%(v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mMsodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50%formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodiumphosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution,sonicated salmon sperm DNA (50 &gr;g/ml), 0.1% SDS, and 10% dextransulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodiumchloride/sodium citrate) and 50% formamide at 55° C., followed by ahigh-stringency wash consisting of 0.1×SSC containing EDTA at 55° C.

“Moderately stringent conditions” may be identified as described bySambrook et al., Molecular Cloning: A Laboratory Manual, New York: ColdSpring Harbor Press, 1989, and include the use of washing solution andhybridization conditions (e.g., temperature, ionic strength and % SDS)less stringent that those described above. An example of moderatelystringent conditions is overnight incubation at 37° C. in a solutioncomprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate),50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextransulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed bywashing the filters in 1×SSC at about 37-50° C. The skilled artisan willrecognize how to adjust the temperature, ionic strength, etc. asnecessary to accommodate factors such as probe length and the like.

A “native sequence” polypeptide is one which has the same amino acidsequence as a polypeptide (e.g., HER receptor or HER ligand) derivedfrom nature, including naturally occurring or allelic variants. Suchnative sequence polypeptides can be isolated from nature or can beproduced by recombinant or synthetic means. Thus, a native sequencepolypeptide can have the amino acid sequence of naturally occurringhuman polypeptide, murine polypeptide, or polypeptide from any othermammalian species.

The term “antibody” herein is used in the broadest sense andspecifically covers monoclonal antibodies, polyclonal antibodies,multispecific antibodies (e.g. bispecific antibodies), and antibodyfragments, so long as they exhibit the desired biological activity.

The term “monoclonal antibody” as used herein refers to an antibody froma population of substantially homogeneous antibodies, i.e., theindividual antibodies comprising the population are identical and/orbind the same epitope(s), except for possible variants that may ariseduring production of the monoclonal antibody, such variants generallybeing present in minor amounts. Such monoclonal antibody typicallyincludes an antibody comprising a polypeptide sequence that binds atarget, wherein the target-binding polypeptide sequence was obtained bya process that includes the selection of a single target bindingpolypeptide sequence from a plurality of polypeptide sequences. Forexample, the selection process can be the selection of a unique clonefrom a plurality of clones, such as a pool of hybridoma clones, phageclones or recombinant DNA clones. It should be understood that theselected target binding sequence can be further altered, for example, toimprove affinity for the target, to humanize the target bindingsequence, to improve its production in cell culture, to reduce itsimmunogenicity in vivo, to create a multispecific antibody, etc., andthat an antibody comprising the altered target binding sequence is alsoa monoclonal antibody of this invention. In contrast to polyclonalantibody preparations which typically include different antibodiesdirected against different determinants (epitopes), each monoclonalantibody of a monoclonal antibody preparation is directed against asingle determinant on an antigen. In addition to their specificity, themonoclonal antibody preparations are advantageous in that they aretypically uncontaminated by other immunoglobulins. The modifier“monoclonal” indicates the character of the antibody as being obtainedfrom a substantially homogeneous population of antibodies, and is not tobe construed as requiring production of the antibody by any particularmethod. For example, the monoclonal antibodies to be used in accordancewith the present invention may be made by a variety of techniques,including, for example, the hybridoma method (e.g., Kohler et al.,Nature, 256:495 (1975); Harlow et al., Antibodies: A Laboratory Manual,(Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling et al.,in: Monoclonal Antibodies and T-Cell Hybridomas 563-681, (Elsevier,N.Y., 1981)), recombinant DNA methods (see, e.g., U.S. Pat. No.4,816,567), phage display technologies (see, e.g., Clackson et al.,Nature, 352:624-628 (1991); Marks et al., J. Mol. Biol., 222:581-597(1991); Sidhu et al., J. Mol. Biol. 338(2):299-310 (2004); Lee et al.,J. Mol. Biol. 340(5):1073-1093 (2004); Fellouse, Proc. Nat. Acad. Sci.USA 101(34):12467-12472 (2004); and Lee et al. J. Immunol. Methods284(1-2):119-132 (2004), and technologies for producing human orhuman-like antibodies in animals that have parts or all of the humanimmunoglobulin loci or genes encoding human immunoglobulin sequences(see, e.g., WO 1998/24893; WO 1996/34096; WO 1996/33735; WO 1991/10741;Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 (1993);Jakobovits et al., Nature, 362:255-258 (1993); Bruggemann et al., Yearin Immuno., 7:33 (1993); U.S. Pat. Nos. 5,545,806; 5,569,825; 5,591,669(all of GenPharm); U.S. Pat. No. 5,545,807; WO 1997/17852; U.S. Pat.Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; and5,661,016; Marks et al., Bio/Technology, 10: 779-783 (1992); Lonberg etal., Nature, 368: 856-859 (1994); Morrison, Nature, 368: 812-813 (1994);Fishwild et al., Nature Biotechnology, 14: 845-851 (1996); Neuberger,Nature Biotechnology, 14: 826 (1996); and Lonberg and Huszar, Intern.Rev. Immunol., 13: 65-93 (1995)).

The monoclonal antibodies herein specifically include “chimeric”antibodies in which a portion of the heavy and/or light chain isidentical with or homologous to corresponding sequences in antibodiesderived from a particular species or belonging to a particular antibodyclass or subclass, while the remainder of the chain(s) is identical withor homologous to corresponding sequences in antibodies derived fromanother species or belonging to another antibody class or subclass, aswell as fragments of such antibodies, so long as they exhibit thedesired biological activity (U.S. Pat. No. 4,816,567; and Morrison etal., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimericantibodies of interest herein include Aprimatized@ antibodies comprisingvariable domain antigen-binding sequences derived from a non-humanprimate (e.g. Old World Monkey, Ape etc) and human constant regionsequences, as well as “humanized” antibodies.

“Humanized” forms of non-human (e.g., rodent) antibodies are chimericantibodies that contain minimal sequence derived from non-humanimmunoglobulin. For the most part, humanized antibodies are humanimmunoglobulins (recipient antibody) in which residues from ahypervariable region of the recipient are replaced by residues from ahypervariable region of a non-human species (donor antibody) such asmouse, rat, rabbit or nonhuman primate having the desired specificity,affinity, and capacity. In some instances, framework region (FR)residues of the human immunoglobulin are replaced by correspondingnon-human residues. Furthermore, humanized antibodies may compriseresidues that are not found in the recipient antibody or in the donorantibody. These modifications are made to further refine antibodyperformance. In general, the humanized antibody will comprisesubstantially all of at least one, and typically two, variable domains,in which all or substantially all of the hypervariable loops correspondto those of a non-human immunoglobulin and all or substantially all ofthe FRs are those of a human immunoglobulin sequence. The humanizedantibody optionally also will comprise at least a portion of animmunoglobulin constant region (Fc), typically that of a humanimmunoglobulin. For further details, see Jones et al., Nature321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); andPresta, Curr. Op. Struct. Biol. 2:593-596 (1992).

Humanized HER2 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3,huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7 and huMAb4D5-8 ortrastuzumab (HERCEPTIN®) as described in Table 3 of U.S. Pat. No.5,821,337 expressly incorporated herein by reference; humanized 520C9(WO93/21319); and humanized 2C4 antibodies such as pertuzumab asdescribed herein.

For the purposes herein, “trastuzumab,” HERCEPTIN®, and “huMAb4D5-8”refer to an antibody comprising the light and heavy chain amino acidsequences in SEQ ID NOs. 9 and 10, respectively.

Herein, “pertuzumab” and “OMNITARG™” refer to an antibody comprising thelight and heavy chain amino acid sequences in SEQ ID NOs. 7 and 8,respectively.

An “intact antibody” herein is one which comprises two antigen bindingregions, and an Fc region. Preferably, the intact antibody has afunctional Fc region.

“Antibody fragments” comprise a portion of an intact antibody,preferably comprising the antigen binding region thereof. Examples ofantibody fragments include Fab, Fab′, F(ab′)₂, and Fv fragments;diabodies; linear antibodies; single-chain antibody molecules; andmultispecific antibodies formed from antibody fragment(s).

“Native antibodies” are usually heterotetrameric glycoproteins of about150,000 daltons, composed of two identical light (L) chains and twoidentical heavy (H) chains. Each light chain is linked to a heavy chainby one covalent disulfide bond, while the number of disulfide linkagesvaries among the heavy chains of different immunoglobulin isotypes. Eachheavy and light chain also has regularly spaced intrachain disulfidebridges. Each heavy chain has at one end a variable domain (V_(H))followed by a number of constant domains. Each light chain has avariable domain at one end (V_(L)) and a constant domain at its otherend. The constant domain of the light chain is aligned with the firstconstant domain of the heavy chain, and the light-chain variable domainis aligned with the variable domain of the heavy chain. Particular aminoacid residues are believed to form an interface between the light chainand heavy chain variable domains.

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areused in the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not evenly distributedthroughout the variable domains of antibodies. It is concentrated inthree segments called hypervariable regions both in the light chain andthe heavy chain variable domains. The more highly conserved portions ofvariable domains are called the framework regions (FRs). The variabledomains of native heavy and light chains each comprise four FRs, largelyadopting a β-sheet configuration, connected by three hypervariableregions, which form loops connecting, and in some cases forming part of,the β-sheet structure. The hypervariable regions in each chain are heldtogether in close proximity by the FRs and, with the hypervariableregions from the other chain, contribute to the formation of theantigen-binding site of antibodies (see Kabat et al., Sequences ofProteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991)). The constantdomains are not involved directly in binding an antibody to an antigen,but exhibit various effector functions, such as participation of theantibody in antibody dependent cellular cytotoxicity (ADCC).

The term “hypervariable region” when used herein refers to the aminoacid residues of an antibody which are responsible for antigen-binding.The hypervariable region generally comprises amino acid residues from a“complementarity determining region” or “CDR” (e.g. residues 24-34 (L1),50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35(H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain;Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.Public Health Service, National Institutes of Health, Bethesda, Md.(1991)) and/or those residues from a “hypervariable loop” (e.g. residues26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domainand 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variabledomain; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). “FrameworkRegion” or “FR” residues are those variable domain residues other thanthe hypervariable region residues as herein defined.

Papain digestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab′)₂ fragment thathas two antigen-binding sites and is still capable of cross-linkingantigen.

“Fv” is the minimum antibody fragment which contains a completeantigen-recognition and antigen-binding site. This region consists of adimer of one heavy chain and one light chain variable domain in tight,non-covalent association. It is in this configuration that the threehypervariable regions of each variable domain interact to define anantigen-binding site on the surface of the V_(H)-V_(L) dimerCollectively, the six hypervariable regions confer antigen-bindingspecificity to the antibody. However, even a single variable domain (orhalf of an Fv comprising only three hypervariable regions specific foran antigen) has the ability to recognize and bind antigen, although at alower affinity than the entire binding site.

The Fab fragment also contains the constant domain of the light chainand the first constant domain (CH1) of the heavy chain. Fab=fragmentsdiffer from Fab fragments by the addition of a few residues at thecarboxy terminus of the heavy chain CH1 domain including one or morecysteines from the antibody hinge region. Fab′-SH is the designationherein for Fab′ in which the cysteine residue(s) of the constant domainsbear at least one free thiol group. F(ab′)₂ antibody fragmentsoriginally were produced as pairs of Fab′ fragments which have hingecysteines between them. Other chemical couplings of antibody fragmentsare also known.

The “light chains” of antibodies from any vertebrate species can beassigned to one of two clearly distinct types, called kappa (κ) andlambda (λ), based on the amino acid sequences of their constant domains.

The term “Fc region” herein is used to define a C-terminal region of animmunoglobulin heavy chain, including native sequence Fc regions andvariant Fc regions. Although the boundaries of the Fc region of animmunoglobulin heavy chain might vary, the human IgG heavy chain Fcregion is usually defined to stretch from an amino acid residue atposition Cys226, or from Pro230, to the carboxyl-terminus thereof. TheC-terminal lysine (residue 447 according to the EU numbering system) ofthe Fc region may be removed, for example, during production orpurification of the antibody, or by recombinantly engineering thenucleic acid encoding a heavy chain of the antibody. Accordingly, acomposition of intact antibodies may comprise antibody populations withall K447 residues removed, antibody populations with no K447 residuesremoved, and antibody populations having a mixture of antibodies withand without the K447 residue.

Unless indicated otherwise, herein the numbering of the residues in animmunoglobulin heavy chain is that of the EU index as in Kabat et al.,Sequences of Proteins of Immunological Interest, 5th Ed. Public HealthService, National Institutes of Health, Bethesda, Md. (1991), expresslyincorporated herein by reference. The “EU index as in Kabat” refers tothe residue numbering of the human IgG1 EU antibody.

A “functional Fc region” possesses an “effector function” of a nativesequence Fc region. Exemplary “effector functions” include Clq binding;complement dependent cytotoxicity; Fc receptor binding;antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g. B cell receptor; BCR), etc.Such effector functions generally require the Fc region to be combinedwith a binding domain (e.g. an antibody variable domain) and can beassessed using various assays as herein disclosed, for example.

A “native sequence Fc region” comprises an amino acid sequence identicalto the amino acid sequence of an Fc region found in nature. Nativesequence human Fc regions include a native sequence human IgG1 Fc region(non-A and A allotypes); native sequence human IgG2 Fc region; nativesequence human IgG3 Fc region; and native sequence human IgG4 Fc regionas well as naturally occurring variants thereof.

A “variant Fc region” comprises an amino acid sequence which differsfrom that of a native sequence Fc region by virtue of at least one aminoacid modification, preferably one or more amino acid substitution(s).Preferably, the variant Fc region has at least one amino acidsubstitution compared to a native sequence Fc region or to the Fc regionof a parent polypeptide, e.g. from about one to about ten amino acidsubstitutions, and preferably from about one to about five amino acidsubstitutions in a native sequence Fc region or in the Fc region of theparent polypeptide. The variant Fc region herein will preferably possessat least about 80% homology with a native sequence Fc region and/or withan Fc region of a parent polypeptide, and most preferably at least about90% homology therewith, more preferably at least about 95% homologytherewith.

Depending on the amino acid sequence of the constant domain of theirheavy chains, intact antibodies can be assigned to different “classes”.There are five major classes of intact antibodies: IgA, IgD, IgE, IgG,and IgM, and several of these may be further divided into Asubclasses@(isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2. The heavy-chainconstant domains that correspond to the different classes of antibodiesare called α, δ, ε, γ, and μ, respectively. The subunit structures andthree-dimensional configurations of different classes of immunoglobulinsare well known.

“Single-chain Fv” or “scFv” antibody fragments comprise the V_(H) andV_(L) domains of antibody, wherein these domains are present in a singlepolypeptide chain. Preferably, the Fv polypeptide further comprises apolypeptide linker between the V_(H) and V_(L) domains which enables thescFv to form the desired structure for antigen binding. For a review ofscFv see Plückthun in The Pharmacology of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315(1994). HER2 antibody scFv fragments are described in WO93/16185; U.S.Pat. No. 5,571,894; and U.S. Pat. No. 5,587,458.

The term “diabodies” refers to small antibody fragments with twoantigen-binding sites, which fragments comprise a variable heavy domain(V_(H)) connected to a variable light domain (V_(L)) in the samepolypeptide chain (V_(H)-V_(L)). By using a linker that is too short toallow pairing between the two domains on the same chain, the domains areforced to pair with the complementary domains of another chain andcreate two antigen-binding sites. Diabodies are described more fully in,for example, EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl.Acad. Sci. USA, 90:6444-6448 (1993).

A “naked antibody” is an antibody that is not conjugated to aheterologous molecule, such as a cytotoxic moiety or radiolabel.

An “isolated” antibody is one which has been identified and separatedand/or recovered from a component of its natural environment.Contaminant components of its natural environment are materials whichwould interfere with diagnostic or therapeutic uses for the antibody,and may include enzymes, hormones, and other proteinaceous ornonproteinaceous solutes. In preferred embodiments, the antibody will bepurified (1) to greater than 95% by weight of antibody as determined bythe Lowry method, and most preferably more than 99% by weight, (2) to adegree sufficient to obtain at least 15 residues of N-terminal orinternal amino acid sequence by use of a spinning cup sequenator, or (3)to homogeneity by SDS-PAGE under reducing or nonreducing conditionsusing Coomassie blue or, preferably, silver stain. Isolated antibodyincludes the antibody in situ within recombinant cells since at leastone component of the antibody's natural environment will not be present.Ordinarily, however, isolated antibody will be prepared by at least onepurification step.

An “affinity matured” antibody is one with one or more alterations inone or more hypervariable regions thereof which result an improvement inthe affinity of the antibody for antigen, compared to a parent antibodywhich does not possess those alteration(s). Preferred affinity maturedantibodies will have nanomolar or even picomolar affinities for thetarget antigen. Affinity matured antibodies are produced by proceduresknown in the art. Marks et al. Bio/Technology 10:779-783 (1992)describes affinity maturation by VH and VL domain shuffling. Randommutagenesis of CDR and/or framework residues is described by: Barbas etal. Proc Nat. Acad. Sci, USA 91:3809-3813 (1994); Schier et al. Gene169:147-155 (1995); Yelton et al. J. Immunol. 155:1994-2004 (1995);Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al, J.Mol. Biol. 226:889-896 (1992).

The term “main species antibody” herein refers to the antibody structurein a composition which is the quantitatively predominant antibodymolecule in the composition. In one embodiment, the main speciesantibody is a HER2 antibody, such as an antibody that binds to Domain IIof HER2, antibody that inhibits HER dimerization more effectively thantrastuzumab, and/or an antibody which binds to a heterodimeric bindingsite of HER2. The preferred embodiment herein of the main speciesantibody is one comprising the variable light and variable heavy aminoacid sequences of SEQ ID Nos. 3 and 4, and most preferably comprisingthe light chain and heavy chain amino acid sequences in SEQ ID Nos. 7and 8 (pertuzumab).

An “amino acid sequence variant” antibody herein is an antibody with anamino acid sequence which differs from a main species antibody.Ordinarily, amino acid sequence variants will possess at least about 70%homology with the main species antibody, and preferably, they will be atleast about 80%, more preferably at least about 90% homologous with themain species antibody. The amino acid sequence variants possesssubstitutions, deletions, and/or additions at certain positions withinor adjacent to the amino acid sequence of the main species antibody.Examples of amino acid sequence variants herein include an acidicvariant (e.g. deamidated antibody variant), a basic variant, an antibodywith an amino-terminal leader extension (e.g. VHS-) on one or two lightchains thereof, an antibody with a C-terminal lysine residue on one ortwo heavy chains thereof, etc, and includes combinations of variationsto the amino acid sequences of heavy and/or light chains. The antibodyvariant of particular interest herein is the antibody comprising anamino-terminal leader extension on one or two light chains thereof,optionally further comprising other amino acid sequence and/orglycosylation differences relative to the main species antibody.

A “glycosylation variant” antibody herein is an antibody with one ormore carbohydrate moeities attached thereto which differ from one ormore carbohydrate moieties attached to a main species antibody. Examplesof glycosylation variants herein include antibody with a G1 or G2oligosaccharide structure, instead a G0 oligosaccharide structure,attached to an Fc region thereof, antibody with one or two carbohydratemoieties attached to one or two light chains thereof, antibody with nocarbohydrate attached to one or two heavy chains of the antibody, etc,and combinations of glycosylation alterations.

Where the antibody has an Fc region, an oligosaccharide structure may beattached to one or two heavy chains of the antibody, e.g. at residue 299(298, Eu numbering of residues). For pertuzumab, G0 was the predominantoligosaccharide structure, with other oligosaccharide structures such asG0-F, G-1, Man5, Man6, G1-1, G1(1-6), G1(1-3) and G2 being found inlesser amounts in the pertuzumab composition.

Unless indicated otherwise, a AG1 oligosaccharide structure@ hereinincludes G-1, G1-1, G1(1-6) and G1(1-3) structures.

An “amino-terminal leader extension” herein refers to one or more aminoacid residues of the amino-terminal leader sequence that are present atthe amino-terminus of any one or more heavy or light chains of anantibody. An exemplary amino-terminal leader extension comprises orconsists of three amino acid residues, VHS, present on one or both lightchains of an antibody variant.

A “deamidated” antibody is one in which one or more asparagine residuesthereof has been derivitized, e.g. to an aspartic acid, a succinimide,or an iso-aspartic acid.

The terms “cancer” and “cancerous” refer to or describe thephysiological condition in mammals that is typically characterized byunregulated cell growth. The cancer treated in accordance with thepresent invention is any type of metastatic HER2 positive breast cancer,including, without limitation, any histologically or cytologicallyconfirmed adenocaracinoma of the breast with locally recurrent ormetastatic disease (where the locally recurrent disease is not amenableto resection with curative intent), HER2-positive metastatic ductalcarcinoma, HER2-positive metastatic lobular carcinoma, specificallyincluding both ER-positive and ER-negative breast cancers, and may, butare not required to, express other HER receptors, such as EGFR and/orHER3 and/or HER4 and/or one or more HER ligands.

An “advanced” cancer is one which has spread outside the site or organof origin, either by local invasion or metastasis.

A “refractory” cancer is one which progresses even though an anti-tumoragent, such as a chemotherapeutic agent, is being administered to thecancer patient. An example of a refractory cancer is one which isplatinum refractory.

A “recurrent” cancer is one which has regrown, either at the initialsite or at a distant site, after a response to initial therapy.

Herein, a “patient” is a human patient. The patient may be a “cancerpatient,” i.e. one who is suffering or at risk for suffering from one ormore symptoms of cancer.

A “tumor sample” herein is a sample derived from, or comprising tumorcells from, a patients tumor, including cancer, as hereinabove defined.Examples of tumor samples herein include, but are not limited to, tumorbiopsies, circulating tumor cells, circulating plasma proteins, asciticfluid, primary cell cultures or cell lines derived from tumors orexhibiting tumor-like properties, as well as preserved tumor samples,such as formalin-fixed, paraffin-embedded tumor samples or frozen tumorsamples.

A “fixed” tumor sample is one which has been histologically preservedusing a fixative.

A “formalin-fixed” tumor sample is one which has been preserved usingformaldehyde as the fixative.

An “embedded” tumor sample is one surrounded by a firm and generallyhard medium such as paraffin, wax, celloidin, or a resin. Embeddingmakes possible the cutting of thin sections for microscopic examinationor for generation of tissue microarrays (TMAs).

A “paraffin-embedded” tumor sample is one surrounded by a purifiedmixture of solid hydrocarbons derived from petroleum.

Herein, a “frozen” tumor sample refers to a tumor sample which is, orhas been, frozen.

A cancer or biological sample which “displays HER expression,amplification, or activation” is one which, in a diagnostic test,expresses (including overexpresses) a HER receptor, has amplified HERgene, and/or otherwise demonstrates activation or phosphorylation of aHER receptor.

A cancer or biological sample which “displays HER activation” is onewhich, in a diagnostic test, demonstrates activation or phosphorylationof a HER receptor. Such activation can be determined directly (e.g. bymeasuring HER phosphorylation by ELISA) or indirectly (e.g. by geneexpression profiling or by detecting HER heterodimers, as describedherein).

Herein, “gene expression profiling” refers to an evaluation ofexpression of one or more genes as a surrogate for determining HERphosphorylation directly.

A “phospho-ELISA assay” herein is an assay in which phosphorylation ofone or more HER receptors, especially HER2, is evaluated in anenzyme-linked immunosorbent assay (ELISA) using a reagent, usually anantibody, to detect phosphorylated HER receptor, substrate, ordownstream signaling molecule. Preferably, an antibody which detectsphosphorylated HER2 is used. The assay may be performed on cell lysates,preferably from fresh or frozen biological samples.

A cancer cell with “HER receptor overexpression or amplification” is onewhich has significantly higher levels of a HER receptor protein or genecompared to a noncancerous cell of the same tissue type. Suchoverexpression may be caused by gene amplification or by increasedtranscription or translation. HER receptor overexpression oramplification may be determined in a diagnostic or prognostic assay byevaluating increased levels of the HER protein present on the surface ofa cell (e.g. via an immunohistochemistry assay; IHC). Alternatively, oradditionally, one may measure levels of HER-encoding nucleic acid in thecell, e.g. via fluorescent in situ hybridization (FISH; see WO98/45479published October, 1998), southern blotting, or polymerase chainreaction (PCR) techniques, such as quantitative real time PCR (qRT-PCR).One may also study HER receptor overexpression or amplification bymeasuring shed antigen (e.g., HER extracellular domain) in a biologicalfluid such as serum (see, e.g., U.S. Pat. No. 4,933,294 issued Jun. 12,1990; WO91/05264 published Apr. 18, 1991; U.S. Pat. No. 5,401,638 issuedMar. 28, 1995; and Sias et al. J. Immunol. Methods 132: 73-80 (1990)).Aside from the above assays, various in vivo assays are available to theskilled practitioner. For example, one may expose cells within the bodyof the patient to an antibody which is optionally labeled with adetectable label, e.g. a radioactive isotope, and binding of theantibody to cells in the patient can be evaluated, e.g. by externalscanning for radioactivity or by analyzing a biopsy taken from a patientpreviously exposed to the antibody.

Conversely, a cancer which “does not overexpress or amplify HERreceptor” is one which does not have higher than normal levels of HERreceptor protein or gene compared to a noncancerous cell of the sametissue type. Antibodies that inhibit HER dimerization, such aspertuzumab, may be used to treat cancer which does not overexpress oramplify HER2 receptor.

Herein, an “anti-tumor agent” refers to a drug used to treat cancer.Non-limiting examples of anti-tumor agents herein includechemotherapeutic agents, HER dimerization inhibitors, HER antibodies,antibodies directed against tumor associated antigens, anti-hormonalcompounds, cytokines, EGFR-targeted drugs, anti-angiogenic agents,tyrosine kinase inhibitors, growth inhibitory agents and antibodies,cytotoxic agents, antibodies that induce apoptosis, COX inhibitors,farnesyl transferase inhibitors, antibodies that binds oncofetal proteinCA 125, HER2 vaccines, Raf or ras inhibitors, liposomal doxorubicin,topotecan, taxane, dual tyrosine kinase inhibitors, TLK286, EMD-7200,pertuzumab, trastuzumab, erlotinib, and bevacizumab.

An “approved anti-tumor agent” is a drug used to treat cancer which hasbeen accorded marketing approval by a regulatory authority such as theFood and Drug Administration (FDA) or foreign equivalent thereof.

Where a HER dimerization inhibitor is administered as a “singleanti-tumor agent” it is the only anti-tumor agent administered to treatthe cancer, i.e. it is not administered in combination with anotheranti-tumor agent, such as chemotherapy.

A “growth inhibitory agent” when used herein refers to a compound orcomposition which inhibits growth of a cell, especially a HER expressingcancer cell either in vitro or in vivo. Thus, the growth inhibitoryagent may be one which significantly reduces the percentage of HERexpressing cells in S phase. Examples of growth inhibitory agentsinclude agents that block cell cycle progression (at a place other thanS phase), such as agents that induce G1 arrest and M-phase arrest.Classical M-phase blockers include the vincas (vincristine andvinblastine), taxanes, and topo II inhibitors such as doxorubicin,epirubicin, daunorubicin, etoposide, and bleomycin. Those agents thatarrest G1 also spill over into S-phase arrest, for example, DNAalkylating agents such as tamoxifen, prednisone, dacarbazine,mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.Further information can be found in The Molecular Basis of Cancer,Mendelsohn and Israel, eds., Chapter 1, entitled “Cell cycle regulation,oncogenes, and antineoplastic drugs” by Murakami et al. (WB Saunders:Philadelphia, 1995), especially p. 13.

Examples of “growth inhibitory” antibodies are those which bind to HER2and inhibit the growth of cancer cells overexpressing HER2. Preferredgrowth inhibitory HER2 antibodies inhibit growth of SK-BR-3 breast tumorcells in cell culture by greater than 20%, and preferably greater than50% (e.g. from about 50% to about 100%) at an antibody concentration ofabout 0.5 to 30 μg/ml, where the growth inhibition is determined sixdays after exposure of the SK-BR-3 cells to the antibody (see U.S. Pat.No. 5,677,171 issued Oct. 14, 1997). The SK-BR-3 cell growth inhibitionassay is described in more detail in that patent and hereinbelow. Thepreferred growth inhibitory antibody is a humanized variant of murinemonoclonal antibody 4D5, e.g., trastuzumab.

An antibody which “induces apoptosis” is one which induces programmedcell death as determined by binding of annexin V, fragmentation of DNA,cell shrinkage, dilation of endoplasmic reticulum, cell fragmentation,and/or formation of membrane vesicles (called apoptotic bodies). Thecell is usually one which overexpresses the HER2 receptor. Preferablythe cell is a tumor cell, e.g. a breast, ovarian, stomach, endometrial,salivary gland, lung, kidney, colon, thyroid, pancreatic or bladdercell. In vitro, the cell may be a SK-BR-3, BT474, Calu 3 cell,MDA-MB-453, MDA-MB-361 or SKOV3 cell. Various methods are available forevaluating the cellular events associated with apoptosis. For example,phosphatidyl serine (PS) translocation can be measured by annexinbinding; DNA fragmentation can be evaluated through DNA laddering; andnuclear/chromatin condensation along with DNA fragmentation can beevaluated by any increase in hypodiploid cells. Preferably, the antibodywhich induces apoptosis is one which results in about 2 to 50 fold,preferably about 5 to 50 fold, and most preferably about 10 to 50 fold,induction of annexin binding relative to untreated cell in an annexinbinding assay using BT474 cells (see below). Examples of HER2 antibodiesthat induce apoptosis are 7C2 and 7F3.

The “epitope 2C4” is the region in the extracellular domain of HER2 towhich the antibody 2C4 binds. In order to screen for antibodies whichbind essentially to the 2C4 epitope, a routine cross-blocking assay suchas that described in Antibodies, A Laboratory Manual, Cold Spring HarborLaboratory, Ed Harlow and David Lane (1988), can be performed.Preferably the antibody blocks 2C4's binding to HER2 by about 50% ormore. Alternatively, epitope mapping can be performed to assess whetherthe antibody binds essentially to the 2C4 epitope of HER2. Epitope 2C4comprises residues from Domain II (SEQ ID NO: 15) in the extracellulardomain of HER2. 2C4 and pertuzumab binds to the extracellular domain ofHER2 at the junction of domains I, II and III (SEQ ID NOs: 14, 15, and16, respectively). Franklin et al. Cancer Cell 5:317-328 (2004).

The “epitope 4D5” is the region in the extracellular domain of HER2 towhich the antibody 4D5 (ATCC CRL 10463) and trastuzumab bind. Thisepitope is close to the transmembrane domain of HER2, and within DomainIV of HER2 (SEQ ID NO: 17). To screen for antibodies which bindessentially to the 4D5 epitope, a routine cross-blocking assay such asthat described in Antibodies, A Laboratory Manual, Cold Spring HarborLaboratory, Ed Harlow and David Lane (1988), can be performed.Alternatively, epitope mapping can be performed to assess whether theantibody binds essentially to the 4D5 epitope of HER2 (e.g. any one ormore residues in the region from about residue 529 to about residue 625,inclusive of the HER2ECD, residue numbering including signal peptide).

The “epitope 7C2/7F3” is the region at the N terminus, within Domain I(SEQ ID NO: 14), of the extracellular domain of HER2 to which the 7C2and/or 7F3 antibodies (each deposited with the ATCC, see below) bind. Toscreen for antibodies which bind essentially to the 7C2/7F3 epitope, aroutine cross-blocking assay such as that described in Antibodies, ALaboratory Manual, Cold Spring Harbor Laboratory, Ed Harlow and DavidLane (1988), can be performed. Alternatively, epitope mapping can beperformed to establish whether the antibody binds essentially to the7C2/7F3 epitope on HER2 (e.g. any one or more of residues in the regionfrom about residue 22 to about residue 53 of the HER2ECD, residuenumbering including signal peptide).

“Treatment” refers to both therapeutic treatment and prophylactic orpreventative measures. Those in need of treatment include those alreadywith cancer as well as those in which cancer is to be prevented. Hence,the patient to be treated herein may have been diagnosed as havingcancer or may be predisposed or susceptible to cancer.

The term “effective amount” refers to an amount of a drug effective totreat cancer in the patient. The effective amount of the drug may reducethe number of cancer cells; reduce the tumor size; inhibit (i.e., slowto some extent and preferably stop) cancer cell infiltration intoperipheral organs; inhibit (i.e., slow to some extent and preferablystop) tumor metastasis; inhibit, to some extent, tumor growth; and/orrelieve to some extent one or more of the symptoms associated with thecancer. To the extent the drug may prevent growth and/or kill existingcancer cells, it may be cytostatic and/or cytotoxic. The effectiveamount may extend progression free survival (e.g. as measured byResponse Evaluation Criteria for Solid Tumors, RECIST, or CA-125changes), result in an objective response (including a partial response,PR, or complete response, CR), increase overall survival time, and/orimprove one or more symptoms of cancer (e.g. as assessed by FOSI).

The term “cytotoxic agent” as used herein refers to a substance thatinhibits or prevents the function of cells and/or causes destruction ofcells. The term is intended to include radioactive isotopes (e.g. At²¹¹,I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactiveisotopes of Lu), chemotherapeutic agents, and toxins such as smallmolecule toxins or enzymatically active toxins of bacterial, fungal,plant or animal origin, including fragments and/or variants thereof.

A “chemotherapeutic agent” is a chemical compound useful in thetreatment of cancer. Examples of chemotherapeutic agents includealkylating agents such as thiotepa and CYTOXAN® cyclosphosphamide; alkylsulfonates such as busulfan, improsulfan and piposulfan; aziridines suchas benzodopa, carboquone, meturedopa, and uredopa; ethylenimines andmethylamelamines including altretamine, triethylenemelamine,trietylenephosphoramide, triethiylenethiophosphoramide andtrimethylolomelamine; TLK 286 (TELCYTA™); acetogenins (especiallybullatacin and bullatacinone); delta-9-tetrahydrocannabinol (dronabinol,MARINOL®); beta-lapachone; lapachol; colchicines; betulinic acid; acamptothecin (including the synthetic analogue topotecan (HYCAMTIN®),CPT-11 (irinotecan, CAMPTOSAR®), acetylcamptothecin, scopolectin, and9-aminocamptothecin); bryostatin; callystatin; CC-1065 (including itsadozelesin, carzelesin and bizelesin synthetic analogues);podophyllotoxin; podophyllinic acid; teniposide; cryptophycins(particularly cryptophycin 1 and cryptophycin 8); dolastatin;duocarmycin (including the synthetic analogues, KW-2189 and CB1-TM1);eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogenmustards such as chlorambucil, chlornaphazine, cholophosphamide,estramustine, ifosfamide, mechlorethamine, mechlorethamine oxidehydrochloride, melphalan, novembichin, phenesterine, prednimustine,trofosfamide, uracil mustard; nitrosureas such as carmustine,chlorozotocin, fotemustine, lomustine, nimustine, and ranimnustine;bisphosphonates, such as clodronate; antibiotics such as the enediyneantibiotics (e.g., calicheamicin, especially calicheamicin gamma1I andcalicheamicin omegaI1 (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33:183-186 (1994)) and anthracyclines such as annamycin, AD 32,alcarubicin, daunorubicin, dexrazoxane, DX-52-1, epirubicin, GPX-100,idarubicin, KRN5500, menogaril, dynemicin, including dynemicin A, anesperamicin, neocarzinostatin chromophore and related chromoproteinenediyne antiobiotic chromophores, aclacinomysins, actinomycin,authramycin, azaserine, bleomycins, cactinomycin, carabicin,caminomycin, carzinophilin, chromomycinis, dactinomycin, detorubicin,6-diazo-5-oxo-L-norleucine, ADRIAMYCIN® doxorubicin (includingmorpholino-doxorubicin, cyanomorpholino-doxorubicin,2-pyrrolino-doxorubicin, liposomal doxorubicin, and deoxydoxorubicin),esorubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolicacid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin,quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin,ubenimex, zinostatin, and zorubicin; folic acid analogues such asdenopterin, pteropterin, and trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, and thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, and floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, and testolactone; anti-adrenals such as aminoglutethimide,mitotane, and trilostane; folic acid replenisher such as folinic acid(leucovorin); aceglatone; anti-folate anti-neoplastic agents such asALIMTA®, LY231514 pemetrexed, dihydrofolate reductase inhibitors such asmethotrexate, anti-metabolites such as 5-fluorouracil (5-FU) and itsprodrugs such as UFT, S-1 and capecitabine, and thymidylate synthaseinhibitors and glycinamide ribonucleotide formyltransferase inhibitorssuch as raltitrexed (TOMUDEX®, TDX); inhibitors of dihydropyrimidinedehydrogenase such as eniluracil; aldophosphamide glycoside;aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate;defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate;an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan;lonidainine; maytansinoids such as maytansine and ansamitocins;mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin;phenamet; pirarubicin; losoxantrone; 2-ethylhydrazide; procarbazine;PSK7 polysaccharide complex (JHS Natural Products, Eugene, Oreg.);razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid;triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (especiallyT-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine(ELDISINE®, FILDESIN®); dacarbazine; mannomustine; mitobronitol;mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”);cyclophosphamide; thiotepa; taxoids and taxanes, e.g., TAXOL® paclitaxel(Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANE™Cremophor-free, albumin-engineered nanoparticle formulation ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, Ill.), andTAXOTERE® docetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil;gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; platinum; platinumanalogs or platinum-based analogs such as cisplatin, oxaliplatin andcarboplatin; vinblastine (VELBAN®); etoposide (VP-16); ifosfamide;mitoxantrone; vincristine (ONCOVIN®); vinca alkaloid; vinorelbine(NAVELBINE®); novantrone; edatrexate; daunomycin; aminopterin; xeloda;ibandronate; topoisomerase inhibitor RFS 2000; difluoromethylornithine(DMFO); retinoids such as retinoic acid; pharmaceutically acceptablesalts, acids or derivatives of any of the above; as well as combinationsof two or more of the above such as CHOP, an abbreviation for a combinedtherapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone,and FOLFOX, an abbreviation for a treatment regimen with oxaliplatin(ELOXATIN™) combined with 5-FU and leucovorin.

Also included in this definition are anti-hormonal agents that act toregulate or inhibit hormone action on tumors such as anti-estrogens andselective estrogen receptor modulators (SERMs), including, for example,tamoxifen (including NOLVADEX® tamoxifen), raloxifene, droloxifene,4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, andFARESTON® toremifene; aromatase inhibitors that inhibit the enzymearomatase, which regulates estrogen production in the adrenal glands,such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE®megestrol acetate, AROMASIN® exemestane, formestanie, fadrozole,RIVISOR® vorozole, FEMARA® letrozole, and ARIMIDEX® anastrozole; andanti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide,and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleosidecytosine analog); antisense oligonucleotides, particularly those thatinhibit expression of genes in signaling pathways implicated in abherantcell proliferation, such as, for example, PKC-alpha, Raf, H-Ras, andepidermal growth factor receptor (EGF-R); vaccines such as gene therapyvaccines, for example, ALLOVECTIN® vaccine, LEUVECTIN® vaccine, andVAXID® vaccine; PROLEUKIN® rIL-2; LURTOTECAN® topoisomerase 1 inhibitor;ABARELIX® rmRH; and pharmaceutically acceptable salts, acids orderivatives of any of the above.

An “antimetabolite chemotherapeutic agent” is an agent which isstructurally similar to a metabolite, but can not be used by the body ina productive manner. Many antimetabolite chemotherapeutic agentsinterfere with the production of the nucleic acids, RNA and DNA.Examples of antimetabolite chemotherapeutic agents include gemcitabine(GEMZAR®), 5-fluorouracil (5-FU), capecitabine (XELODA™),6-mercaptopurine, methotrexate, 6-thioguanine, pemetrexed, raltitrexed,arabinosylcytosine ARA-C cytarabine (CYTOSAR-U®), dacarbazine(DTIC-DOME®), azocytosine, deoxycytosine, pyridmidene, fludarabine(FLUDARA®), cladrabine, 2-deoxy-D-glucose etc. The preferredantimetabolite chemotherapeutic agent is gemcitabine.

“Gemcitabine” or A “2′-deoxy-2′,2′-difluorocytidine monohydrochloride(b-isomer)” is a nucleoside analogue that exhibits antitumor activity.The empirical formula for gemcitabine HCl is C9H11F2N3O4 A HCl.Gemcitabine HCl is sold by Eli Lilly under the trademark GEMZAR®.

A “platinum-based chemotherapeutic agent” comprises an organic compoundwhich contains platinum as an integral part of the molecule. Examples ofplatinum-based chemotherapeutic agents include carboplatin, cisplatin,and oxaliplatinum.

By “platinum-based chemotherapy” is intended therapy with one or moreplatinum-based chemotherapeutic agents, optionally in combination withone or more other chemotherapeutic agents.

By “chemotherapy-resistant” cancer is meant that the cancer patient hasprogressed while receiving a chemotherapy regimen (i.e. the patient is“chemotherapy refractory”), or the patient has progressed within 12months (for instance, within 6 months) after completing a chemotherapyregimen.

By “platinum-resistant” cancer is meant that the cancer patient hasprogressed while receiving platinum-based chemotherapy (i.e. the patientis “platinum refractory”), or the patient has progressed within 12months (for instance, within 6 months) after completing a platinum-basedchemotherapy regimen.

An “anti-angiogenic agent” refers to a compound which blocks, orinterferes with to some degree, the development of blood vessels. Theanti-angiogenic factor may, for instance, be a small molecule orantibody that binds to a growth factor or growth factor receptorinvolved in promoting angiogenesis. The preferred anti-angiogenic factorherein is an antibody that binds to vascular endothelial growth factor(VEGF), such as bevacizumab (AVASTIN®).

The term “cytokine” is a generic term for proteins released by one cellpopulation which act on another cell as intercellular mediators.Examples of such cytokines are lymphokines, monokines, and traditionalpolypeptide hormones. Included among the cytokines are growth hormonesuch as human growth hormone, N-methionyl human growth hormone, andbovine growth hormone; parathyroid hormone; thyroxine; insulin;proinsulin; relaxin; prorelaxin; glycoprotein hormones such as folliclestimulating hormone (FSH), thyroid stimulating hormone (TSH), andluteinizing hormone (LH); hepatic growth factor; fibroblast growthfactor; prolactin; placental lactogen; tumor necrosis factor-α and -β;mullerian-inhibiting substance; mouse gonadotropin-associated peptide;inhibin; activin; vascular endothelial growth factor; integrin;thrombopoietin (TPO); nerve growth factors such as NGF-β;platelet-growth factor; transforming growth factors (TGFs) such as TGF-αand TGF-β; insulin-like growth factor-I and -II; erythropoietin (EPO);osteoinductive factors; interferons such as interferon-α, -β, and -γ;colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF);granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF);interleukins (ILs) such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6,IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; a tumor necrosis factor such asTNF-α or TNF-β; and other polypeptide factors including LIF and kitligand (KL). As used herein, the term cytokine includes proteins fromnatural sources or from recombinant cell culture and biologically activeequivalents of the native sequence cytokines.

As used herein, the term “EGFR-targeted drug” refers to a therapeuticagent that binds to EGFR and, optionally, inhibits EGFR activation.Examples of such agents include antibodies and small molecules that bindto EGFR. Examples of antibodies which bind to EGFR include MAb 579 (ATCCCRL HB 8506), MAb 455 (ATCC CRL HB8507), MAb 225 (ATCC CRL 8508), MAb528 (ATCC CRL 8509) (see, U.S. Pat. No. 4,943,533, Mendelsohn et al.)and variants thereof, such as chimerized 225 (C225 or Cetuximab;ERBUTIX®) and reshaped human 225 (H225) (see, WO 96/40210, ImcloneSystems Inc.); IMC-11F8, a fully human, EGFR-targeted antibody(Imclone); antibodies that bind type II mutant EGFR (U.S. Pat. No.5,212,290); humanized and chimeric antibodies that bind EGFR asdescribed in U.S. Pat. No. 5,891,996; and human antibodies that bindEGFR, such as ABX-EGF (see WO98/50433, Abgenix); EMD 55900 (Stragliottoet al. Eur. J. Cancer 32A:636-640 (1996)); EMD7200 (matuzumab) ahumanized EGFR antibody directed against EGFR that competes with bothEGF and TGF-alpha for EGFR binding; and mAb 806 or humanized mAb 806(Johns et al., J. Biol. Chem. 279(29):30375-30384 (2004)). The anti-EGFRantibody may be conjugated with a cytotoxic agent, thus generating animmunoconjugate (see, e.g., EP659,439A2, Merck Patent GmbH). Examples ofsmall molecules that bind to EGFR include ZD1839 or Gefitinib (IRESSA;Astra Zeneca); CP-358774 or Erlotinib (TARCEVA™; Genentech/OSI); andAG1478, AG1571 (SU 5271; Sugen); EMD-7200.

A “tyrosine kinase inhibitor” is a molecule which inhibits tyrosinekinase activity of a tyrosine kinase such as a HER receptor. Examples ofsuch inhibitors include the EGFR-targeted drugs noted in the precedingparagraph; small molecule HER2 tyrosine kinase inhibitor such as TAK165available from Takeda; CP-724,714, an oral selective inhibitor of theErbB2 receptor tyrosine kinase (Pfizer and OSI); dual-HER inhibitorssuch as EKB-569 (available from Wyeth) which preferentially binds EGFRbut inhibits both HER2 and EGFR-overexpressing cells; GW572016(available from Glaxo) an oral HER2 and EGFR tyrosine kinase inhibitor;PKI-166 (available from Novartis); pan-HER inhibitors such as canertinib(CI-1033; Pharmacia); Raf-1 inhibitors such as antisense agent ISIS-5132available from ISIS Pharmaceuticals which inhibits Raf-1 signaling;non-HER targeted TK inhibitors such as Imatinib mesylate (Gleevac™)available from Glaxo; MAPK extracellular regulated kinase I inhibitorCI-1040 (available from Pharmacia); quinazolines, such as PD 153035,4-(3-chloroanilino) quinazoline; pyridopyrimidines; pyrimidopyrimidines;pyrrolopyrimidines, such as CGP 59326, CGP 60261 and CGP 62706;pyrazolopyrimidines, 4-(phenylamino)-7H-pyrrolo[2,3-d]pyrimidines;curcumin (diferuloyl methane, 4,5-bis(4-fluoroanilino)phthalimide);tyrphostines containing nitrothiophene moieties; PD-0183805(Warner-Lamber); antisense molecules (e.g. those that bind toHER-encoding nucleic acid); quinoxalines (U.S. Pat. No. 5,804,396);tryphostins (U.S. Pat. No. 5,804,396); ZD6474 (Astra Zeneca); PTK-787(Novartis/Schering AG); pan-HER inhibitors such as CI-1033 (Pfizer);Affinitac (ISIS 3521; Isis/Lilly); Imatinib mesylate (Gleevac;Novartis); PKI 166 (Novartis); GW2016 (Glaxo SmithKline); CI-1033(Pfizer); EKB-569 (Wyeth); Semaxinib (Sugen); ZD6474 (AstraZeneca);PTK-787 (Novartis/Schering AG); INC-1C11 (Imclone); or as described inany of the following patent publications: U.S. Pat. No. 5,804,396;WO99/09016 (American Cyanimid); WO98/43960 (American Cyanamid);WO97/38983 (Warner Lambert); WO99/06378 (Warner Lambert); WO99/06396(Warner Lambert); WO96/30347 (Pfizer, Inc); WO96/33978 (Zeneca);WO96/3397 (Zeneca); and WO96/33980 (Zeneca).

A “fixed” or “flat” dose of a therapeutic agent herein refers to a dosethat is administered to a human patient without regard for the weight(WT) or body surface area (BSA) of the patient. The fixed or flat doseis therefore not provided as a mg/kg dose or a mg/m² dose, but rather asan absolute amount of the therapeutic agent.

A “loading” dose herein generally comprises an initial dose of atherapeutic agent administered to a patient, and is followed by one ormore maintenance dose(s) thereof. Generally, a single loading dose isadministered, but multiple loading doses are contemplated herein.Usually, the amount of loading dose(s) administered exceeds the amountof the maintenance dose(s) administered and/or the loading dose(s) areadministered more frequently than the maintenance dose(s), so as toachieve the desired steady-state concentration of the therapeutic agentearlier than can be achieved with the maintenance dose(s).

A “maintenance” dose herein refers to one or more doses of a therapeuticagent administered to the patient over a treatment period. Usually, themaintenance doses are administered at spaced treatment intervals, suchas approximately every week, approximately every 2 weeks, approximatelyevery 3 weeks, or approximately every 4 weeks.

II. Production of Antibodies

The HER antigen to be used for production of antibodies may be, e.g., asoluble form of the extracellular domain of a HER receptor or a portionthereof, containing the desired epitope. Alternatively, cells expressingHER at their cell surface (e.g. NIH-3T3 cells transformed to overexpressHER2; or a carcinoma cell line such as SK-BR-3 cells, see Stancovski etal. PNAS (USA) 88:8691-8695 (1991)) can be used to generate antibodies.Other forms of HER receptor useful for generating antibodies will beapparent to those skilled in the art.

(i) Polyclonal Antibodies

Polyclonal antibodies are preferably raised in animals by multiplesubcutaneous (sc) or intraperitoneal (ip) injections of the relevantantigen and an adjuvant. It may be useful to conjugate the relevantantigen to a protein that is immunogenic in the species to be immunized,e.g., keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, orsoybean trypsin inhibitor using a bifunctional or derivatizing agent,for example, maleimidobenzoyl sulfosuccinimide ester (conjugationthrough cysteine residues), N-hydroxysuccinimide (through lysineresidues), glutaraldehyde, succinic anhydride, SOCl₂, or R¹N═C═NR, whereR and R¹ are different alkyl groups.

Animals are immunized against the antigen, immunogenic conjugates, orderivatives by combining, e.g., 100 μg or 5 μg of the protein orconjugate (for rabbits or mice, respectively) with 3 volumes of Freund'scomplete adjuvant and injecting the solution intradermally at multiplesites. One month later the animals are boosted with ⅕ to 1/10 theoriginal amount of peptide or conjugate in Freund's complete adjuvant bysubcutaneous injection at multiple sites. Seven to 14 days later theanimals are bled and the serum is assayed for antibody titer. Animalsare boosted until the titer plateaus. Preferably, the animal is boostedwith the conjugate of the same antigen, but conjugated to a differentprotein and/or through a different cross-linking reagent. Conjugatesalso can be made in recombinant cell culture as protein fusions. Also,aggregating agents such as alum are suitably used to enhance the immuneresponse.

(ii) Monoclonal Antibodies

Various methods for making monoclonal antibodies herein are available inthe art. For example, the monoclonal antibodies may be made using thehybridoma method first described by Kohler et al., Nature, 256:495(1975), by recombinant DNA methods (U.S. Pat. No. 4,816,567).

In the hybridoma method, a mouse or other appropriate host animal, suchas a hamster, is immunized as hereinabove described to elicitlymphocytes that produce or are capable of producing antibodies thatwill specifically bind to the protein used for immunization.Alternatively, lymphocytes may be immunized in vitro. Lymphocytes thenare fused with myeloma cells using a suitable fusing agent, such aspolyethylene glycol, to form a hybridoma cell (Goding, MonoclonalAntibodies: Principles and Practice, pp. 59-103 (Academic Press, 1986)).

The hybridoma cells thus prepared are seeded and grown in a suitableculture medium that preferably contains one or more substances thatinhibit the growth or survival of the unfused, parental myeloma cells.For example, if the parental myeloma cells lack the enzyme hypoxanthineguanine phosphoribosyl transferase (HGPRT or HPRT), the culture mediumfor the hybridomas typically will include hypoxanthine, aminopterin, andthymidine (HAT medium), which substances prevent the growth ofHGPRT-deficient cells.

Preferred myeloma cells are those that fuse efficiently, support stablehigh-level production of antibody by the selected antibody-producingcells, and are sensitive to a medium such as HAT medium. Among these,preferred myeloma cell lines are murine myeloma lines, such as thosederived from MOPC-21 and MPC-11 mouse tumors available from the SalkInstitute Cell Distribution Center, San Diego, Calif. USA, and SP-2 orX63-Ag8-653 cells available from the American Type Culture Collection,Rockville, Md. USA. Human myeloma and mouse-human heteromyeloma celllines also have been described for the production of human monoclonalantibodies (Kozbor, J. Immunol., 133:3001 (1984); and Brodeur et al.,Monoclonal Antibody Production Techniques and Applications, pp. 51-63(Marcel Dekker, Inc., New York, 1987)).

Culture medium in which hybridoma cells are growing is assayed forproduction of monoclonal antibodies directed against the antigen.Preferably, the binding specificity of monoclonal antibodies produced byhybridoma cells is determined by immunoprecipitation or by an in vitrobinding assay, such as radioimmunoassay (RIA) or enzyme-linkedimmunoabsorbent assay (ELISA).

The binding affinity of the monoclonal antibody can, for example, bedetermined by the Scatchard analysis of Munson et al., Anal. Biochem.,107:220 (1980).

After hybridoma cells are identified that produce antibodies of thedesired specificity, affinity, and/or activity, the clones may besubcloned by limiting dilution procedures and grown by standard methods(Goding, Monoclonal Antibodies: Principles and Practice, pp. 59-103(Academic Press, 1986)). Suitable culture media for this purposeinclude, for example, D-MEM or RPMI-1640 medium. In addition, thehybridoma cells may be grown in vivo as ascites tumors in an animal.

The monoclonal antibodies secreted by the subclones are suitablyseparated from the culture medium, ascites fluid, or serum byconventional antibody purification procedures such as, for example,protein A-Sepharose, hydroxylapatite chromatography, gelelectrophoresis, dialysis, or affinity chromatography.

DNA encoding the monoclonal antibodies is readily isolated and sequencedusing conventional procedures (e.g., by using oligonucleotide probesthat are capable of binding specifically to genes encoding the heavy andlight chains of murine antibodies). The hybridoma cells serve as apreferred source of such DNA. Once isolated, the DNA may be placed intoexpression vectors, which are then transfected into host cells such asE. coli cells, simian COS cells, Chinese Hamster Ovary (CHO) cells, ormyeloma cells that do not otherwise produce antibody protein, to obtainthe synthesis of monoclonal antibodies in the recombinant host cells.Review articles on recombinant expression in bacteria of DNA encodingthe antibody include Skerra et al., Curr. Opinion in Immunol., 5:256-262(1993) and Plückthun, Immunol. Revs., 130:151-188 (1992).

In a further embodiment, monoclonal antibodies or antibody fragments canbe isolated from antibody phage libraries generated using the techniquesdescribed in McCafferty et al., Nature, 348:552-554 (1990). Clackson etal., Nature, 352:624-628 (1991) and Marks et al., J. Mol. Biol.,222:581-597 (1991) describe the isolation of murine and humanantibodies, respectively, using phage libraries. Subsequent publicationsdescribe the production of high affinity (nM range) human antibodies bychain shuffling (Marks et al., Bio/Technology, 10:779-783 (1992)), aswell as combinatorial infection and in vivo recombination as a strategyfor constructing very large phage libraries (Waterhouse et al., Nuc.Acids. Res., 21:2265-2266 (1993)). Thus, these techniques are viablealternatives to traditional monoclonal antibody hybridoma techniques forisolation of monoclonal antibodies.

The DNA also may be modified, for example, by substituting the codingsequence for human heavy chain and light chain constant domains in placeof the homologous murine sequences (U.S. Pat. No. 4,816,567; andMorrison, et al., Proc. Natl. Acad. Sci. USA, 81:6851 (1984)), or bycovalently joining to the immunoglobulin coding sequence all or part ofthe coding sequence for a non-immunoglobulin polypeptide.

Typically such non-immunoglobulin polypeptides are substituted for theconstant domains of an antibody, or they are substituted for thevariable domains of one antigen-combining site of an antibody to createa chimeric bivalent antibody comprising one antigen-combining sitehaving specificity for an antigen and another antigen-combining sitehaving specificity for a different antigen.

(iii) Humanized Antibodies

Methods for humanizing non-human antibodies have been described in theart. Preferably, a humanized antibody has one or more amino acidresidues introduced into it from a source which is non-human. Thesenon-human amino acid residues are often referred to as “import”residues, which are typically taken from an “import” variable domain.Humanization can be essentially performed following the method of Winterand co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann etal., Nature, 332:323-327 (1988); Verhoeyen et al., Science,239:1534-1536 (1988)), by substituting hypervariable region sequencesfor the corresponding sequences of a human antibody. Accordingly, such“humanized” antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567)wherein substantially less than an intact human variable domain has beensubstituted by the corresponding sequence from a non-human species. Inpractice, humanized antibodies are typically human antibodies in whichsome hypervariable region residues and possibly some FR residues aresubstituted by residues from analogous sites in rodent antibodies.

The choice of human variable domains, both light and heavy, to be usedin making the humanized antibodies is very important to reduceantigenicity. According to the so-called “best-fit” method, the sequenceof the variable domain of a rodent antibody is screened against theentire library of known human variable-domain sequences. The humansequence which is closest to that of the rodent is then accepted as thehuman framework region (FR) for the humanized antibody (Sims et al., J.Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901(1987)). Another method uses a particular framework region derived fromthe consensus sequence of all human antibodies of a particular subgroupof light or heavy chains. The same framework may be used for severaldifferent humanized antibodies (Carter et al., Proc. Natl. Acad. Sci.USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993)).

It is further important that antibodies be humanized with retention ofhigh affinity for the antigen and other favorable biological properties.To achieve this goal, according to a preferred method, humanizedantibodies are prepared by a process of analysis of the parentalsequences and various conceptual humanized products usingthree-dimensional models of the parental and humanized sequences.Three-dimensional immunoglobulin models are commonly available and arefamiliar to those skilled in the art. Computer programs are availablewhich illustrate and display probable three-dimensional conformationalstructures of selected candidate immunoglobulin sequences. Inspection ofthese displays permits analysis of the likely role of the residues inthe functioning of the candidate immunoglobulin sequence, i.e., theanalysis of residues that influence the ability of the candidateimmunoglobulin to bind its antigen. In this way, FR residues can beselected and combined from the recipient and import sequences so thatthe desired antibody characteristic, such as increased affinity for thetarget antigen(s), is achieved. In general, the hypervariable regionresidues are directly and most substantially involved in influencingantigen binding.

U.S. Pat. No. 6,949,245 describes production of exemplary humanized HER2antibodies which bind HER2 and block ligand activation of a HERreceptor. A humanized antibody used in the methods of the presentinvention is rhuMAb 2C4 (pertuzumab), or an antibody that bindsessentially to the same epitope within the HER2 extracellular domain aspertuzumab. In other embodiments, one of the antibodies used in themethods of the present invention blocks EGF, TGF-α and/or HRG mediatedactivation of MAPK essentially as effectively as murine monoclonalantibody 2C4 (or a Fab fragment thereof) and/or binds HER2 essentiallyas effectively as murine monoclonal antibody 2C4 (or a Fab fragmentthereof). The humanized antibody herein may, for example, comprisenonhuman hypervariable region residues incorporated into a humanvariable heavy domain and may further comprise a framework region (FR)substitution at a position selected from the group consisting of 69H,71H and 73H utilizing the variable domain numbering system set forth inKabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.Public Health Service, National Institutes of Health, Bethesda, Md.(1991). In one embodiment, the humanized antibody comprises FRsubstitutions at two or all of positions 69H, 71H and 73H.

An exemplary humanized antibody of interest herein comprises variableheavy domain complementarity determining residues GFTFTDYTMX (SEQ ID NO:18), where X is preferrably D or S; DVNPNSGGSIYNQRFKG (SEQ ID NO:19);and/or NLGPSFYFDY (SEQ ID NO:20), optionally comprising amino acidmodifications of those CDR residues, e.g. where the modificationsessentially maintain or improve affinity of the antibody. For example,an antibody variant for use in the methods of the present invention mayhave from about one to about seven or about five amino acidsubstitutions in the above variable heavy CDR sequences. Such antibodyvariants may be prepared by affinity maturation, e.g., as describedbelow.

The humanized antibody may comprise variable light domaincomplementarity determining residues KASQDVSIGVA (SEQ ID NO:21);SASYX¹X²X³, where X¹ is preferably R or L, X² is preferably Y or E, andX³ is preferably T or S (SEQ ID NO:22); and/or QQYYIYPYT (SEQ ID NO:23),e.g. in addition to those variable heavy domain CDR residues in thepreceding paragraph. Such humanized antibodies optionally comprise aminoacid modifications of the above CDR residues, e.g. where themodifications essentially maintain or improve affinity of the antibody.For example, the antibody variant of interest may have from about one toabout seven or about five amino acid substitutions in the above variablelight CDR sequences. Such antibody variants may be prepared by affinitymaturation, e.g., as described below.

The present application also contemplates affinity matured antibodieswhich bind HER2. The parent antibody may be a human antibody or ahumanized antibody, e.g., one comprising the variable light and/orvariable heavy sequences of SEQ ID Nos. 7 and 8, respectively (i.e.comprising the VL and/or VH of pertuzumab). An affinity matured variantof pertuzumab preferably binds to HER2 receptor with an affinitysuperior to that of murine 2C4 or pertuzumab (e.g. from about two orabout four fold, to about 100 fold or about 1000 fold improved affinity,e.g. as assessed using a HER2-extracellular domain (ECD) ELISA).Exemplary variable heavy CDR residues for substitution include H28, H30,H34, H35, H64, H96, H99, or combinations of two or more (e.g. two,three, four, five, six, or seven of these residues). Examples ofvariable light CDR residues for alteration include L28, L50, L53, L56,L91, L92, L93, L94, L96, L97 or combinations of two or more (e.g. two tothree, four, five or up to about ten of these residues).

Humanization of murine 4D5 antibody to generate humanized variantsthereof, including trastuzumab, is described in U.S. Pat. Nos.5,821,337, 6,054,297, 6,407,213, 6,639,055, 6,719,971, and 6,800,738, aswell as Carter et al. PNAS (USA), 89:4285-4289 (1992). HuMAb4D5-8(trastuzumab) bound HER2 antigen 3-fold more tightly than the mouse 4D5antibody, and had secondary immune function (ADCC) which allowed fordirected cytotoxic activity of the humanized antibody in the presence ofhuman effector cells. HuMAb4D5-8 comprised variable light (V_(L)) CDRresidues incorporated in a V_(L) subgroup I consensuse framework, andvariable heavy (V_(H)) CDR residues incorporated into a V_(H) subgroupIII consensus framework. The antibody further comprised framework region(FR) substitutions as positions: 71, 73, 78, and 93 of the V_(H) (Kabatnumbering of FR residues; and a FR substitution at position 66 of theV_(L) (Kabat numbering of FR residues). Trastuzumab comprises non-Aallotype human γ 1 Fc region.

Various forms of the humanized antibody or affinity matured antibody arecontemplated. For example, the humanized antibody or affinity maturedantibody may be an antibody fragment, such as a Fab, which is optionallyconjugated with one or more cytotoxic agent(s) in order to generate animmunoconjugate. Alternatively, the humanized antibody or affinitymatured antibody may be an intact antibody, such as an intact IgG1antibody.

(iv) Human Antibodies

As an alternative to humanization, human antibodies can be generated.For example, it is now possible to produce transgenic animals (e.g.,mice) that are capable, upon immunization, of producing a fullrepertoire of human antibodies in the absence of endogenousimmunoglobulin production. For example, it has been described that thehomozygous deletion of the antibody heavy-chain joining region (J_(H))gene in chimeric and germ-line mutant mice results in completeinhibition of endogenous antibody production. Transfer of the humangerm-line immunoglobulin gene array in such germ-line mutant mice willresult in the production of human antibodies upon antigen challenge.See, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551(1993); Jakobovits et al., Nature, 362:255-258 (1993); Bruggermann etal., Year in Immuno., 7:33 (1993); and U.S. Pat. Nos. 5,591,669,5,589,369 and 5,545,807. Alternatively, phage display technology(McCafferty et al., Nature 348:552-553 (1990)) can be used to producehuman antibodies and antibody fragments in vitro, from immunoglobulinvariable (V) domain gene repertoires from unimmunized donors. Accordingto this technique, antibody V domain genes are cloned in-frame intoeither a major or minor coat protein gene of a filamentousbacteriophage, such as M13 or fd, and displayed as functional antibodyfragments on the surface of the phage particle. Because the filamentousparticle contains a single-stranded DNA copy of the phage genome,selections based on the functional properties of the antibody alsoresult in selection of the gene encoding the antibody exhibiting thoseproperties. Thus, the phage mimics some of the properties of the B-cell.Phage display can be performed in a variety of formats; for their reviewsee, e.g., Johnson, Kevin S, and Chiswell, David J., Current Opinion inStructural Biology 3:564-571 (1993). Several sources of V-gene segmentscan be used for phage display. Clackson et al., Nature, 352:624-628(1991) isolated a diverse array of anti-oxazolone antibodies from asmall random combinatorial library of V genes derived from the spleensof immunized mice. A repertoire of V genes from unimmunized human donorscan be constructed and antibodies to a diverse array of antigens(including self-antigens) can be isolated essentially following thetechniques described by Marks et al., J. Mol. Biol. 222:581-597 (1991),or Griffith et al., EMBO J. 12:725-734 (1993). See, also, U.S. Pat. Nos.5,565,332 and 5,573,905.

As discussed above, human antibodies may also be generated by in vitroactivated B cells (see U.S. Pat. Nos. 5,567,610 and 5,229,275).

Human HER2 antibodies are described in U.S. Pat. No. 5,772,997 issuedJun. 30, 1998 and WO 97/00271 published Jan. 3, 1997.

(v) Antibody Fragments

Various techniques have been developed for the production of antibodyfragments comprising one or more antigen binding regions. Traditionally,these fragments were derived via proteolytic digestion of intactantibodies (see, e.g., Morimoto et al., Journal of Biochemical andBiophysical Methods 24:107-117 (1992); and Brennan et al., Science,229:81 (1985)). However, these fragments can now be produced directly byrecombinant host cells. For example, the antibody fragments can beisolated from the antibody phage libraries discussed above.Alternatively, Fab′-SH fragments can be directly recovered from E. coliand chemically coupled to form F(ab′)₂ fragments (Carter et al.,Bio/Technology 10:163-167 (1992)). According to another approach,F(ab′)₂ fragments can be isolated directly from recombinant host cellculture. Other techniques for the production of antibody fragments willbe apparent to the skilled practitioner. In other embodiments, theantibody of choice is a single chain Fv fragment (scFv). See WO93/16185; U.S. Pat. No. 5,571,894; and U.S. Pat. No. 5,587,458. Theantibody fragment may also be a “linear antibody”, e.g., as described inU.S. Pat. No. 5,641,870 for example. Such linear antibody fragments maybe monospecific or bispecific.

(vi) Bispecific Antibodies

Bispecific antibodies are antibodies that have binding specificities forat least two different epitopes. Exemplary bispecific antibodies maybind to two different epitopes of the HER2 protein. Other suchantibodies may combine a HER2 binding site with binding site(s) forEGFR, HER3 and/or HER4. Alternatively, a HER2 arm may be combined withan arm which binds to a triggering molecule on a leukocyte such as aT-cell receptor molecule (e.g. CD2 or CD3), or Fc receptors for IgG(FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as tofocus cellular defense mechanisms to the HER2-expressing cell.Bispecific antibodies may also be used to localize cytotoxic agents tocells which express HER2. These antibodies possess a HER2-binding armand an arm which binds the cytotoxic agent (e.g. saporin,anti-interferon-α, vinca alkaloid, ricin A chain, methotrexate orradioactive isotope hapten). Bispecific antibodies can be prepared asfull length antibodies or antibody fragments (e.g. F(ab)₂ bispecificantibodies).

WO 96/16673 describes a bispecific HER2/FcγRIII antibody and U.S. Pat.No. 5,837,234 discloses a bispecific HER2/FcγRI antibody IDM1 (Osidem).A bispecific HER2/Fcα antibody is shown in WO98/02463. U.S. Pat. No.5,821,337 teaches a bispecific HER2/CD3 antibody. MDX-210 is abispecific HER2-FcγRIII Ab.

Methods for making bispecific antibodies are known in the art.Traditional production of full length bispecific antibodies is based onthe coexpression of two immunoglobulin heavy chain-light chain pairs,where the two chains have different specificities (Millstein et al.,Nature, 305:537-539 (1983)). Because of the random assortment ofimmunoglobulin heavy and light chains, these hybridomas (quadromas)produce a potential mixture of 10 different antibody molecules, of whichonly one has the correct bispecific structure. Purification of thecorrect molecule, which is usually done by affinity chromatographysteps, is rather cumbersome, and the product yields are low. Similarprocedures are disclosed in WO 93/08829, and in Traunecker et al., EMBOJ., 10:3655-3659 (1991).

According to a different approach, antibody variable domains with thedesired binding specificities (antibody-antigen combining sites) arefused to immunoglobulin constant domain sequences. The fusion preferablyis with an immunoglobulin heavy chain constant domain, comprising atleast part of the hinge, CH2, and CH3 regions. It is preferred to havethe first heavy-chain constant region (CH1) containing the sitenecessary for light chain binding, present in at least one of thefusions. DNAs encoding the immunoglobulin heavy chain fusions and, ifdesired, the immunoglobulin light chain, are inserted into separateexpression vectors, and are co-transfected into a suitable hostorganism. This provides for great flexibility in adjusting the mutualproportions of the three polypeptide fragments in embodiments whenunequal ratios of the three polypeptide chains used in the constructionprovide the optimum yields. It is, however, possible to insert thecoding sequences for two or all three polypeptide chains in oneexpression vector when the expression of at least two polypeptide chainsin equal ratios results in high yields or when the ratios are of noparticular significance.

In a preferred embodiment of this approach, the bispecific antibodiesare composed of a hybrid immunoglobulin heavy chain with a first bindingspecificity in one arm, and a hybrid immunoglobulin heavy chain-lightchain pair (providing a second binding specificity) in the other arm. Itwas found that this asymmetric structure facilitates the separation ofthe desired bispecific compound from unwanted immunoglobulin chaincombinations, as the presence of an immunoglobulin light chain in onlyone half of the bispecific molecule provides for a facile way ofseparation. This approach is disclosed in WO 94/04690. For furtherdetails of generating bispecific antibodies see, for example, Suresh etal., Methods in Enzymology, 121:210 (1986).

According to another approach described in U.S. Pat. No. 5,731,168, theinterface between a pair of antibody molecules can be engineered tomaximize the percentage of heterodimers which are recovered fromrecombinant cell culture. The preferred interface comprises at least apart of the C_(H)3 domain of an antibody constant domain. In thismethod, one or more small amino acid side chains from the interface ofthe first antibody molecule are replaced with larger side chains (e.g.tyrosine or tryptophan). Compensatory “cavities” of identical or similarsize to the large side chain(s) are created on the interface of thesecond antibody molecule by replacing large amino acid side chains withsmaller ones (e.g. alanine or threonine). This provides a mechanism forincreasing the yield of the heterodimer over other unwanted end-productssuch as homodimers.

Bispecific antibodies include cross-linked or “heteroconjugate”antibodies. For example, one of the antibodies in the heteroconjugatecan be coupled to avidin, the other to biotin. Such antibodies have, forexample, been proposed to target immune system cells to unwanted cells(U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO91/00360, WO 92/200373, and EP 03089). Heteroconjugate antibodies may bemade using any convenient cross-linking methods. Suitable cross-linkingagents are well known in the art, and are disclosed in U.S. Pat. No.4,676,980, along with a number of cross-linking techniques.

Techniques for generating bispecific antibodies from antibody fragmentshave also been described in the literature. For example, bispecificantibodies can be prepared using chemical linkage. Brennan et al.,Science, 229: 81 (1985) describe a procedure wherein intact antibodiesare proteolytically cleaved to generate F(ab′)₂ fragments. Thesefragments are reduced in the presence of the dithiol complexing agentsodium arsenite to stabilize vicinal dithiols and prevent intermoleculardisulfide formation. The Fab′ fragments generated are then converted tothionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives isthen reconverted to the Fab′-thiol by reduction with mercaptoethylamineand is mixed with an equimolar amount of the other Fab′-TNB derivativeto form the bispecific antibody. The bispecific antibodies produced canbe used as agents for the selective immobilization of enzymes.

Recent progress has facilitated the direct recovery of Fab′-SH fragmentsfrom E. coli, which can be chemically coupled to form bispecificantibodies. Shalaby et al., J. Exp. Med., 175: 217-225 (1992) describethe production of a fully humanized bispecific antibody F(ab′)₂molecule. Each Fab′ fragment was separately secreted from E. coli andsubjected to directed chemical coupling in vitro to form the bispecificantibody. The bispecific antibody thus formed was able to bind to cellsoverexpressing the HER2 receptor and normal human T cells, as well astrigger the lytic activity of human cytotoxic lymphocytes against humanbreast tumor targets.

Various techniques for making and isolating bispecific antibodyfragments directly from recombinant cell culture have also beendescribed. For example, bispecific antibodies have been produced usingleucine zippers. Kostelny et al., J. Immunol., 148(5):1547-1553 (1992).The leucine zipper peptides from the Fos and Jun proteins were linked tothe Fab′ portions of two different antibodies by gene fusion. Theantibody homodimers were reduced at the hinge region to form monomersand then re-oxidized to form the antibody heterodimers. This method canalso be utilized for the production of antibody homodimers. The“diabody” technology described by Hollinger et al., Proc. Natl. Acad.Sci. USA, 90:6444-6448 (1993) has provided an alternative mechanism formaking bispecific antibody fragments. The fragments comprise aheavy-chain variable domain (V_(H)) connected to a light-chain variabledomain (V_(L)) by a linker which is too short to allow pairing betweenthe two domains on the same chain. Accordingly, the V_(H) and V_(L)domains of one fragment are forced to pair with the complementary V_(L)and V_(H) domains of another fragment, thereby forming twoantigen-binding sites. Another strategy for making bispecific antibodyfragments by the use of single-chain Fv (sFv) dimers has also beenreported. See Gruber et al., J. Immunol., 152:5368 (1994).

Antibodies with more than two valencies are contemplated. For example,trispecific antibodies can be prepared. Tutt et al. J. Immunol. 147: 60(1991).

(vii) Other Amino Acid Sequence Modifications

Amino acid sequence modification(s) of the antibodies described hereinare contemplated. For example, it may be desirable to improve thebinding affinity and/or other biological properties of the antibody.Amino acid sequence variants of the antibody are prepared by introducingappropriate nucleotide changes into the antibody nucleic acid, or bypeptide synthesis. Such modifications include, for example, deletionsfrom, and/or insertions into and/or substitutions of, residues withinthe amino acid sequences of the antibody. Any combination of deletion,insertion, and substitution is made to arrive at the final construct,provided that the final construct possesses the desired characteristics.The amino acid changes also may alter post-translational processes ofthe antibody, such as changing the number or position of glycosylationsites.

A useful method for identification of certain residues or regions of theantibody that are preferred locations for mutagenesis is called “alaninescanning mutagenesis” as described by Cunningham and Wells Science,244:1081-1085 (1989). Here, a residue or group of target residues areidentified (e.g., charged residues such as arg, asp, his, lys, and glu)and replaced by a neutral or negatively charged amino acid (mostpreferably alanine or polyalanine) to affect the interaction of theamino acids with antigen. Those amino acid locations demonstratingfunctional sensitivity to the substitutions then are refined byintroducing further or other variants at, or for, the sites ofsubstitution. Thus, while the site for introducing an amino acidsequence variation is predetermined, the nature of the mutation per seneed not be predetermined. For example, to analyze the performance of amutation at a given site, ala scanning or random mutagenesis isconducted at the target codon or region and the expressed antibodyvariants are screened for the desired activity.

Amino acid sequence insertions include amino- and/or carboxyl-terminalfusions ranging in length from one residue to polypeptides containing ahundred or more residues, as well as intrasequence insertions of singleor multiple amino acid residues. Examples of terminal insertions includeantibody with an N-terminal methionyl residue or the antibody fused to acytotoxic polypeptide. Other insertional variants of the antibodymolecule include the fusion to the N- or C-terminus of the antibody toan enzyme (e.g. for ADEPT) or a polypeptide which increases the serumhalf-life of the antibody.

Another type of variant is an amino acid substitution variant. Thesevariants have at least one amino acid residue in the antibody moleculereplaced by a different residue. The sites of greatest interest forsubstitutional mutagenesis include the hypervariable regions, but FRalterations are also contemplated. Conservative substitutions are shownin Table 1 under the heading of “preferred substitutions”. If suchsubstitutions result in a change in biological activity, then moresubstantial changes, denominated “exemplary substitutions” in Table 1,or as further described below in reference to amino acid classes, may beintroduced and the products screened.

TABLE 1 Original Exemplary Preferred Residue Substitutions SubstitutionsAla (A) Val; Leu; Ile Val Arg (R) Lys; Gln; Asn Lys Asn (N) Gln; His;Asp, Lys; Arg Gln Asp (D) Glu; Asn Glu Cys (C) Ser; Ala Ser Gln (Q) Asn;Glu Asn Glu (E) Asp; Gln Asp Gly (G) Ala Ala His (H) Asn; Gln; Lys; ArgArg Ile (I) Leu; Val; Met; Ala; Leu Phe; Norleucine Leu (L) Norleucine;Ile; Val; Ile Met; Ala; Phe Lys (K) Arg; Gln; Asn Arg Met (M) Leu; Phe;Ile Leu Phe (F) Trp; Leu; Val; Ile; Ala; Tyr Tyr Pro (P) Ala Ala Ser (S)Thr Thr Thr (T) Val; Ser Ser Trp (W) Tyr; Phe Tyr Tyr (Y) Trp; Phe; Thr;Ser Phe Val (V) Ile; Leu; Met; Phe; Leu Ala; Norleucine

Substantial modifications in the biological properties of the antibodyare accomplished by selecting substitutions that differ significantly intheir effect on maintaining (a) the structure of the polypeptidebackbone in the area of the substitution, for example, as a sheet orhelical conformation, (b) the charge or hydrophobicity of the moleculeat the target site, or (c) the bulk of the side chain. Amino acids maybe grouped according to similarities in the properties of their sidechains (in A. L. Lehninger, in Biochemistry, second ed., pp. 73-75,Worth Publishers, New York (1975)):

(1) non-polar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp(W), Met (M)

(2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn(N), Gln (O)

(3) acidic: Asp (D), Glu (E)

(4) basic: Lys (K), Arg (R), His(H)

Alternatively, naturally occurring residues may be divided into groupsbased on common side-chain properties:

(1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;

(2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

(3) acidic: Asp, Glu;

(4) basic: His, Lys, Arg;

(5) residues that influence chain orientation: Gly, Pro;

(6) aromatic: Trp, Tyr, Phe.

Non-conservative substitutions will entail exchanging a member of one ofthese classes for another class.

Any cysteine residue not involved in maintaining the proper conformationof the antibody also may be substituted, generally with serine, toimprove the oxidative stability of the molecule and prevent aberrantcrosslinking. Conversely, cysteine bond(s) may be added to the antibodyto improve its stability (particularly where the antibody is an antibodyfragment such as an Fv fragment).

A particularly preferred type of substitutional variant involvessubstituting one or more hypervariable region residues of a parentantibody (e.g. a humanized or human antibody). Generally, the resultingvariant(s) selected for further development will have improvedbiological properties relative to the parent antibody from which theyare generated. A convenient way for generating such substitutionalvariants involves affinity maturation using phage display. Briefly,several hypervariable region sites (e.g. 6-7 sites) are mutated togenerate all possible amino substitutions at each site. The antibodyvariants thus generated are displayed in a monovalent fashion fromfilamentous phage particles as fusions to the gene III product of M13packaged within each particle. The phage-displayed variants are thenscreened for their biological activity (e.g. binding affinity) as hereindisclosed. In order to identify candidate hypervariable region sites formodification, alanine scanning mutagenesis can be performed to identifyhypervariable region residues contributing significantly to antigenbinding. Alternatively, or additionally, it may be beneficial to analyzea crystal structure of the antigen-antibody complex to identify contactpoints between the antibody and human HER2. Such contact residues andneighboring residues are candidates for substitution according to thetechniques elaborated herein. Once such variants are generated, thepanel of variants is subjected to screening as described herein andantibodies with superior properties in one or more relevant assays maybe selected for further development.

Another type of amino acid variant of the antibody alters the originalglycosylation pattern of the antibody. By altering is meant deleting oneor more carbohydrate moieties found in the antibody, and/or adding oneor more glycosylation sites that are not present in the antibody.

Glycosylation of antibodies is typically either N-linked or O-linked.N-linked refers to the attachment of the carbohydrate moiety to the sidechain of an asparagine residue. The tripeptide sequencesasparagine-X-serine and asparagine-X-threonine, where X is any aminoacid except proline, are the recognition sequences for enzymaticattachment of the carbohydrate moiety to the asparagine side chain.Thus, the presence of either of these tripeptide sequences in apolypeptide creates a potential glycosylation site. O-linkedglycosylation refers to the attachment of one of the sugarsN-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, mostcommonly serine or threonine, although 5-hydroxyproline or5-hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is convenientlyaccomplished by altering the amino acid sequence such that it containsone or more of the above-described tripeptide sequences (for N-linkedglycosylation sites). The alteration may also be made by the additionof, or substitution by, one or more serine or threonine residues to thesequence of the original antibody (for O-linked glycosylation sites).

Where the antibody comprises an Fc region, the carbohydrate attachedthereto may be altered. For example, antibodies with a maturecarbohydrate structure that lacks fucose attached to an Fc region of theantibody are described in US Pat Appl No US 2003/0157108 A1, Presta, L.See also US 2004/0093621 A1 (Kyowa Hakko Kogyo Co., Ltd). Antibodieswith a bisecting N-acetylglucosamine (GlcNAc) in the carbohydrateattached to an Fc region of the antibody are referenced in WO03/011878,Jean-Mairet et al. and U.S. Pat. No. 6,602,684, Umana et al. Antibodieswith at least one galactose residue in the oligosaccharide attached toan Fc region of the antibody are reported in WO97/30087, Patel et al.See, also, WO98/58964 (Raju, S.) and WO99/22764 (Raju, S.) concerningantibodies with altered carbohydrate attached to the Fc region thereof.

It may be desirable to modify the antibody of the invention with respectto effector function, e.g. so as to enhance antigen-dependentcell-mediated cyotoxicity (ADCC) and/or complement dependentcytotoxicity (CDC) of the antibody. This may be achieved by introducingone or more amino acid substitutions in an Fc region of the antibody.Alternatively or additionally, cysteine residue(s) may be introduced inthe Fc region, thereby allowing interchain disulfide bond formation inthis region. The homodimeric antibody thus generated may have improvedinternalization capability and/or increased complement-mediated cellkilling and antibody-dependent cellular cytotoxicity (ADCC). See Caronet al., J. Exp Med. 176:1191-1195 (1992) and Shopes, B. J. Immunol.148:2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumoractivity may also be prepared using heterobifunctional cross-linkers asdescribed in Wolff et al. Cancer Research 53:2560-2565 (1993).Alternatively, an antibody can be engineered which has dual Fc regionsand may thereby have enhanced complement lysis and ADCC capabilities.See Stevenson et al. Anti-Cancer Drug Design 3:219-230 (1989).

WO00/42072 (Presta, L.) describes antibodies with improved ADCC functionin the presence of human effector cells, where the antibodies compriseamino acid substitutions in the Fc region thereof. Preferably, theantibody with improved ADCC comprises substitutions at positions 298,333, and/or 334 of the Fc region (Eu numbering of residues). Preferablythe altered Fc region is a human IgG1 Fc region comprising or consistingof substitutions at one, two or three of these positions. Suchsubstitutions are optionally combined with substitution(s) whichincrease Clq binding and/or CDC.

Antibodies with altered Clq binding and/or complement dependentcytotoxicity (CDC) are described in WO99/51642, U.S. Pat. No.6,194,551B1, U.S. Pat. No. 6,242,195B1, U.S. Pat. No. 6,528,624B1 andU.S. Pat. No. 6,538,124 (Idusogie et al.). The antibodies comprise anamino acid substitution at one or more of amino acid positions 270, 322,326, 327, 329, 313, 333 and/or 334 of the Fc region thereof (Eunumbering of residues).

To increase the serum half life of the antibody, one may incorporate asalvage receptor binding epitope into the antibody (especially anantibody fragment) as described in U.S. Pat. No. 5,739,277, for example.As used herein, the term “salvage receptor binding epitope” refers to anepitope of the Fc region of an IgG molecule (e.g., IgG₁, IgG₂, IgG₃, orIgG₄) that is responsible for increasing the in vivo serum half-life ofthe IgG molecule.

Antibodies with improved binding to the neonatal Fc receptor (FcRn), andincreased half-lives, are described in WO00/42072 (Presta, L.) andUS2005/0014934A1 (Hinton et al.). These antibodies comprise an Fc regionwith one or more substitutions therein which improve binding of the Fcregion to FcRn. For example, the Fc region may have substitutions at oneor more of positions 238, 250, 256, 265, 272, 286, 303, 305, 307, 311,312, 314, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424, 428 or434 (Eu numbering of residues). The preferred Fc region-comprisingantibody variant with improved FcRn binding comprises amino acidsubstitutions at one, two or three of positions 307, 380 and 434 of theFc region thereof (Eu numbering of residues).

Engineered antibodies with three or more (preferably four) functionalantigen binding sites are also contemplated (US Appln No. US2002/0004587A1, Miller et al.).

Nucleic acid molecules encoding amino acid sequence variants of theantibody are prepared by a variety of methods known in the art. Thesemethods include, but are not limited to, isolation from a natural source(in the case of naturally occurring amino acid sequence variants) orpreparation by oligonucleotide-mediated (or site-directed) mutagenesis,PCR mutagenesis, and cassette mutagenesis of an earlier prepared variantor a non-variant version of the antibody.

(viii) Screening for Antibodies with the Desired Properties

Techniques for generating antibodies have been described above. One mayfurther select antibodies with certain biological characteristics, asdesired.

To identify an antibody which blocks ligand activation of a HERreceptor, the ability of the antibody to block HER ligand binding tocells expressing the HER receptor (e.g. in conjugation with another HERreceptor with which the HER receptor of interest forms a HERhetero-oligomer) may be determined. For example, cells naturallyexpressing, or transfected to express, HER receptors of the HERhetero-oligomer may be incubated with the antibody and then exposed tolabeled HER ligand. The ability of the antibody to block ligand bindingto the HER receptor in the HER hetero-oligomer may then be evaluated.

For example, inhibition of HRG binding to MCF7 breast tumor cell linesby HER2 antibodies may be performed using monolayer MCF7 cultures on icein a 24-well-plate format essentially as described in U.S. Pat. No.6,949,245. HER2 monoclonal antibodies may be added to each well andincubated for 30 minutes. 125I-labeled rHRGβ1177-224 (25 pm) may then beadded, and the incubation may be continued for 4 to 16 hours. Doseresponse curves may be prepared and an IC50 value may be calculated forthe antibody of interest. In one embodiment, the antibody which blocksligand activation of a HER receptor will have an IC50 for inhibiting HRGbinding to MCF7 cells in this assay of about 50 nM or less, morepreferably 10 nM or less. Where the antibody is an antibody fragmentsuch as a Fab fragment, the IC50 for inhibiting HRG binding to MCF7cells in this assay may, for example, be about 100 nM or less, morepreferably 50 nM or less.

Alternatively, or additionally, the ability of an antibody to block HERligand-stimulated tyrosine phosphorylation of a HER receptor present ina HER hetero-oligomer may be assessed. For example, cells endogenouslyexpressing the HER receptors or transfected to expressed them may beincubated with the antibody and then assayed for HER ligand-dependenttyrosine phosphorylation activity using an anti-phosphotyrosinemonoclonal (which is optionally conjugated with a detectable label). Thekinase receptor activation assay described in U.S. Pat. No. 5,766,863 isalso available for determining HER receptor activation and blocking ofthat activity by an antibody.

In one embodiment, one may screen for an antibody which inhibits HRGstimulation of p180 tyrosine phosphorylation in MCF7 cells essentiallyas described in U.S. Pat. No. 6,949,245. For example, the MCF7 cells maybe plated in 24-well plates and monoclonal antibodies to HER2 may beadded to each well and incubated for 30 minutes at room temperature;then rHRGβ₁₁₇₇₋₂₄₄ may be added to each well to a final concentration of0.2 nM, and the incubation may be continued for 8 minutes. Media may beaspirated from each well, and reactions may be stopped by the additionof 100 μl of SDS sample buffer (5% SDS, 25 mM DTT, and 25 mM Tris-HCl,pH 6.8). Each sample (25 μl) may be electrophoresed on a 4-12% gradientgel (Novex) and then electrophoretically transferred to polyvinylidenedifluoride membrane. Antiphosphotyrosine (at 1 μg/ml) immunoblots may bedeveloped, and the intensity of the predominant reactive band atM_(r)−180,000 may be quantified by reflectance densitometry. Theantibody selected will preferably significantly inhibit HRG stimulationof p180 tyrosine phosphorylation to about 0-35% of control in thisassay. A dose-response curve for inhibition of HRG stimulation of p180tyrosine phosphorylation as determined by reflectance densitometry maybe prepared and an IC₅₀ for the antibody of interest may be calculated.In one embodiment, the antibody which blocks ligand activation of a HERreceptor will have an IC₅₀ for inhibiting HRG stimulation of p180tyrosine phosphorylation in this assay of about 50 nM or less, morepreferably 10 nM or less. Where the antibody is an antibody fragmentsuch as a Fab fragment, the IC₅₀ for inhibiting HRG stimulation of p180tyrosine phosphorylation in this assay may, for example, be about 100 nMor less, more preferably 50 nM or less.

One may also assess the growth inhibitory effects of the antibody onMDA-MB-175 cells, e.g, essentially as described in Schaefer et al.Oncogene 15:1385-1394 (1997). According to this assay, MDA-MB-175 cellsmay be treated with a HER2 monoclonal antibody (10 μg/mL) for 4 days andstained with crystal violet. Incubation with a HER2 antibody may show agrowth inhibitory effect on this cell line similar to that displayed bymonoclonal antibody 2C4. In a further embodiment, exogenous HRG will notsignificantly reverse this inhibition. Preferably, the antibody will beable to inhibit cell proliferation of MDA-MB-175 cells to a greaterextent than monoclonal antibody 4D5 (and optionally to a greater extentthan monoclonal antibody 7F3), both in the presence and absence ofexogenous HRG.

To identify growth inhibitory HER2 antibodies, one may screen forantibodies which inhibit the growth of cancer cells which overexpressHER2. In one embodiment, the growth inhibitory antibody of choice isable to inhibit growth of SK-BR-3 cells in cell culture by about 20-100%and preferably by about 50-100% at an antibody concentration of about0.5 to 30 μg/ml. To identify such antibodies, the SK-BR-3 assaydescribed in U.S. Pat. No. 5,677,171 can be performed. According to thisassay, SK-BR-3 cells are grown in a 1:1 mixture of F12 and DMEM mediumsupplemented with 10% fetal bovine serum, glutamine and penicillinstreptomycin. The SK-BR-3 cells are plated at 20,000 cells in a 35 mmcell culture dish (2 mls/35 mm dish). 0.5 to 30 μg/ml of the HER2antibody is added per dish. After six days, the number of cells,compared to untreated cells are counted using an electronic COULTER™cell counter. Those antibodies which inhibit growth of the SK-BR-3 cellsby about 20-100% or about 50-100% may be selected as growth inhibitoryantibodies. See U.S. Pat. No. 5,677,171 for assays for screening forgrowth inhibitory antibodies, such as 4D5 and 3E8.

In order to select for antibodies which induce apoptosis, an annexinbinding assay using BT474 cells is available. The BT474 cells arecultured and seeded in dishes as discussed in the preceding paragraph.The medium is then removed and replaced with fresh medium alone ormedium containing 10 μg/ml of the monoclonal antibody. Following a threeday incubation period, monolayers are washed with PBS and detached bytrypsinization. Cells are then centrifuged, resuspended in Ca²⁺ bindingbuffer and aliquoted into tubes as discussed above for the cell deathassay. Tubes then receive labeled annexin (e.g. annexin V-FTIC) (1μg/ml). Samples may be analyzed using a FACSCAN™ flow cytometer andFACSCONVERT™ CellQuest software (Becton Dickinson). Those antibodieswhich induce statistically significant levels of annexin bindingrelative to control are selected as apoptosis-inducing antibodies. Inaddition to the annexin binding assay, a DNA staining assay using BT474cells is available. In order to perform this assay, BT474 cells whichhave been treated with the antibody of interest as described in thepreceding two paragraphs are incubated with 9 μg/ml HOECHST 33342™ for 2hr at 37° C., then analyzed on an EPICS ELITE™ flow cytometer (CoulterCorporation) using MODFIT LT™ software (Verity Software House).Antibodies which induce a change in the percentage of apoptotic cellswhich is 2 fold or greater (and preferably 3 fold or greater) thanuntreated cells (up to 100% apoptotic cells) may be selected aspro-apoptotic antibodies using this assay. See WO98/17797 for assays forscreening for antibodies which induce apoptosis, such as 7C2 and 7F3.

To screen for antibodies which bind to an epitope on HER2 bound by anantibody of interest, a routine cross-blocking assay such as thatdescribed in Antibodies, A Laboratory Manual, Cold Spring HarborLaboratory, Ed Harlow and David Lane (1988), can be performed to assesswhether the antibody cross-blocks binding of an antibody, such as 2C4 orpertuzumab, to HER2. Alternatively, or additionally, epitope mapping canbe performed by methods known in the art and/or one can study theantibody-HER2 structure (Franklin et al. Cancer Cell 5:317-328 (2004))to see what domain(s) of HER2 is/are bound by the antibody.

(ix) Pertuzumab Compositions

In one embodiment of a HER2 antibody composition, the compositioncomprises a mixture of a main species pertuzumab antibody and one ormore variants thereof. The preferred embodiment herein of a pertuzumabmain species antibody is one comprising the variable light and variableheavy amino acid sequences in SEQ ID Nos. 3 and 4, and most preferablycomprising a light chain amino acid sequence of SEQ ID No. 7, and aheavy chain amino acid sequence of SEQ ID No. 8 (including deamidatedand/or oxidized variants of those sequences). In one embodiment, thecomposition comprises a mixture of the main species pertuzumab antibodyand an amino acid sequence variant thereof comprising an amino-terminalleader extension. Preferably, the amino-terminal leader extension is ona light chain of the antibody variant (e.g. on one or two light chainsof the antibody variant). The main species HER2 antibody or the antibodyvariant may be an full length antibody or antibody fragment (e.g. Fab ofF(ab=)2 fragments), but preferably both are full length antibodies. Theantibody variant herein may comprise an amino-terminal leader extensionon any one or more of the heavy or light chains thereof. Preferably, theamino-terminal leader extension is on one or two light chains of theantibody. The amino-terminal leader extension preferably comprises orconsists of VHS-. Presence of the amino-terminal leader extension in thecomposition can be detected by various analytical techniques including,but not limited to, N-terminal sequence analysis, assay for chargeheterogeneity (for instance, cation exchange chromatography or capillaryzone electrophoresis), mass spectrometry, etc. The amount of theantibody variant in the composition generally ranges from an amount thatconstitutes the detection limit of any assay (preferably N-terminalsequence analysis) used to detect the variant to an amount less than theamount of the main species antibody. Generally, about 20% or less (e.g.from about 1% to about 15%, for instance from 5% to about 15%) of theantibody molecules in the composition comprise an amino-terminal leaderextension. Such percentage amounts are preferably determined usingquantitative N-terminal sequence analysis or cation exchange analysis(preferably using a high-resolution, weak cation-exchange column, suchas a PROPAC WCX-10™ cation exchange column). Aside from theamino-terminal leader extension variant, further amino acid sequencealterations of the main species antibody and/or variant arecontemplated, including but not limited to an antibody comprising aC-terminal lysine residue on one or both heavy chains thereof, adeamidated antibody variant, etc.

Moreover, the main species antibody or variant may further compriseglycosylation variations, non-limiting examples of which includeantibody comprising a G1 or G2 oligosaccharide structure attached to theFc region thereof, antibody comprising a carbohydrate moiety attached toa light chain thereof (e.g. one or two carbohydrate moieties, such asglucose or galactose, attached to one or two light chains of theantibody, for instance attached to one or more lysine residues),antibody comprising one or two non-glycosylated heavy chains, orantibody comprising a sialidated oligosaccharide attached to one or twoheavy chains thereof etc.

The composition may be recovered from a genetically engineered cellline, e.g. a Chinese Hamster Ovary (CHO) cell line expressing the HER2antibody, or may be prepared by peptide synthesis.

(x) Trastuzumab Compositions

The trastuzumab composition generally comprises a mixture of a mainspecies antibody (comprising light and heavy chain sequences of SEQ IDNOS: 9 and 10, respectively), and variant forms thereof, in particularacidic variants (including deamidated variants). Preferably, the amountof such acidic variants in the composition is less than about 25%. See,U.S. Pat. No. 6,339,142. See, also, Harris et al., J. Chromatography, B752:233-245 (2001) concerning forms of trastuzumab resolvable bycation-exchange chromatography, including Peak A (Asn30 deamidated toAsp in both light chains); Peak B (Asn55 deamidated to isoAsp in oneheavy chain); Peak 1 (Asn30 deamidated to Asp in one light chain); Peak2 (Asn30 deamidated to Asp in one light chain, and Asp102 isomerized toisoAsp in one heavy chain); Peak 3 (main peak form, or main speciesantibody); Peak 4 (Asp102 isomerized to isoAsp in one heavy chain); andPeak C (Asp102 succinimide (Asu) in one heavy chain). Such variant formsand compositions are included in the invention herein.

(xi) Immunoconjugates

The invention also pertains to immunoconjugates comprising an antibodyconjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin(e.g. a small molecule toxin or an enzymatically active toxin ofbacterial, fungal, plant or animal origin, including fragments and/orvariants thereof), or a radioactive isotope (i.e., a radioconjugate).

Chemotherapeutic agents useful in the generation of suchimmunoconjugates have been described above. Conjugates of an antibodyand one or more small molecule toxins, such as a calicheamicin, amaytansine (U.S. Pat. No. 5,208,020), a trichothene, and CC1065 are alsocontemplated herein.

In one preferred embodiment of the invention, the antibody is conjugatedto one or more maytansine molecules (e.g. about 1 to about 10 maytansinemolecules per antibody molecule). Maytansine may, for example, beconverted to May-SS-Me which may be reduced to May-SH3 and reacted withmodified antibody (Chari et al. Cancer Research 52: 127-131 (1992)) togenerate a maytansinoid-antibody immunoconjugate.

Another immunoconjugate of interest comprises an antibody conjugated toone or more calicheamicin molecules. The calicheamicin family ofantibiotics are capable of producing double-stranded DNA breaks atsub-picomolar concentrations. Structural analogues of calicheamicinwhich may be used include, but are not limited to, γ₁ ^(I), α₂ ^(I), α₃^(I), N-acetyl-γ₁ ^(I), PSAG and θ^(I) ₁ (Hinman et al. Cancer Research53: 3336-3342 (1993) and Lode et al. Cancer Research 58: 2925-2928(1998)). See, also, U.S. Pat. Nos. 5,714,586; 5,712,374; 5,264,586; and5,773,001 expressly incorporated herein by reference.

Enzymatically active toxins and fragments thereof which can be usedinclude diphtheria A chain, nonbinding active fragments of diphtheriatoxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain,abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordiiproteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII,and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonariaofficinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin,enomycin and the tricothecenes. See, for example, WO 93/21232 publishedOct. 28, 1993.

The present invention further contemplates an immunoconjugate formedbetween an antibody and a compound with nucleolytic activity (e.g. aribonuclease or a DNA endonuclease such as a deoxyribonuclease; DNase).

A variety of radioactive isotopes are available for the production ofradioconjugated HER2 antibodies. Examples include At²¹¹, I¹³¹, I¹²⁵,Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³² and radioactive isotopes of Lu.

Conjugates of the antibody and cytotoxic agent may be made using avariety of bifunctional protein coupling agents such asN-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP),succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate,iminothiolane (IT), bifunctional derivatives of imidoesters (such asdimethyl adipimidate HCL), active esters (such as disuccinimidylsuberate), aldehydes (such as glutareldehyde), bis-azido compounds (suchas bis(p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (suchas bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin canbe prepared as described in Vitetta et al. Science 238: 1098 (1987).Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent forconjugation of radionucleotide to the antibody. See WO94/11026. Thelinker may be a Acleavable linker@ facilitating release of the cytotoxicdrug in the cell. For example, an acid-labile linker,peptidase-sensitive linker, dimethyl linker or disulfide-containinglinker (Chari et al. Cancer Research 52: 127-131 (1992)) may be used.

Alternatively, a fusion protein comprising the antibody and cytotoxicagent may be made, e.g. by recombinant techniques or peptide synthesis.

Other immunoconjugates are contemplated herein. For example, theantibody may be linked to one of a variety of nonproteinaceous polymers,e.g., polyethylene glycol, polypropylene glycol, polyoxyalkylenes, orcopolymers of polyethylene glycol and polypropylene glycol. The antibodyalso may be entrapped in microcapsules prepared, for example, bycoacervation techniques or by interfacial polymerization (for example,hydroxymethylcellulose or gelatin-microcapsules andpoly-(methylmethacylate) microcapsules, respectively), in colloidal drugdelivery systems (for example, liposomes, albumin microspheres,microemulsions, nano-particles and nanocapsules), or in macroemulsions.Such techniques are disclosed in Remington's Pharmaceutical Sciences,16th edition, Oslo, A., Ed., (1980).

The antibodies disclosed herein may also be formulated asimmunoliposomes. Liposomes containing the antibody are prepared bymethods known in the art, such as described in Epstein et al., Proc.Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al., Proc. Natl. Acad.Sci. USA, 77:4030 (1980); U.S. Pat. Nos. 4,485,045 and 4,544,545; andWO97/38731 published Oct. 23, 1997. Liposomes with enhanced circulationtime are disclosed in U.S. Pat. No. 5,013,556.

Particularly useful liposomes can be generated by the reverse phaseevaporation method with a lipid composition comprisingphosphatidylcholine, cholesterol and PEG-derivatizedphosphatidylethanolamine (PEG-PE). Liposomes are extruded throughfilters of defined pore size to yield liposomes with the desireddiameter. Fab′ fragments of the antibody of the present invention can beconjugated to the liposomes as described in Martin et al. J. Biol. Chem.257: 286-288 (1982) via a disulfide interchange reaction. Achemotherapeutic agent is optionally contained within the liposome. SeeGabizon et al. J. National Cancer Inst. 81(19)1484 (1989).

(xii) Docetaxel

Docetaxel is an anti-neoplastic agent that binds to free tubulin andpromotes the assembly of tubulin into stable microtubules whilesimultaneously inhibiting their assembly. This leads to the productionof microtubule bundles without normal function and to the stabilizationof microtubules, blocking cells in the M-phase of the cell cycle andleading to cell death.

III. Selecting Patients for Therapy

The present invention concerns the treatment of patients who haveHER2-positive metastatic breast cancer and have not received priorchemotherapy or biologic therapy (including approved or investigationaltyrosine kinase/HER inhibitors or vaccines) for their metastaticdisease. Patient could have received one prior hormonal treatment formetastatic breast cancer. Patients may have received systemic breastcancer treatment in the neo-adjuvant or adjuvant setting, provided thatthe patient has experienced a disease-free interval (DFI) of ≧12 monthsfrom completion of adjuvant systemic treatment (excluding hormonaltherapy) to metastatic diagnosis. Patients may have received trastuzumaband/or a taxane during the neo-adjuvant or adjuvant treatment.

Detection of HER2 protein overexpression is important for selection ofpatients for treatment in accordance with the present invention. SeveralFDA-approved commercial assays are available to identify breast cancerpatients whose cancer overexpresses HER2. These methods includeHERCEPTEST™ (Dako) and PATHWAY® HER-2/neu (immunohistochemistry (IHC)assays) and PathVysion® and HER2FISH pharmDx™ (FISH assays). Usersshould refer to the package inserts of specific assay kits forinformation on the validation and performance of each assay.

For example, HER2 overexpression may be analyzed by IHC, e.g. using theHERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumorbiopsy may be subjected to the IHC assay and accorded a HER2 proteinstaining intensity criteria as follows:

Score 0 no staining is observed or membrane staining is observed in lessthan 10% of tumor cells.

Score 1+ a faint/barely perceptible membrane staining is detected inmore than 10% of the tumor cells. The cells are only stained in part oftheir membrane.

Score 2+ a weak to moderate complete membrane staining is observed inmore than 10% of the tumor cells.

Score 3+ a moderate to strong complete membrane staining is observed inmore than 10% of the tumor cells.

Those tumors with 0 or 1+ scores for HER2 overexpression assessment maybe characterized as not overexpressing HER2, whereas those tumors with2+ or 3+ scores may be characterized as overexpressing HER2.

Tumors overexpressing HER2 may be rated by immunohistochemical scorescorresponding to the number of copies of HER2 molecules expressed percell, and can been determined biochemically:

0=0-10,000 copies/cell,

1+=at least about 200,000 copies/cell,

2+=at least about 500,000 copies/cell,

3+=at least about 2,000,000 copies/cell.

Overexpression of HER2 at the 3+ level, which leads toligand-independent activation of the tyrosine kinase (Hudziak et al.,Proc. Natl. Acad. Sci. USA, 84:7159-7163 (1987)), occurs inapproximately 30% of breast cancers, and in these patients, relapse-freesurvival and overall survival are diminished (Slamon et al., Science,244:707-712 (1989); Slamon et al., Science, 235:177-182 (1987)).

The presence of HER2 protein overexpression and gene amplification arehighly correlated, therefore, alternatively, or additionally, the use ofFISH assays to detect gene amplification may also be employed forselection of patients appropriate for treatment in accordance with thepresent invention. FISH assays such as the INFORM™ (sold by Ventana,Arizona) or PathVysion® (Vysis, Illinois) may be carried out onformalin-fixed, paraffin-embedded tumor tissue to determine the extent(if any) of HER2 amplification in the tumor.

Most commonly, HER2-positive status is confirmed using archivalparaffin-embedded tumor tissue, using any of the foregoing methods.

Preferably, HER2-positive patients having a 3+ IHC score or a ≧2.0 FISHamplification ratio are selected for treatment in accordance with thepresent invention.

IV. Pharmaceutical Formulations

Therapeutic formulations of the HER2 antibodies used in accordance withthe present invention are prepared for storage by mixing an antibodyhaving the desired degree of purity with optional pharmaceuticallyacceptable carriers, excipients or stabilizers (Remington'sPharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), generally inthe form of lyophilized formulations or aqueous solutions. Antibodycrystals are also contemplated (see US Pat Appln 2002/0136719).Acceptable carriers, excipients, or stabilizers are nontoxic torecipients at the dosages and concentrations employed, and includebuffers such as phosphate, citrate, and other organic acids;antioxidants including ascorbic acid and methionine; preservatives (suchas octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride;benzalkonium chloride, benzethonium chloride; phenol, butyl or benzylalcohol; alkyl parabens such as methyl or propyl paraben; catechol;resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecularweight (less than about 10 residues) polypeptides; proteins, such asserum albumin, gelatin, or immunoglobulins; hydrophilic polymers such aspolyvinylpyrrolidone; amino acids such as glycine, glutamine,asparagine, histidine, arginine, or lysine; monosaccharides,disaccharides, and other carbohydrates including glucose, mannose, ordextrins; chelating agents such as EDTA; sugars such as sucrose,mannitol, trehalose or sorbitol; salt-forming counter-ions such assodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionicsurfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).Lyophilized antibody formulations are described in WO 97/04801,expressly incorporated herein by reference.

Lyophilized antibody formulations are described in U.S. Pat. Nos.6,267,958, 6,685,940 and 6,821,515, expressly incorporated herein byreference. The preferred HERCEPTIN® (trastuzumab) formulation is asterile, white to pale yellow preservative-free lyophilized powder forintravenous (IV) administration, comprising 440 mg trastuzumab, 400 mg.alphaα,α-trehalose dihyrate, 9.9 mg L-histidine-HCl, 6.4 mgL-histidine, and 1.8 mg polysorbate 20, USP. Reconsitution of 20 mL ofbacteriostatic water for injection (BWFI), containing 1.1% benzylalcohol as a preservative, yields a multi-dose solution containing 21mg/mL trastuzumab, at pH of approximately 6.0. For further details, seethe trastuzumab prescribing information.

The preferred pertuzumab formulation for therapeutic use comprises 30mg/mL pertuzumab in 20 mM histidine acetate, 120 mM sucrose, 0.02%polysorbate 20, at pH 6.0. An alternate pertuzumab formulation comprises25 mg/mL pertuzumab, 10 mM histidine-HCl buffer, 240 mM sucrose, 0.02%polysorbate 20, pH 6.0.

The formulation of the placebo used in the clinical trials described inthe Examples is equivalent to pertuzumab, without the active agent.

The formulation herein may also contain more than one active compound asnecessary for the particular indication being treated, preferably thosewith complementary activities that do not adversely affect each other.Various drugs which can be combined with the HER dimerization inhibitorare described in the Method Section below. Such molecules are suitablypresent in combination in amounts that are effective for the purposeintended.

The active ingredients may also be entrapped in microcapsules prepared,for example, by coacervation techniques or by interfacialpolymerization, for example, hydroxymethylcellulose orgelatin-microcapsules and poly-(methylmethacylate) microcapsules,respectively, in colloidal drug delivery systems (for example,liposomes, albumin microspheres, microemulsions, nano-particles andnanocapsules) or in macroemulsions. Such techniques are disclosed inRemington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

Sustained-release preparations may be prepared. Suitable examples ofsustained-release preparations include semipermeable matrices of solidhydrophobic polymers containing the antibody, which matrices are in theform of shaped articles, e.g. films, or microcapsules. Examples ofsustained-release matrices include polyesters, hydrogels (for example,poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides(U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradablelactic acid-glycolic acid copolymers such as the LUPRON DEPOT™(injectable microspheres composed of lactic acid-glycolic acid copolymerand leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid.

The formulations to be used for in vivo administration must be sterile.This is readily accomplished by filtration through sterile filtrationmembranes.

V. Treatment Methods

The treatment methods of the present invention comprise, consistessentially of, or consist of the administration of a growth inhibitoryHER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In aparticular embodiment, the treatment methods of the present inventioncomprise, consist essentially of, or consist of the administration of anantibody binding essentially to epitope 2C4, a HER2 antibody bindingessentially to epitope 4D5, and a taxane to HER2 positive metastaticbreast cancer patients as hereinabove defined, who did not receive priorchemotherapy or biologic therapy for their metastatic disease. In apreferred embodiment, the treatment comprises, consists essentially ofor consists of treatment with pertuzumab+trastuzumab+docetaxel. Thetreatment methods herein may result in a synergistic, or greater thanadditive, therapeutic benefit to the patient.

Therapy in accordance with the present invention extendsprogression-free survival (PFS) and/or overall survival (OS) of thepatient treatment. In one embodiment, the treatment extends PFS or OS atleast about 5%, or at least about 10%, or at least about 15% or at leastabout 20%, or at least about 25% more than PFS or OS achieved byadministering trastuzumab+docetaxel to the metastatic breast cancerpatient to be treated.

Antibodies binding essentially to epitope 2C4 specifically include,without limitation, rhuMAb 2C4 (pertuzumab). Antibodies bindingessentially to epitope 4D5 specifically include, without limitation,huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6,huMAb4D5-7 and huMAb4D5-8 (trastuzumab).

The antibodies and taxane, such as pertuzumab, trastuzumab, anddocetaxel are administered to a human patient in accord with knownmethods, such as intravenous administration, e.g., as a bolus or bycontinuous infusion over a period of time, by intramuscular,intraperitoneal, intracerobrospinal, subcutaneous, intra-articular,intrasynovial, intrathecal, oral, topical, or inhalation routes. Forantibodies, Intravenous administration is preferred.

According to one preferred embodiment of the invention, a fixed dose ofHER dimerization inhibitor (e.g. pertuzumab) of approximately 840 mg(loading dose) is administered, followed by one or more doses ofapproximately 420 mg (maintenance dose(s)) of the antibody. Themaintenance doses are preferably administered about every 3 weeks, for atotal of at least two doses, until radiographic or clinical progressivedisease, or unmanageable toxicity, preferably up to 17 or more doses.

The growth inhibitory HER2 antibody preferably is trastuzumab, whichtypically is administered as an intravenous loading dose of about 8mg/kg, followed by the administration of 6 mg/kg doses in subsequentcycles. Trastuzumab is typically administered every 3 weeks untilradiographic or clinical progressive disease or unmanageable toxicity,preferably up to 17 or more doses.

The taxane preferably is docetaxel, which is typically administered asan IV dose of 75 mg/m² every 3 weeks for at least 6 cycles untilradiographic or clinical progressive disease or unmanageable toxicity.

The HER2 antibodies preferably are administered as naked antibodies.However, the inhibitor administered may be conjugated with a cytotoxicagent. Preferably, the conjugated inhibitor and/or antigen to which itis bound is/are internalized by the cell, resulting in increasedtherapeutic efficacy of the conjugate in killing the cancer cell towhich it binds. In a preferred embodiment, the cytotoxic agent targetsor interferes with nucleic acid in the cancer cell. Examples of suchcytotoxic agents include maytansinoids, calicheamicins, ribonucleasesand DNA endonucleases.

In one embodiment, treatment starts with the administration ofpertuzumab, or HER2 dimerization inhibitor antibody, followed byadministration of trastuzumab or another growth inhibitory HER2 antibodyand a taxane, e.g. docetaxel, on the following day. In anotherembodiment, treatment starts with trastuzumab, or another growthinhibitory HER2 antibody, followed by the administration of pertuzumab,or another HER2 dimerization inhibitor antibody, and a taxane, e.g.docetaxel. In yet another embodiment, all three agents are administeredon the same day, in any order.

The dosages and treatment protocols described herein are for informationpurposes only, and can be altered by a skilled physician consideringfactors specific to the patient and cancer to be treated, such as thepatient's age, weight, overall physical condition, treatment history,the severity and type of the breast cancer to be treated, the extent andnature of the metastasis, and the like.

VI. Deposit of Materials

The following hybridoma cell lines have been deposited with the AmericanType Culture Collection, 10801 University Boulevard, Manassas, Va.20110-2209, USA (ATCC):

Antibody Designation ATCC No. Deposit Date 7C2 ATCC HB-12215 Oct. 17,1996 7F3 ATCC HB-12216 Oct. 17, 1996 4D5 ATCC CRL 10463 May 24, 1990 2C4ATCC HB-12697 Apr. 8, 1999

These deposits were made under the provisions of the Budapest Treaty onthe International Recognition of the Deposit of Microorganisms for thePurpose of Patent Procedure and the Regulations thereunder (BudapestTreaty). This assures maintenance of a viable culture of the deposit for30 years from the date of deposit. The deposits will be made availableby ATCC under the terms of the Budapest Treaty, and subject to anagreement between Genentech, Inc. and ATCC, which assures that allrestrictions imposed by the depositor on the availability to the publicof the deposited material will be irrevocably removed upon the grantingof the pertinent U.S. patent, assures permanent and unrestrictedavailability of the progeny of the culture of the deposit to the publicupon issuance of the pertinent U.S. patent or upon laying open to thepublic of any U.S. or foreign patent application, whichever comes first,and assures availability of the progeny to one determined by the U.S.Commissioner of Patents and Trademarks to be entitled thereto accordingto 35 USC §122 and the Commissioner's rules pursuant thereto (including37 CFR §1.14 with particular reference to 8860G 638).

Further details of the invention are illustrated by the followingnon-limiting Examples. The disclosures of all citations in thespecification are expressly incorporated herein by reference.

Glossary of abbreviations:

FACT-B Functional Assessment of Cancer Therapy-Breast

FFPE Formalin-fixed paraffin-embedded

FISH Fluorescence in situ hybridization

GGT Gamma-glutamyl transferase

ICH International Conference on harmonization

IHC Immunohistochemistry

ITT Intent to treat

IV Intravenous

JVP Jugular Venous Pressure

LDH Lactate dehydrogenase

LLN Lower limit of normal

MBC Metastatic breast cancer

MRI Magnetic resonance imaging

NCI-CTC National Cancer Institute Common Toxicity Criteria

NCI-CTCAE National Cancer Institute Common Terminology Criteria forAdverse Events

ORR Objective response rate

OS Overall survival

PD Progressive disease

PFS Progression-free survival

PK Pharmacokinetic

PR Partial response

PS Performance status

aRTT Activated partial thromboplastin time

RECIST Response Evaluation Criteria in Solid Tumors

SAE Serious adverse event

SD Stable disease

TOI-PFB Trial Outcome Index-Physician Function Breast

ULN Upper limit of normal

Example 1 Phase III Clinical Study to Evaluate the Efficacy and Safetyof Pertuzumab+Trastuzumab+Docetaxel Treatment of Previously UntreatedMetastatic Breast Cancer

Primary Objectives

The primary objective of this study is to compare progression-freesurvival (PFS) based on tumor assessments by an independent reviewfacility (IRF) between patients in two treatment arms:

placebo+trastuzumab+docetaxel vs. pertuzumab+trastuzumab+docetaxel.

Secondary Objectives

-   -   To compare overall survival (OS) between the two arms    -   To compare PFS between the two treatment arms based upon        investigator assessment of progression    -   To compare the overall objective response rate between the two        treatment arms    -   To compare the duration of objective response between the two        treatment arms    -   To compare the safety profile between the two treatment arms    -   To compare time to symptom progression, as assessed by the FACT        Trial Outcome Index-Physical Functional Breast (TOI-PFB)    -   To evaluate if biomarkers from tumor tissues or blood samples        (e.g., HER3 expression, Fcγ, and serum ECD/HER2 and/or HER        ligands concentrations) correlate with clinical outcomes.

Target Population

The study enrolls 800 patients from approximately 250 sites worldwide.The study population is patients with HER2-positive metastatic breastcancer (MBC) who have not previously been treated with chemotherapyand/or biologic therapy for their MBC. Patients with Stage IV disease atinitial disease presentation as well as those who have progressedfollowing either neo-adjuvant or adjuvant therapy with a disease-freeinterval of at least 12 months are included, and they may have receivedtrastuzumab and/or taxanes in the adjuvant setting.

Investigational Drug

The investigational drug is pertuzumab in combination with trastuzumaband docetaxel, compared to the administration of placebo in combinationwith trastuzumab and docetaxel.

Blinded Pertuzumab/Placebo

Pertuzumab/placebo are administered as an IV loading dose of 840 mg forCycle I, and 420 mg for subsequent cycles. Pertuzumab/placebo areadministered every 3 weeks until investigator-assessed radiographic orclinical progressive disease, or unmanageable toxicity. Administrationmay be delayed to assess or treat adverse events such as cardiac adverseevents or mylosuppression. No dose reduction is allowed.

If the patient misses a dose of pertuzumab/placebo for 1 cycle (i.e.,the 2 sequential administration times are 6 weeks or more apart), are-loading dose of pertuzumab/placebo (840 mg) should be given. Ifre-loading is required for a given cycle, the 3 study therapies shouldbe given on the same schedule as Cycle 1, i.e., pertuzumab/placebo onDay 1, and trastuzumab and docetaxel on Day 2. Subsequent maintenancepertuzumab doses of 420 mg are then given every 3 weeks, starting 3weeks later.

Because the pertuzumab/placebo formulation does not contain apreservative, the vial seal may only be punctured once. Any remainingsolution should be discarded.

The indicated volume of pertuzumab/placebo solution should be withdrawnfrom the vials and added to a 250-cc IV bag of 0.9% sodium chlorideinjection.

Trastuzumab

Trastuzumab is administered as an IV loading does of 8 mg/kg for Cycle1, and 6 mg/kg for subsequent cycles. The dose of trastuzumab does notneed to be recalculated unless the body weight has changed by more than±10% from baseline.

Trastuzumab is administered every 3 weeks until investigator-assessedradiographic or clinical progressive disease, or unmanageable toxicity.Administration may be delayed to assessed or treat adverse events suchas cardiac adverse events or myelosuppression. No dose reduction isallowed.

If the patient misses a dose of trastuzumab for 1 cycle (i.e., the 2sequential administration times are 6 weeks or more apart), a re-loadingdose of pertuzumab/placebo (8 mg/kg) should be given. If re-loading isrequired for a given cycle, the 3 study therapies should be given on thesame schedule as Cycle 1, i.e., pertuzumab/placebo on Day 1, andtrastuzumab and docetaxel on Day 2. Subsequent maintenance trastuzumabdoses of 6 mg/kg are then given every 3 weeks, starting 3 weeks later.

For administration, each vial of trastuzumab 150 mg is reconstitutedwith 7.2 mL of Sterile Water for Injection (SWFI). This formulation doesnot contain a preservative and is suitable for single use only.

Each vial of trastuzumab 440 mg is reconstituted with 20 mL of eitherSWFI or Bacteriostatic Water for Injection (BWFI), USP, 1.1% benzylalcohol preserved, as supplied. If the trastuzumab is reconstituted withSWFI, it is suitable for single use only.

The reconstituted solution contains 21 mg/mL of trastuzumab, at a pH ofapproximately 6.0, and the appropriate calculated volume will be addedin to 250 mL of 0.9 Sodium Chloride Injection. The appropriate volume iscalculated (in mL) using the following formula:

Body Weight (in kg)×Dose (8 mg/kg for loading or 6 mg/kg formaintenance)/21 mg/mL (concentration of reconstituted solution).

Docetaxel

Docetaxel is administered as an IV dose of 75 mg/m² every 3 weeks for atleast 6 cycles until investigator-assessed radiographic or clinicalprogressive disease or unmanageable toxicity. At the discretion of thetreating physician, the docetaxel dose is increased to 100 mg/m² forpatients who tolerate at least 1 cycle without any of the followingtoxicitiesL febrile neurtopenia, Grade 4 neutropenia for >5 days or ANC<100 μL for more than 1 day, or other non-hematoloical toxicities ofGrade >2 (NCI/CTCAE, Version 3). For further details, refer to docetaxelPackage Insert.

Treatment Schedule

For the first cycle of treatment, blinded pertuzumab/placebo is given ofDay 1 over 60 minutes followed by a 60-minute observation period.Trastuzumab and docetaxel is administered on Day 2 of Cycle I using thelabeled guidelines for administration.

If the administrations of all three agents are well tolerated in Cycle1, they may be given sequentially on Day 1 in subsequent cyclesthereafter. If the subject cannot tolerate all three drugs given on thesame day, the Cycle 1 dosing schedule (pertuzumab/placebo on Day 1,trastuzumab and docetaxel on Day 2) is followed.

If one of both of the monoclonal antibody study drugs needs to bepermanently discontinued or is held for more than two cycles, thesubject is taken off the study treatment. However, if docetaxel needs tobe permanently discontinued for reasons related to toxicity, the subjectcan continue on monoclonal antibody study drugs.

Inclusion Criteria

Disease-Specific Inclusion Criteria

1. Histologically or cytologically confirmed adenocarcinoma of thebreast with locally recurrent or metastatic disease, and candidate forchemotherapy. Patients with measurable and nonmeasurable lesion areeligible.

Locally recurrent disease must not be amenable to resection withcurative intent.

Note: Patients with de-novo Stage IV disease are eligible.

2. HER2-positive (defined as 3+ IHC or FISH amplification ratio ≧2.0)MBC confirmed by a Sponsor-designated central laboratory. It is stronglyrecommended that a formalin-fixed paraffin-embedded (FFPE) tissue blockfrom the primary tumor be submitted for central laboratory confirmationof HER2 eligibility; however, if that is not possible, 25 unstained andfreshly cut slides will be submitted. (Tissue will subsequently be usedfor assessment of biomarkers.)

General Inclusion Criteria:

3. Age ≧18 years

4. Left Ventricular Ejection Fraction (LVEF) ≧50% at baseline (within 42days of randomization) as determined by either ECHO or MUGA (ECHO is thepreferred method. If the patient is randomized, the same method of LVEFassessment, ECHO or MUGA, must be used throughout the study, and to theextent possible, be obtained at the same institution). All pre-studyLVEF values during and post-trastuzumab adjuvant treatment for patientswho received such adjuvant therapy prior to enrollment into the studywill be collected.

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0or 1

6. For women of childbearing potential, agreement to use an effectiveform of contraception (patient and/or partner, e.g., surgicalsterilization, a reliable barrier method) and to continue its use forthe duration of study treatment and for 6 months after the last dose ofstudy treatment.

7. Signed, written informed consent (approved by the InstitutionalReview Board or Independent Ethics Committee) obtained prior to anystudy procedure.

Cancer-Related Exclusion Criteria

1. History of anticancer therapy for MBC (with the exception of oneprior hormonal regimen for MBC). This includes any EGFR or anti-HER2agents or vaccines, cytotoxic chemotherapy, or more than one priorhormonal regimen for MBC.

2. History of approved or investigative tyrosine kinase/HER inhibitorsfor breast cancer in any treatment setting, except trastuzumab used inthe neoadjuvant or adjuvant setting

3. History of systemic breast cancer treatment in the neo-adjuvant oradjuvant setting with a disease-free interval from completion of thesystemic treatment (excluding hormonal therapy) to metastatic diagnosisof <12 months.

4. History of persistent Grade ≧2 hematologic toxicity resulting fromprevious adjuvant therapy.

5. Current peripheral neuropathy of NCI-CTCAE, Version 3.0, Grade ≧3 atrandomization.

6. History of other malignancy within the last 5 years, except forcarcinoma in situ of the cervix or basal cell carcinoma.

7. Current clinical or radiographic evidence of central nervous system(CNS) metastases. CT or MRI scan of the brain is mandatory (within 28days of randomization) in cases of clinical suspicion of brainmetastases.

8. History of exposure to the following cumulative doses ofanthracyclines:

-   -   doxorubicin or liposomal doxorubicin >360 mg/m2    -   epirubicin >720 mg/m2    -   mitoxantrone >120 mg/m2 and idarubicin >90 mg/m2    -   Other (e.g., liposomal doxorubicin or other anthracycline >the        equivalent of 360 mg/m2 of doxorubicin)    -   If more than 1 anthracycline has been used, then the cumulative        dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.

Hematological, Biochemical, and Organ Function

9. Current uncontrolled hypertension (systolic >150 mmHg and/ordiastolic >100 mmHg) or unstable angina

10. History of CHF of any New York Heart Association (NYHA) criteria, orserious cardiac arrhythmia requiring treatment (exception, atrialfibrillation, paroxysmal supraventricular tachycardia)

11. History of myocardial infarction within 6 months of randomization

12. History of LVEF decline to below 50% during or after priortrastuzumab neo-adjuvant or adjuvant therapy

13. Current dyspnea at rest due to complications of advanced malignancy,or other diseases that require continuous oxygen therapy.

General Exclusion Criteria

14. Inadequate organ function, evidenced by the following laboratoryresults within 28 days prior to randomization:

-   -   Absolute neutrophil count <1,500 cells/mm3    -   Platelet count <100,000 cells/mm3    -   Hemoglobin <9 g/dL    -   Total bilirubin >upper limit of normal (ULN) (unless the patient        has documented Gilbert's syndrome)    -   AST (SGOT) and ALT (SGPT)>2.5×ULN    -   AST (SGOT) or ALT (SGPT)>1.5×ULN with concurrent serum alkaline        phosphatase >2.5×ULN (unless bone metastases are present)    -   Serum creatinine >2.0 mg/dL or 177 μmol/L    -   International normalized ratio (INR) and activated partial        thromboplastin time (aPTT)>1.5×ULN (unless on therapeutic        coagulation)

15. Current severe, uncontrolled systemic disease (e.g., clinicallysignificant cardiovascular, pulmonary, or metabolic disease; woundhealing disorders; ulcers; or bone fractures)

16. Major surgical procedure or significant traumatic injury within 28days prior to study treatment start or anticipation of the need formajor surgery during the course of study treatment

17. Pregnant or lactating women

18. History of receiving any investigational treatment within 28 days ofrandomization

19. Current known infection with HIV, HBV, or HCV

20. Receipt of IV antibiotics for infection within 14 days ofrandomization

21. Current chronic daily treatment with corticosteroids (dose of >10mg/day methylprednisolone equivalent) (excluding inhaled steroids)

22. Known hypersensitivity to any of the study drugs

23. Assessed by the investigator to be unable or unwilling to complywith the requirements of the protocol.

Assessments

Efficacy

The primary endpoint is PFS based on IRF evaluations. PFS is defined asthe time from randomization to the first documented radiographicalprogressive disease, as determined by the IRF using current RECIST(Therasse et al. 2000), or death from any cause, whichever occurs first.

Carcinomatous meningitis diagnosed by cytologic evaluation of cerebralspinal fluid will also define progressive disease. Medical photographywill also be allowed to monitor chest wall recurrences of subcutaneouslesions.

Overall survival is the key secondary endpoint, and is defined as thetime from the date of randomization to the date of death from any cause.

Safety

Safety outcome measures are as follows:

Incidence of Symptomatic left ventricular systolic dysfunction[Congestive Heart Failure (CHF)] and asymptomatic left ventricularejection fraction (LVEF) events

LVEF measurements over the course of the study

Incidence and severity of adverse events (AEs) and serious adverseevents (SAEs)

Laboratory test abnormalities

Pharmacokinetics/QT (Substudy)

A subset of principal investigators and patients participates in apharmacokinetic, drug-drug interaction, and QTc interval substudy asdetailed in a separate protocol (see Example 2). Separate IRB/IECapproval and Informed Consent Form will be required for participation inthe substudy.

Quality of Life/Pharmacoeconomics

Patient-Reported Outcomes Assessments: This study uses the FunctionalAssessment of Cancer Therapy-Breast (FACT-B), Version 4. The FACT-B hasa 28-item generic score for all patients, plus nine items specific tobreast cancer. Patients rate all items on a five-point scale rangingfrom “not at all” to “very much.” The FACT-B provides supplementaldomain valuative ratings or utility weights, thus providing an estimateof the relative importance of each quality of life domain to anindividual patient. The FACT-B provides a total QoL score as well asinformation about physical well-being, social/family well-being,functional well-being, and disease-specific concerns. The FACT-B hasbeen used extensively and has demonstrated reliability, validity, andsensitivity to change over time. Only female patients on this study willbe asked to complete the FACT-B questionnaire.

Pharmacoeconomic Assessments

An economic assessment comparing various costs between the two treatmentarms is conducted by evaluating hospitalizations while on studytreatment. The number of hospital visits, number of days admitted, andtype of visits (emergency room vs. inpatient care) will be collected.This information will be collected from information submitted on AE andSAE electronic case report forms (eCRFs).

Sample Collection

Archival tumor samples from the primary tumor (or metastatic sites, ifthe primary tumor is not available) are submitted from all subjectsduring screening and submitted to a central pathology laboratory forassessment of HER2 status via IHC and FISH for study eligibility, aswell as for the assessment of tumor tissue biomarkers forpertuzumab/trastuzumab response prediction. Tumor tissue samples aresubmitted in the form of either paraffin blocks or unstained, freshlycut slides containing formalin-fixed tumor tissue. Because uncontrolledoxidation processes on the slides may affect slides, tumor tissue blocksare preferred. However, if a tumor block is not available, 25 unstainedfreshly cut slides of 4 μm are submitted (the number of slides submittedmay be reduced pending on the regulatory and or IEC requirements of somecounties). The slides must be sent to the central lab within 2 days ofbeing cut. From submitted tumor blocks, at the central laboratory amaximum of 15 slides will be cut and 2 cores will be removed in order toconstruct tissue microarrays (TMAs) for later analysis. The remainingpart of the tumor block will be returned to the institution. HER2testing will be prioritized and the tissue will subsequently be used forassessment of biomarkers.

For the assessment of tumor tissue biomarkers, a variety of analysismethodologies may be used, including but not limited to, qRT-PCR, IHC,in-situ hybridization, and gene expression profiling. At the end of thecollection process, the most suitable analytical methodologies will beselected and employed.

Tissue Microarray (TMA) Construction

The tumor blocks are also used to set up a TMA: a maximum of 2 tissuecores of 1.5 mm each are taken out using a puncher and then rearrangedas an array into a block of wax. A single array may include tissue coresfrom different patients. This process protects the tissue againstoxidation and allows for long-term storage and later analysis.

For later analysis, tissue sections can be generated using the lattertissue microarray. This technology allows a high throughput (manypatient samples on one glass slide) analysis of biomarkers.

DNA/RNA Extraction

The submitted tumor blocks are used to generate sections on glass slidesfor the extraction of tumor DNA and RNA for later analysis. These slidesare prepared in a central lab to ensure the same quality for all samplesand in later studies. Note that as tumorigenesis is a multiple-stepprocess linked to somatic events, DNA analysis will focus on sporadicmutations specifically found in tumor tissue but not inherited changesfound in the whole body. For this purpose, some sections containingtumor will be taken from the block and used for the extraction process.The tumor tissue samples will be stored at the study Sponsors' facilityor a contract laboratory facility for up to 7 years after databaseclosure, at which time the samples will be destroyed.

Metastatic Tumor Tissue Samples for Biomarker Analysis (Optional)

If a biopsy of the patient's metastatic tumor tissue is available, it issubmitted from consenting patients at baseline (after the patient hasbeen determined to be eligible for the study, but before the firstadministration of study medication) for the assessment of tumor tissuebiomarkers for pertuzumab/trastuzumab response prediction.

Serum Samples for ECD/HER2 and HER Ligands Analysis

For assessment of serum biomarkers that may indicate response topertuzumab and trastuzumab, serum samples (from an approximately 5 mLblood draw) are collected at baseline (after the patient has beendetermined to be eligible for the study but before the firstadministration of study medication) and during the study at the time ofeach tumor assessment. Biomarker assessments with these samples willinclude levels of ECD/HER2, selected HER ligands, and/or markers thoughtto be important for HER family signaling or response to HER inhibitorsand HER activation. Leftovers of samples may be used for re-testing ordeveloping and validating existing and/or new diagnostic tests relatedto pertuzumab or trastuzumab, or both.

Whole Blood Sample for Fcγ Polymorphism Analysis (Clinical Genotyping)

A whole blood sample (3 mL) for assessment of Fcγ polymorphism iscollected from patients at baseline (after the patient has beendetermined to be eligible for the study but before the firstadministration of study medication). An analysis of Fcγ-receptorpolymorphism is correlated with clinical outcome in order to furtherevaluate the mechanism of action of both trastuzumab and pertuzumab.Mandatory blood collection for polymorphic analysis will be pending onthe regulatory and or IEC requirements of the individual countries.

Serum and Plasma for Biomarker Sample Repository (BSR) Research(Optional)

Blood samples for extraction of serum and plasma samples (approximately5 mL per sample) for biomarker discovery, validation, and applicationwill be collected from consenting patients. These samples are collectedat baseline (after the patient has been determined to be eligible forthe study but before the first administration of study medication) andduring the study every 9 weeks at the time of every tumor assessmentuntil IRF-determined progressive disease. If IRF-determined PD occursprior to post-treatment Week 18, BSR samples will continue to becollected every 9 weeks until posttreatment Week 18.

The collected BSR samples will be stored with the study Sponsor'sfacility or a contract laboratory facility for up to 15 years after theend of the associated study (database closure), at which time thesamples will be destroyed. These samples will be used only for researchpurposes to identify dynamic biomarkers that may be predictive ofresponse to pertuzumab and trastuzumab treatment (in terms of dose,safety, tolerability, and efficacy) and will help to better understandthe pathogenesis, course, and outcome of breast cancer and relateddiseases and adverse events.

The collected blood samples may be used to develop and validatediagnostic assays and allow the generation of statistically meaningfulbiomarker data related to HER2-positive breast cancer disease orresponse to pertuzumab and/or trastuzumab. Since the identification ofnew markers that correlate with disease activity and the efficacy orsafety of treatment is rapidly developing, the definitive list ofanalyses remains to be determined.

Study Duration

Patients remain in the treatment phase of the study untilinvestigator-assessed radiographic or clinical progressive disease,unmanageable toxicity, or study termination by the Sponsors. Patientswill not receive open-label pertuzumab after discontinuation from studytreatment. After discontinuation of study treatment, tumor assessmentswill continue until IRF-assessed progression. In addition, patients willbe followed for survival until death, loss to follow-up, withdrawal ofconsent, or study termination by the Sponsors. Tumor assessments will beconducted every 9 weeks from the date of randomization. Delays intreatment administration will not impact the timing of the tumorassessments. If a tumor assessment must be performed early/late,subsequent assessments will be conducted according to the originalschedule of every 9 weeks from the date of randomization. Tumorassessments must be conducted until IRF-determined progressive disease(PD), even if treatment has been discontinued due to aninvestigator-determined PD or unacceptable toxicity.

After termination of study treatment, patients will continue be followedfor survival until death, loss to follow-up, or study termination.

Sample Size

A sample size of 800 patients is needed to provide 80% power to detect a33% improvement in OS(HR=0.75) at the two-sided significance level of5%. Since both PFS and OS analyses are event-driven, and to avoidprolonged waiting period after final PFS analysis for OS data to reachthe required number of events, the trial is designed to enrollsufficient number of patients such that approximately 50% of therequired deaths will have been observed at the time of the final PFSanalysis.

Assuming that the median OS in the control arm is 36 months and OS isexponentially distributed, one interim analysis at 50% of total requireddeaths, and a Lan-DeMets alpha-spending function with theO'Brien-Fleming stopping boundary, approximately 385 deaths will berequired. In addition, assuming that the accrual rate is approximately40 patients per month after a 9-month ramp-up period, v800 patients willneed to be enrolled and followed for an additional 29.5 months to obtain385 deaths. The enrollment period is estimated to be 26.5 months, and50% of the required deaths will be reached at around 33.5 months.

Assuming that PFS is exponentially distributed with a median of 10.5months in the control arm, it is estimated that 381 IRF-assessed PFSevents, corresponding to approximately 448 investigator-assessed events,will have occurred when 50% of the required deaths (193 deaths) isreached. Final primary analysis of PFS will be performed after 381IRF-assessed PFS events have occurred.

Statistical Methods

Efficacy Analyses

Analyses of PFS, OS, and time to symptom progression will be based onthe intent-to-treat (ITT) population, defined as patients who have beenrandomized. For objective response, only patients with measurabledisease at baseline will be included in the analysis. For duration ofresponse, only responders will be included in the analysis. All efficacyanalyses will be based on the treatment arm to which patients wererandomized

Analysis of Primary Variable

The primary endpoint is PFS based on IRF assessments. For patients whodiscontinue study treatment due to reasons other than death orIRF-assessed progression, every effort will be made to continue tumorassessments until IRF-determined progressive disease or patient death.Data for patients who do not have documented progressive disease or whohave not died within 18 weeks of the last tumor assessment will becensored at the time of the last IRF-evaluable tumor assessment (or, ifno tumor assessments are performed after the baseline visit, at the timeof randomization plus 1 day).

For patients whose IRF-determined progression event is not available,surrogating death at any time as a progressive event can artificiallyprolong the PFS time because of a much longer life expectancy in thispatient population compared with PFS. Therefore, only deaths within 18weeks of the last tumor assessments will be included as an event in theprimary analysis. However, a sensitivity analysis will be performedincluding all deaths as an event.

The log-rank test, stratified by prior treatment status (de novo andprior adjuvant or neo-adjuvant therapy) and region (Europe, NorthAmerica, South America, and Asia), will be used to compare PFS betweenthe two treatment arms. The unstratified log-rank test results will alsobe provided as a sensitivity analysis. The Kaplan-Meier approach will beused to estimate median PFS for each treatment arm. The Cox proportionalhazard model, stratified by prior treatment status and region, will beused to estimate the HR between the two treatment arms (i.e., themagnitude of treatment effect) and its 95% confidence interval (CI).

The aforementioned analyses will be performed in demographic subgroupsas appropriate. For example analysis may be performed in patientsubgroups based on racial origin provided there is a reasonable samplesize in the subgroups of interest.

Secondary Variables

Overall survival. Patients who are alive or lost to follow-up at thetime of the analysis will be censored at the last known alive date.Patients with no post-baseline information will be censored at the timeof randomization plus 1 day. Analysis methods are the same as thosedescribed for the primary endpoint. To minimize the chance of a biasedOS estimate resulting from scheduled survival follow-up every 18 weeks,immediately prior to the data cutoff for the final PFS analysis andfinal OS analysis, the investigative sites will contact every patientthat is alive to confirm current survival status. (The study Sponsorswill notify all investigators of the timing of this survival datasweep.)

PFS based on investigator assessments. Data for patients who do not havedocumented progressive disease or who have not died within 18 weeks ofthe last tumor assessment will be censored at the time of the lastinvestigator tumor assessment (or, if no tumor assessments are performedafter the baseline visit, at the time of randomization plus 1 day).Analysis methods are the same as those described for the primaryendpoint.

Objective response. Only patients with measurable disease at baselinewill be included in the analysis of the objective response. Patientswithout a post-baseline tumor assessment will be considered to benon-responders. Analysis of objective response will be based on IRFassessments.

An estimate of the objective response rate and its 95% CI will becalculated for each treatment arm. The difference in objective responserate will also be provided with 95% CIs. The Mantel-Haenszel χ2 teststratified by prior treatment status and region will be used to comparethe objective response rate between the two treatment arms. Anunadjusted Fisher's exact test result will also be provided as asensitivity analysis.

Duration of objective response. Only patients with an objective responsewill be included in the analysis of duration of objective response. Themethod for handling censoring is the same as that described for theprimary endpoint. Analysis of duration of objective response will bebased on IRF assessments.

Median duration of objective response for each arm will be estimatedusing the Kaplan-Meier approach. The hazard ratio between the two armswill also be estimated using Cox regression.

Time to symptom progression. A decrease of five points in TOI-PFB isconsidered symptom progression. Data for patients who do not have anobserved symptom progression will be censored at the last observedTOI-PFB assessment date. If baseline TOI-PFB assessment is unavailable,or if there is no post-baseline TOI-PFB assessment performed, data willbe censored at the time of randomization plus 1 day. Analysis methodsare the same as those described for the primary endpoint.

Biomarker analyses. To evaluate the effect of molecular markers onefficacy outcome, efficacy outcomes will be summarized for all patients,and by treatment arm, within each subgroup determined by exploratorymarkers. Markers to be considered include the status of HER receptors,HER ligands, Fc-γ, shed antigens (e.g., ECD/HER2), and other markersrelevant for the HER family pathway. Special emphasis will be put onmarkers that have shown association with clinical outcome in patientstreated with pertuzumab in previous studies:

qRT-PCR markers: tumor gene expression profiles associated with HER2activation

Baseline serum markers: levels of ECD/HER2 and HER ligands

Efficacy outcomes considered for this analysis will include PFS,objective response rate, and OS. The PFS and objective response will bebased on the IRF assessments.

The biomarker analyses at the time of protocol development do not takethe form of testing fixed hypotheses involving specific cutoffs or otherpre-specified prediction rules. It is planned for the StatisticalAnalysis Plan (to be generated prior to unblinding of this trial) to useall available scientific evidence from independent studies orpublications to specify testable prediction rules. In addition, thisplan will specify in due detail how data-adaptive prediction rules willbe derived (e.g., systematic cutoff search) and how the inherentmultiplicity/bias will be corrected in order to prevent biasedconclusions.

The difference in treatment benefit across biomarker statuses defined bya suitable prediction rule will be evaluated by testing the interactioneffect of treatment and the prediction status using Cox regression forPFS and OS, and using logistic regression for response rate. Thesemodels involving an interaction term will also be used to estimate theconditional efficacy outcomes, conditional on biomarker predictionstatus or treatment arm, including and excluding the stratificationfactors into the model.

Clinical covariates can be of prognostic value and could interact withtreatment benefit and with biomarker status. Candidates here arebaseline variables of prognostic value describing tumour properties andmorbidity status or common lab values. Biomarker prediction will bechecked involving relevant clinical covariates, which could be part ofthe biomarker prediction function, if necessary.

Safety Analyses The safety of pertuzumab in combination with trastuzumaband chemotherapy will be assessed through summaries of AEs,cardiac-specific AEs, LVEF measurements, and laboratory test results.Patients who receive any amount of study treatment will be included insafety analyses. Safety results will be summarized by the treatmentpatients actually receive.

Example 2 Pharmacokinetic, Drug-Drug Interaction, and QTc IntervalSubstudy

This substudy has two main goals: (1) to describe the potential effectsof pertuzumab on the QTc interval, and (2) to evaluate thepharmacokinetic profile of pertuzumab in the presence of trastuzumab anddocetaxel and to describe any drug-drug interactions that might beobserved when all three drugs are co-administered.

QTC Prolongation

Drug-induced prolongation of the QT/corrected QT (QTc) intervalresulting in increased susceptibility to cardiac arrhythmia is arecognized complication of many drugs across a wide therapeutic spectrum(Morissette et al. Can J Cardiol 2005; 21:857-64). Prolongation of theQT/QTc interval, which is usually asymptomatic, may be manifested bysyncope resulting from cardiac arrhythmias such as torsades de pointes(TdP), ventricular arrhythmia, and sudden cardiac death (Morganroth rnstSchering Res Found Workshop 2007; 59:171-84).

Measurement of QT is made by an electrocardiogram (ECG) and is asurrogate for ventricular repolarization. The QT interval is defined asthe time from the beginning of the QRS complex to the end of the T-wave.Because the QT interval is inversely related to the heart rate, thefollowing formulae are commonly used to correct the QT interval (Strevelet al. J Clin Oncol 2007; 25:3362-71).

-   -   Fridericia's Correction (QTcF): QTcF=QT/RR^(0.33)    -   Bazett's Correction (QTcB): QTcB=QT/RR^(0.5)

QTc is considered prolonged when it is greater than 450 milliseconds(ms) in duration. The QT/QTc interval can be affected by the location ofthe ECG lead, gender, time of day, drug therapy, or congenitalconditions. Several pre-disposing factors may influence drug-inducedarrhythmia secondary to prolonged QT/QTc, including electrolyteimbalance, bradycardia, toxins, cerebrovascular disease, inhibition ofcytochrome p450, and inhibition of p-glycoprotein (Kannankeril and RodenCurr Opin Cardiol 2007; 22:39-43, Morissette et al 2005, supra).

The common mechanism of drug-induced QT/QTc interval prolongation is thedirect blockade of specific potassium channels, encoded by the humanether-a-go-go (hERG)-related gene, that regulate cardiac repolarizationor disrupt hERG channel protein trafficking, or both. Drugs have beenclassified by their propensity to prolong the QTc interval; theclassification provided in Table 2 is commonly used (Woosleyhttp//www.arizonacert.org (updated as of Mar. 1, 2006). To date, thedrugs known to block potassium channels are small molecules, such asantiarrhythmics, some antibiotics, antiemetics, antihistamines,antipsychotics, antidepressants, bronchodilators, and some centralnervous system (CNS) stimulants (Morissette et al. 2005m supra, Woosley2006, supra). The binding site for potassium channel blockade is locatedon an intracellular domain, a site that is difficult for large molecules(i.e., monoclonal antibodies) to access.

Classes of molecularly-targeted oncology therapeutic agents associatedwith effects on the QT interval have been identified, including farnesylprotein transferase inhibitors, arsenic, Scr/Abl kinase inhibitors,multi-targeted tyrosine kinase inhibitors, histone deacetylaseinhibitors, vascular disruption agents, and protein kinase C inhibitors.A direct mechanism common to these agents in association with QT effectshas not been described (Streval et al. J Clin Oncol 2007; 25:3362-71).

TABLE 2 Classification of Drugs by Propensity to Prolong QTc IntervalDrug List 1 Generally accepted by authorities to have a risk of causingtorsades de pointes Drug List 2 Drugs that in some reports may beassociated with torsades de pointes but at this time lack substantialevidence for causing torsades de pointes Drug List 3 Drugs to be avoidedfor use in patients with diagnosed or suspected congenital long QTsyndrome. Drugs on Lists 1, 2, and 4 should also be avoided by patientswith QT syndrome Drug List 4 Drugs that, in some reports, have beenweakly associated with torsades de pointes, and/or QT prolongation butthat are unlikely to be a risk for torsades de pointes when used in theusual recommended dosages and in patients with out other risk factors(e.g., concomitant QT prolonging drugs, bradycardia, electrolytedisturbances, congenital long QT syndrome, concomitant drugs thatinhibit metabolism) Females > Males Substantial evidence indicates agreater risk (usually > 2 fold) of torsades de pointes in women

Pertuzumab Mechanism of Action and Nonclinical Experience

As described earlier, pertuzumab is a humanized monoclonal antibodybased on human IgG1 (κ) framework sequences and consists of two heavychains (449 residues) and two light chains (214 residues). Liketrastuzumab (Herceptin®), pertuzumab is produced in Chinese hamsterovary (CHO) cells and is directed against HER2. However, it differs fromtrastuzumab in the epitope-binding regions of the light chain (12 aminoacid differences) and heavy chain (29 amino acid differences). As aresult, pertuzumab binds to a different epitope on HER2.

Pertuzumab acts by blocking the association of HER2 with other HERfamily members, including HER1 (EGFR), HER3, and HER4. As a result, itinhibits ligand-initiated intracellular signaling through two majorsignal pathways, MAP kinase and PI3 kinase. Inhibition of thesesignaling pathways can result in growth arrest and apoptosis,respectively (Hanahan and Weinberg Cell 2000; 100:57-70). Nonclinicaldata have demonstrated that overexpression of HER2 is not required forthe anti-tumor activity of pertuzumab.

Proarrhythmias secondary to abnormal ventricular repolarization and QTprolongation have been of concern in drug development. Two InternationalConference on Harmonization (ICH) guidelines for nonclinical (S7B) andclinical (E14) testing were recently developed (International Conferenceon Harmonization of Technical Requirements for Registration ofPharmaceuticals for Human Use 2005). Based on these guidelines, theeffect of pertuzumab on QTc in patients with breast cancer will beinvestigated in this substudy.

In order to fully characterize any potential effects of pertuzumab onthe heart, additional cardiac endpoints have been included in twononclinical multi-dose toxicology studies performed to support theclinical development of pertuzumab. In a 7-week intravenous toxicity andtoxicokinetic study in cynomolgus monkeys with a 4-week recovery period(Study 00-377-1821), telemetry was measured in two animals per sex inthe control and high-dose (150 mg/kg/dose) groups to collectelectrocardiographic endpoints. At two timepoints before the initiationof treatment, and on Days 1 and 28, telemetered animals had systolic,diastolic, and mean arterial blood pressure, heart rate, PR interval,QRS, QT, and Lead II ECG data recorded. Four 1-minute tracings werecollected for each animal from 2 to 22 hours after dosing andinterpreted by a board-certified veterinary cardiologist. In addition tothe routine serum chemistry parameters evaluated, serum was alsoanalyzed for creatinine kinase isozymes and Troponin T on Study Days 2/3and 44/45 for all animals. In a 26-week intravenous toxicity andtoxicokinetic study with pertuzumab in cynomolgus monkeys with an 8-weekrecovery period (Study 01-458-1821), ECG (standard surface leads) andblood pressure measurements were recorded on all animals. Recordingswere taken at two timepoints before the initiation of treatment and onceduring Weeks 4, 16, and 26 on anesthetized animals and were interpretedby a board-certified veterinary cardiologist. In addition to the routineserum chemistry parameters evaluated, serum was also analyzed forTroponin T on Day 1 predose and on Days 114, 184, and 239 (recovery) forall animals. Results from both multidose toxicity studies concluded thatthere was no evidence of cardiac injury caused by pertuzumab treatment,as determined by histopathology, lack of increases in relevant serumchemistry parameters (Troponin T and creatine kinase isozymes), andnormal ECGs, blood pressures, and heart rates.

In clinical trials as of November 2006, there has been no associationnoted of an increase of TdP in pertuzumab-treated patients.

Pertuzumab Pharmacokinetics

Summary

Pharmacokinetic (PK) results observed in previous pertuzumab studiesshowed no change in clearance at doses from 2.0 to 15.0 mg/kg (140mg-1050 mg for a 70 kg patient). A two-compartment model adequatelydescribed the concentration-time data, with a systemic serum clearanceof approximately 0.24 L/day and a terminal half-life of approximately 17days for a typical patient. Based on these data, a dosing interval of 3weeks is recommended in clinical studies. In Phase II studies, a loadingdose of 840 mg (followed by 420 mg every 3 weeks), led to the attainmentof steady-state trough (C_(min)) and peak (C_(max)) concentrations bythe second cycle and achieved a PK target of 20 μg/mL (based onpre-clinical tumor xenograft models). Population PK modeling of datafrom Phase Ia and Phase II studies support the continued use of fixed,non-weight-based dosing in female patients. There was no evidence thatpertuzumab impacted the PK of co-administered chemotherapeutic agents(docetaxel and capecitabine in Phase Ib studies and gemcitabine in aPhase II study).

Pharmacokinetics in Single-Agent Studies

In Phase II single-agent studies (Studies TOC2689g and B016934),concentration-time data show that the loading dose 840 mg (followed by420 mg every 3 weeks) resulted in the achievement of steady-stateC_(min) and C_(max) by the second cycle, and also achieved serumpertuzumab target concentrations >20 mg/mL in most patients. Mean serumC_(min) and C_(max) for the first two cycles of treatment in ovarian andmetastatic breast cancer (MBC) patients are presented in Table 3. FIG. 6shows the concentration-time profiles for the first 84 days.

TABLE 3 Mean (±SD) Peak and Trough Serum Concentrations at the End ofthe First and Second Treatment Cycles (Studies TOC2689g and BO16934)Cycle 1 Cycle 2 C_(min) C_(max) C_(min) C_(max) Study Dose μg/mL μg/mLμg/mL μg/mL TOC2689g  420 mg 64.6 (±20.9) 231.7 66.5 (±38.0) 237.6Ovarian (n = 61) (±50.6) (±55.0) cancer 1050 mg 90.1 (±68.1) 390.9 94.7(±47.3) 357.2 (n = 62) (±114.7) (±112.4) BO16934  420 mg 56.5 (±21.2)202.9 62.6 (±21.1) 181.2 Metastatic (n = 40) (±78.4) (±63.0) breastcancer 1050 mg 75.9 (±34.5) 425.6 136.6 (±53.5)  542.9 (n = 35) (±166.9)(±173.7)

PK parameters were estimated using a two-compartment model (see Table4). The mean systemic clearance for these patients (0.225-0.285 L/day),and the mean volume of distribution of the central compartment(2.70-3.11 L; i.e., approximately the serum volume), were similar tothat observed in the Phase Ia study (Study TOC2297g). The mean initialhalf-life and the mean terminal half-life were also within the rangesobserved across 2-15 mg/kg dose groups in the Phase Ia study.

TABLE 4 Estimates^(a) of Selected Pertuzumab Pharmacokinetic Parametersfollowing Intravenous Infusion (Mean ± SD)^(b) CL V_(c) V_(ss) t_(1/2)initial t_(1/2) terminal Study Dose Group (L/day) (L) (L) (days) (days)TOC2689g  420 mg 0.244 ± 0.095 2.70 ± 0.39 4.73 ± 0.78 1.37 ± 0.12 16.2± 4.7 (Ovarian (n = 61) cancer) 1050 mg 0.285 ± 0.119 3.11 ± 0.72 5.39 ±1.31 1.34 ± 0.11 15.8 ± 5.2 (n = 62) BO16934  420 mg 0.255 ± 0.096 2.98± 0.67 5.12 ± 0.98 1.36 ± 0.13 16.3 ± 3.5 (Metastatic (n = 40) breast1050 mg 0.225 ± 0.121 2.95 ± 0.81 5.11 ± 1.12 1.39 ± 0.15 20.5 ± 8.1cancer) (n = 35) CL = systemic clearance; V_(c =) = volume of centralcompartment; V_(ss) = steady-state volume of distribution; t_(1/2)initial = initial distribution half-life; t_(1/2) terminal = terminalhalf-life ^(a)Pharmacokinetic parameters estimated by post-hoc analysisfrom 2-compartment population pharmacokinetic model.^(b)Pharmacokinetics not performed for Study TOC2572g.

Pharmacokinetics in Combination Therapy Studies

Analyses of the PK data from Phase Ib studies of capecitabine (StudyB017003) and docetaxel (Study BO17021) indicate that pertuzumab does notalter the PK of these two cytotoxic agents. In both studies, the PKparameters for pertuzumab were similar to the PK parameters obtained insingle-agent pertuzumab studies.

Preliminary PK analysis from a Phase II study to evaluate the efficacyof pertuzumab in combination with gemcitabine in patients withplatinum-resistant ovarian cancer (Study TOC3258g) indicates thatpertuzumab does not alter the PK of gemcitabine or its major metabolite,dFdU. In addition, the serum concentrations of pertuzumab were similarto the concentrations in the single-agent Phase II studies in ovariancancer and MBC (Studies TOC2689g and B016934)

Pertuzumab Dose Regimen

A dosing regimen of pertuzumab administered every 3 weeks to patients inPhase II studies (Studies TOC2689g and B016934) using a fixed 840 mgloading dose (equivalent to 12 mg/kg for a 70 kg patient) for treatmentCycle 1 and a fixed 420 mg maintenance dose (equivalent to 6 mg/kg for a70 kg patient) for subsequent treatment cycles resulted in steady-stateserum C_(min) of approximately 60 μg/mL by the second treatment cycle.In nonclinical dose-response xenograft studies using nude mice implantedwith non-small cell lung cancer (NSCLC) and breast cancer tumors (lowand high HER2 expression levels), >80% suppression of tumor growth wasachieved when steady-state trough concentrations of pertuzumab reached5-25 μg/mL. Thus, the steady-state C_(min) that were observed inpatients in the Phase II studies are in excess of concentrations shownto be efficacious in animal tumor models, and therefore expected toresult in a biologic effect.

A preliminary population PK analysis of the Phase Ia (Study TOC2297g)and Phase IIa studies (Studies TOC2689g and BO16934), comprising a totalof 153 patients (weight range: 45.0-150.6 kg) and 1458concentration-timepoints, showed that the population variability ofsteady-state trough concentration and exposure were similar withfixed-dosing, body surface area-based dosing, and weight-based dosing.Therefore, a dose based on body-surface area or weight was not superiorto a fixed dose. These data support the continued use of a fixed dose ofpertuzumab in female patients with MBC and ovarian cancer.

The dependence of pertuzumab serum clearance on body weight for bothfemale and male patients will be evaluated further using all availableclinical PK data from the pertuzumab studies.

Objectives

Pharmacokinetic Objectives

The PK objectives of this substudy are the following:

-   -   To characterize the pharmacokinetics of pertuzumab in patients        with HER2-positive MBC, and to compare these data with PK data        from other clinical studies.    -   To characterize the potential of a drug-drug interaction of        pertuzumab on the pharmacokinetics of docetaxel (in the presence        of trastuzumab), and on the pharmacokinetics of trastuzumab (in        the presence of docetaxel).

Electrocardiogram Objectives

The ECG objectives are exploratory and may include the following:

-   -   To describe the effect of pertuzumab on the change from baseline        in QTc interval as calculated using Fridericia's correction        (QTcF)    -   To describe the effect of pertuzumab on the change from baseline        in QTc interval as calculated using Bazett's correction (QTcB)    -   To describe the proportion of patients with QTc interval        prolongation and change from baseline in QTc interval,        calculated using both the Fridericia's and Bazett's corrections    -   To describe the effect of pertuzumab on the following ECG        parameters: heart rate, QT interval, PR interval, and QRS        duration

Study Design

Description of the Study

This is a supplemental study to Study TOC4129g/WO20698 that is designedto evaluate the effect of pertuzumab on QTc interval, further evaluatethe pharmacokinetics of pertuzumab, and characterize the drug-druginteraction of pertuzumab on docetaxel pharmacokinetics (in the presenceof trastuzumab), and on trastuzumab pharmacokinetics (in the presence ofdocetaxel).

A subset of investigative sites participating in Study TOC4129g/WO20698will participate in this substudy. Patients at these sites who haveconsented to participate in and have been determined to be eligible forenrollment into Study TOC4129g/WO20698 will be invited to participate inthis substudy. Participation in this substudy is optional; therefore,informed consent for this substudy will be obtained separately from theconsent to participate in Study TOC4129g/WO20698. Refusal to participatein this substudy will not affect a patient's eligibility a patient'seligibility for Study TOC4129g/WO20698. Fifty evaluable patients (25 pertreatment arm) will be enrolled to this substudy.

Each enrolled patient will receive treatment as specified inTOC4129g/WO20698. Day 1 of TOC4129g/WO20698 will correspond to Day 1 ofthis substudy.

All patients participating in this substudy will have alpha-1-acidglycoprotein tested at baseline by a local laboratory, in addition tothe standard hematology and serum chemistry tests in StudyTOC4129g/WO20698.

Triplicate 12-lead ECG measurements will be taken during thepre-treatment baseline period from Day −7 to Day −1 (i.e., within 7 daysprior to Cycle 1 Day 1), at Cycle 1 Day 1, at Cycle 1 Day 3, coincidentwith the 23-hour docetaxel PK sample, and at Cycle 3 Day 1(corresponding to pertuzumab/placebo steady-state C_(min) and C_(max)).On Day 1 of Cycle 1 and Cycle 3, triplicate 12-lead ECG measurementswill be taken at the following timepoints: −30 and −15 minutespre-pertuzumab/placebo infusion (any premedication that is requiredbefore the pertuzumab/placebo infusion must be given between these twopre-dose timepoints), immediately post-pertuzumab/placebo infusion, and60-75 minutes post-pertuzumab/placebo infusion. ECG results will be sentto a central core cardiology laboratory for the determination of theQT/QTc interval, which will be used as the data for this substudy.

To minimize variations due to circadian rhythms, the Cycle 1 and Cycle 3pertuzumab/placebo infusions should be administered at the same time ofday, and the baseline (Day −7 to Day −1) ECG readings must be taken atthe same corresponding time of day as the Cycle 1 and Cycle 3 ECGmeasurements. The severity of QTc prolongation will be graded accordingto the National Cancer Institute Common Toxicity Criteria for AdverseEvents (NCI-CTCAE), Version 3.0. A treatment algorithm is provided toguide study treatment decisions based upon the observed QT/QTc intervalat each timepoint. If at any time during this substudy the QTc intervalexceeds 500 ms or a high degree of artifact is present on the ECG,cardiac consultation with the ECG core laboratory is available.

Blood samples for pertuzumab PK evaluation will be drawn before andafter the pertuzumab/placebo infusions at Cycles 1, 3, 6, 9, 12, 15, 18,with an additional sample drawn at the Treatment Discontinuation Visit(28-42 days after the last dose of study treatment). At Cycles 1 and 3,the post-pertuzumab PK samples will be drawn 60-75 minutes after the endof the pertuzumab/placebo infusion to correspond with the ECGs performedon those days.

Blood samples for trastuzumab PK evaluation will be collected at Cycles1 and 3, before and after the trastuzumab infusions.

Blood samples for the docetaxel PK evaluation will be collected at Cycle1 at the following timepoints after the initiation of docetaxel infusion(Timepoint 0): 0.5 hour (during infusion), 1.0 hour (at the end ofinfusion, EOI), 1.25 hours (15 minutes after the EOI), 2 hours (1 hourafter EOI), 4 hours (3 hours after EOI), 6 hours (5 hours after EOI), 8hours (7 hours after EOI), and 24 hours (Cycle 1 Day 3, 23 hours afterEOI).

Rationale for Study Design

Rationale for QTc Study Design

The study will evaluate the effect of pertuzumab on the QTc interval inpatients with HER2-positive MBC. Ordinarily, a thorough QTc study isperformed in healthy volunteers when feasible. Because the QTc is to beevaluated in a cancer population with multiple confounders (baselineillness, baseline medications, including antiemetics, antibiotics, andother supportive care medications), this substudy has been designed todescribe the change in QTc interval from baseline to steady-state inpertuzumab-treated and placebo control patients. If patients requireantiemetics or other premedications prior to the infusion ofpertuzumab/placebo, they must be given between the two pre-dose ECGmeasurements in an attempt to control for concomitant medication effectson the QT/QTc interval. ICH guidance recommends that studies shouldcharacterize the effect of a drug on the QT/QTc and perform ECGrecordings at timepoints around the C_(max).

As stated in the ICH E14 guidance, Bazett's correction generallyover-corrects at elevated heart rates and under-corrects at heart ratesbelow 60 beats per minute (bpm). Fridericia's correction has been chosenas the primary correction because it accounts for the effect of alteredheart rates on QT interval.

Pertuzumab PK samples will be drawn at the time of the Cycles 1 and 3ECG readings when therapeutic serum concentrations of pertuzumab areexpected to be achieved. Pertuzumab exposure will be correlated withQTc. Cycle 3 Day 1 (assuming 21-day cycles) was chosen for themeasurement of QTc at steady-state concentration based on the Phase IIstudies, during which a loading dose of 840 mg (followed by 420 mg every3 weeks) resulted in the achievement of steady-state C_(min) and C_(max)by the second cycle. Therefore, the majority of the population should beat steady state by Cycle 3.

Although a positive-control comparison drug (e.g., moxifloxacin) isrecommended by ICH guidelines to validate assay sensitivity, a positivecontrol drug will not be administered to patients in this substudy as itis felt that the use of a positive-control medication would not beethical in a metastatic cancer patient population. Furthermore, patientshave baseline variability secondary to medications already beingadministered.

Per ICH recommendations, rates of selected adverse events, if observed(TdP; sudden death; ventricular tachycardia; ventricular fibrillationand flutter; syncope; and seizures) will be compared between thepertuzumab-treated and control patients, as part of data collected forStudy TOC4129g/WO20698. Additionally, the incidence of QTc intervalprolongation and the change from baseline in QTc interval will besummarized.

Rationale for Pharmacokinetic Sampling

The proposed sampling scheme for pertuzumab concentration assessments inthis substudy should allow for the adequate characterization of thepharmacokinetics of pertuzumab. The pertuzumab concentration resultswill be compared with available data from other pertuzumab clinicalstudies. In addition, the pertuzumab concentration data will be used forpopulation PK modeling to generate PK parameter estimates. These datamay also contribute to a future population PK analysis to investigatethe effect of physiologic and disease-related covariates on PKparameters.

Study TOC4129g/WO20698 proposes to combine pertuzumab with trastuzumaband docetaxel.

Based on the clearance mechanisms for pertuzumab, there is noexpectation that pertuzumab will alter the pharmacokinetics ofdocetaxel. However, the concentrations of docetaxel will be measured toassess a potential PK-related interaction between docetaxel andpertuzumab (in the presence of trastuzumab). In addition, concentrationsof trastuzumab will be measured to assess a potential PK-relatedinteraction between trastuzumab and pertuzumab (in the presence ofdocetaxel).

Dose-ranging pharmacokinetics will not be performed, and asupratherapeutic dose will not be administered in StudyTOC4129g/WO20698.

Outcome Measures

Pharmacokinetic Outcome Measures: The PK outcome measures are thefollowing:

-   -   Observed minimum and maximum pertuzumab serum concentrations        (C_(min) and C_(max)), and PK parameter estimates (CL, AUC, Vd,        t_(1/2))    -   Minimum and maximum trastuzumab serum concentrations (C_(min)        and C_(max))    -   Area-under-the-curve (AUC) for docetaxel plasma concentrations        -   Electrocardiogram Outcome Measures: The ECG outcome measures            are the following:    -   Time-matched baseline-adjusted placebo-corrected QTcF    -   Time-matched baseline-adjusted placebo-corrected QTcB    -   Proportion of patients at each timepoint whose ECG recordings        meet the following criteria:

New incidence of absolute QTc interval prolongation (based onFridericia's correction) of >450 ms, >470 ms, and >500 ms

The following changes from baseline in QTc interval (based onFridericia's correction): QTc increases >30 ms, QTc increases >60 ms

Change from baseline in heart rate of 25%, resulting in a final heartrate <50 beats per minute (bpm) or >120 bpm

New incidence of abnormal U waves

New incidence of abnormal T waves

New incidence of abnormal ECG morphology

-   -   The time-matched baseline-adjusted placebo-corrected differences        in the following ECG parameters: heart rate, QT, PR interval,        and QRS duration.

Safety Plan

Clinically significant ECG changes detected during this substudy will bereported and managed according to the safety reporting and monitoringrequirements of Study TOC4129g/WO20698. The degree of QTc prolongationwill be graded according to the NCI-CTCAE, Version 3.0. A treatmentalgorithm is provided to guide study treatment decisions in the event ofQT/QTc prolongation during the study. A central ECG core laboratory willbe available to evaluate any cases of QT/QTc prolongation.

Control Group

Because Study TOC4129g/WO20698 is a randomized, double-blind,placebo-controlled study, the control group will consist of patientsrandomized to receive placebo instead of pertuzumab.

Minimization of Bias

For purposes of the main study, unblinding procedures will be performedaccording to the TOC4129g/WO20698 protocol. For this substudy, patienttreatment (pertuzumab vs. control) will be determined by the analysis ofPK serum samples for the presence or absence of pertuzumab; therefore,to maintain blinding of the main study, Sponsor personnel involved inthe analysis of pertuzumab PK samples and analysis of this substudy willnot be involved with any of the operational or analysis aspects of theStudy TOC4129g/WO20698. All study personnel involved in the mainTOC4129g/WO20698 study will remain blinded (e.g., site personnel,investigators, patients, statisticians, etc.). Centralized ECG readerswill be blinded to patient treatment and ECG timepoint.

Patients

Patient Selection

Patients who have consented to participate in Study TOC4129g/WO20698 ata subset of investigative sites will be eligible for enrollment intothis substudy.

-   -   Inclusion Criteria: Patients must meet the following criteria to        be eligible for substudy entry:    -   Enrollment in Study TOC4129g/WO20698    -   Signed Informed Consent Form for this substudy        -   Exclusion Criteria Patients who meet any of the following            criteria will be excluded from substudy entry:    -   Implantable pacemaker or automatic implantable cardioverter        defibrillator (AICD)    -   Congenital long QT syndrome    -   Family history of long QT syndrome    -   Baseline QTc >450 ms as assessed locally at each study site    -   Patients currently requiring regular use of medications that are        known to prolong QTc interval or induce TdP (see Appendix B)    -   Clinically significant bradycardia (defined as <50 bpm) at        baseline    -   Evidence of heart block    -   Hypokalemia, hypomagnesemia, and hypocalcemia that cannot be        corrected with electrolyte supplement

Method of Treatment Assignment and Blinding

Treatment assignment will be in accordance with the protocol describedin Example 1.

Unblinding of study treatment will be in accordance with the proceduresspecified in Example 1. Centralized ECG readers will remain blinded topatient treatment and ECG timepoints.

Study Treatment

Study treatment will be as specified in Example 1.

Concomitant and Excluded Therapies

Clinical judgment should be applied when determining treatment optionsand supportive care treatment for each patient.

Other concomitant and excluded medications will be as directed inExample 1.

Study Assessments

Study treatment infusions, ECG measurements, and blood draws should beconsistently administered, recorded, and collected at the same time ofday, between 9:00 AM-12:00 PM and >1 hour postprandial, in order tominimize variations due to circadian rhythms.

Screening and Pretreatment Assessments

Informed consent must be obtained before study-specific evaluations areperformed. The informed consent process should be documented in thepatient's medical chart.

The following substudy evaluations and procedures will be performedduring the baseline period of the study described in Example 1:

-   -   Written informed consent    -   Review of inclusion and exclusion criteria    -   Serum chemistry to evaluate electrolyte values    -   Collection of blood sample for alpha-1-acid glycoprotein test        and analysis by a local laboratory, as an addition to the        standard hematology and chemistry testing in the study described        in Example 1.

ECG Measurements

Serum potassium, magnesium and calcium levels must be within normallimits before performing ECGs, as determined by local laboratory testingperformed as specified in the main protocol TOC4129g/WO20698. Patientsmay receive electrolyte supplement per institutional standard practiceto bring electrolyte levels within normal limits prior to performing theECGs; retesting of potassium, magnesium, and calcium levels should beperformed according to institutional standard practice.

Triplicate 12-lead ECG readings will be taken during the baseline period(Day −7 to Day −1; i.e., within 7 days prior to Cycle 1 Day 1) at thesame time of day at which ECG measurements will be performed at Cycles 1and 3.

To minimize postural variability, it is important that patients areresting and in a supine position for at least 10 minutes prior to eachECG collection. Blood draws and other procedures should be avoidedduring the period immediately before ECG measurement, and activityshould be controlled as much as possible in order to minimizevariability due to the effects of physiologic stress. Meals should bestandardized as much as possible between patients, to avoid postprandialeffects. If possible, ECGs should be collected on the same type ofmachine for each site involved in the study, and the same machine shouldbe used for all ECGs for a specific patient. Detailed instructions onECG acquisitions are provided in the central ECG core laboratory manual.

Triplicate runs of 12-lead ECG measurements must be obtained at eachassessment timepoint, and should be collected over a period of 2 minutes(e.g., a single ECG each minute).

Assessments During Treatment

All visits and assessments during treatment are to be performed on thedays indicated. Per the protocol described in Example 1, a cycle is 21days in length.

ECG Measurements During Cycle 1 Day 1, Cycle 1 Day 3, and Cycle 3 Day 1

The 12-lead ECGs (triplicate runs) will be performed before collectingthe corresponding PK samples. All ECGs for a patient should be obtainedon the same machine.

Serum potassium, magnesium and calcium levels must be within normallimits before performing ECGs, as determined by local laboratory testingperformed as specified in the main protocol TOC4129g/WO20698. Patientsmay receive electrolyte supplement per institutional standard practiceto bring electrolyte levels within normal limits prior to performing theECGs; retesting of potassium, magnesium, and calcium levels should beperformed according to institutional standard practice.

Triplicate 12-lead ECG readings will be taken during Cycle 1 Day 1 andCucle 3 Day 1 at the same time as the baseline ECG measurements, at thefollowing times of day: 30 minutes and 15 minutes (±5 minutes) prior topertuzumab/placebo infusion

Any premedications that are required for pertuzumab/placebo infusionsmust be given between the two pre-infusion ECG measurements

-   -   0-15 minutes post-pertuzumab/placebo infusion    -   60-75 minutes post-pertuzumab/placebo infusion

Triplicate 12-lead ECG readings will be also taken during Cycle 1 Day 3,post-docetaxel infusion and coincident with the 23-hour PK sample.

Pharmacokinetic Blood Samples

Unless otherwise specified, blood samples for PK evaluations should bedrawn at the following timepoints:

-   -   Pre-dose: within 15 minutes before the infusion    -   Post-dose: within 15 minutes after the end of infusion

Approximately 5 mL of blood will be drawn at each PK timepoint.

Pertuzumab Pharmacokinetics

Blood samples for pertuzumab PK evaluation will be drawn pre- andpost-pertuzumab/placebo infusion at the following cycles: Cycles 1, 3,6, 9, 12, 15, and 18. An additional sample will be drawn at theTreatment Discontinuation Visit (28-42 days after the last dose of studytreatment).

-   -   At Cycles 1 and 3, the post-pertuzumab PK sample will be drawn        60-75 minutes after the end of the pertuzumab/placebo infusion        (prior to administration of trastuzumab).    -   At Cycles 1 and 3, the pre-pertuzumab and 60-75 minutes        post-pertuzumab PK samples must be collected after the        corresponding ECGs are performed at those timepoints.

Trastuzumab Pharmacokinetics

Blood samples for trastuzumab PK evaluation will be drawn pre- andpost-trastuzumab infusion at Cycles 1 and 3.

At Cycle 3, the trastuzumab dose should be delayed until after the 60-75minute post-pertuzumab ECG assessments and PK sample collection havebeen completed.

Docetaxel Pharmacokinetics

Blood samples for docetaxel PK evaluation will be collected at Cycle 1at the following timepoints after the initiation of the docetaxelinfusion (Timepoint 0):

-   -   Cycle 1 Day 2

0.5 hour (during infusion)

1.0 hours (EOI)

1.25 hours (15 minutes after EOI)

2 hours (1 hour after EOI)

4 hours (3 hours after EOI)

6 hours (5 hours after EOI)

8 hours (7 hours after EOI)

-   -   Cycle 1: Day 3

24 hours (Cycle 1: Day 3, 23 hours after EOI)

Adverse Events

Adverse events will be collected and followed according to therequirements of the protocol of the study described in Example 1.

Assay Methods

Docetaxel Pharmacokinetic Assay

Plasma samples will be analyzed for docetaxel concentrations using ahigh-performance liquid chromatography (HPLC) method (or equivalent),and the plasma concentrations will be quantified by comparing theresults against known standards. The lower limit of quantification(LLOQ) for docetaxel in human plasma will be determined according tovalidated assay methods established by the laboratory contracted toperform the analyses.

Pertuzumab Pharmacokinetic Assay

Serum samples will be assayed for pertuzumab concentrations using anELISA that is currently being developed. The minimum quantifiableconcentration (MQC) for pertuzumab in human serum measured by this assayis to be determined.

Trastuzumab Pharmacokinetic Assay

Serum samples collected at baseline will be assayed for trastuzumabconcentrations using a receptor-binding ELISA. This assay usesimmobilized antigen HER2-ECD to capture trastuzumab from serum samples.The MQC for trastuzumab in human serum measured by this assay is 156ng/mL.

Serum samples collected after pertuzumab administration will be assayedfor trastuzumab concentrations using an ELISA that is currently beingdeveloped. The MQC for pertuzumab in human serum measured by this assayis to be determined.

Patient Discontinuation

Patients may voluntarily withdraw or be discontinued from this substudyat any time. Patients who withdraw from this substudy may continueparticipation in Study TOC4129g/WO20698. Reasons for patientdiscontinuation from the substudy include, but are not limited to, thefollowing:

-   -   Voluntary withdrawal of consent    -   Non-compliance    -   Investigator determination that it is not in the patient's best        interest to continue (e.g., illness or condition that requires        the use of prohibited drugs or treatment)    -   Patient withdrawal from Protocol TOC4129g/WO20698

The primary reason for early discontinuation must be recorded on theappropriate electronic case report form (eCRF).

Statistical Methods

Due to the small sample size, the emphasis of all analyses will be onestimations. No formal statistical hypothesis testing is planned.

Analysis of the Conduct of the Study

Enrollment and discontinuations from this substudy will be summarized.

Analysis of Treatment Group Comparability

Demographic and baseline characteristics, such as age, sex, and race,will be summarized using means, standard deviations, medians, ranges(for continuous variables), and frequencies and percentages (forcategorical variables). Summaries will be presented by study treatmentpatients actually received.

Pharmacokinetic Analyses

Population modeling will be used to derive post-hoc PK parameterestimates (CL, AUC, V_(d), and t_(1/2)) for pertuzumab, and will besummarized for the treatment cohort. Observed C_(max) and C_(min) forpertuzumab and trastuzumab will be summarized for each specified PKsampling timepoint. Descriptive statistics will include means, medians,ranges, and standard deviations, as appropriate. Pertuzumab PKparameters and serum concentration-time data will be compared withavailable data from other pertuzumab clinical studies.

PK samples for docetaxel will be obtained on Days 2 and 3 of Cycle 1only. Plasma concentrations and the AUC for docetaxel will be summarizedby treatment arm using descriptive statistics as described above. Thegeometric mean ratio for AUC between the experimental and control armswill be computed and the corresponding 90% confidence intervals will beprovided.

Electrocardiogram Analyses

The ECG-evaluable analysis population will comprise all patients whoreceive any study drug (as per Protocol TOC4129g/WO20698) and who haveECG data available for baseline, the pre-pertuzumab/placebo timepoint onCycle 1 Day 1, and at least one timepoint following pertuzumab/placeboadministration at Cycle 1 or Cycle 3. The average of the triplicate ECGreadings for each timepoint will be utilized in the analyses.

Descriptive statistics will be used for absolute QTcF value and changefrom baseline in QTcF for each timepoint. The difference in meanbaseline-adjusted QTcF between the two treatment arms (ddQTcF) will beprovided as well as the two-sided 90% confidence interval.

The time-matched, baseline-adjusted, and placebo-corrected QTcB, HR, PR,and QRS will be summarized in a similar fashion.

The number and percentage of patients with ECG recordings meeting thecriteria as described in Section 3.2.2 will be tabulated for eachtreatment arm and each post-baseline time point as appropriate.

Missing Data

No missing ECG data will be imputed. As long as one of the triplicateECGs is interpretable at each timepoint, a QTc will be calculated. Ifpatients do not have corresponding ECGs at baseline and post-baselinetimepoint of interest, they will not be included in the analysis forthat timepoint.

Determination of Sample Size

At least 50 ECG-evaluable patients will be enrolled to this substudy.The sample size for this substudy has been primarily chosen to providean estimate of key PK and ECG parameters. No formal statisticalhypothesis testing is planned. Assuming an equal rate of participationbetween treatment arms (25 patients per treatment arm) and an estimatedstandard deviation of 20 ms, the two-sided 90% confidence interval forthe baseline-adjusted difference in QTcF between treatment arms (ddQTcF)will be within 10 ms of the observed difference.

It is expected that at least 40 patients enrolled to this substudy willbe PK-evaluable. A PK-evaluable patient is defined as a patient who hashad complete PK samples collected at Cycle 1 and Cycle 3. With a samplesize of 40 evaluable patients and an inter-patient coefficient ofvariation in AUC of 30%, the 90% confidence interval for the ratio ofthe geometric mean docetaxel concentrations between treatment arms willbe (86%, 117%) if the observed geometric mean AUCs for both treatmentarms are identical.

An ECG-evaluable patient is defined as a patient who has aninterpretable baseline ECG as well as an interpretable ECG at Cycle 3Day 1 immediately post-pertuzumab/placebo infusion (steady-stateC_(max)). With this sample size of 40 evaluable patients and anestimated standard deviation of 20 ms, a 95% confidence interval for thedifference between treatment arms in mean change in QTcF from baselineto Cycle 3 will be ±12.4 ms from the observed mean change.

What is claimed is:
 1. A method for the treatment of breast cancer,comprising administering to a HER2 positive metastatic breast cancerpatient an effective amount of a growth inhibitory HER2 antibody, a HER2dimerization inhibitor antibody, and a taxane, wherein the patient didnot receive prior chemotherapy or biologic therapy for their metastaticbreast cancer.
 2. The method of claim 1 wherein the growth inhibitoryHER2 antibody binds to an epitope within Domain IV (SEQ ID NO: 17) ofthe HER2 amino acid sequence.
 3. The method of claim 2 wherein thegrowth inhibitory HER2 antibody binds essentially to epitope 4D5 ofHER2.
 4. The method of claim 1 wherein the HER2 dimerization inhibitorantibody binds HER2 at the junction of domains I, II and III (SEQ IDNOs: 14, 15, and 16).
 5. The method of claim 4 wherein the HER2dimerization inhibitor antibody binds essentially to epitope 2C4.
 6. Themethod of claim 1 wherein the growth inhibitory and/or the HER2dimerization inhibitor antibody is an antibody fragment.
 7. The methodof claim 1 wherein the growth inhibitory and/or the HER2 dimerizationinhibitor antibody is chimeric, humanized, or human.
 8. The method ofclaim 1 wherein the growth inhibitory antibody is trastuzumab, or afragment thereof, the HER2 dimerization antibody is pertuzumab, or afragment thereof, and the taxane is docetaxel.
 9. A method for thetreatment of breast cancer, comprising administering to a HER2 positivemetastatic breast cancer patient an effective amount of a first HER2antibody binding essentially to epitope 2C4, a second HER2 antibodybinding essentially to epitope 4D5, and a taxane, wherein the patientdid not receive prior chemotherapy or biologic therapy for theirmetastatic breast cancer.
 10. The method of claim 9 wherein the patientis a human patient.
 11. The method of claim 10 wherein said first andsecond antibodies are monoclonal antibodies.
 12. The method of claim 10wherein at least one of said first and said second antibody is anantibody fragment.
 13. The method of claim 11 wherein at least one ofsaid first and said second antibody is chimeric humanized, or human. 14.The method of claim 10 wherein said first antibody is pertuzumab. 15.The method of claim 10 or claim 14 wherein said second antibody istrastuzumab.
 16. The method of claim 14 wherein said taxane isdocetaxel.
 17. The method of claim 15 wherein said taxane is docetaxel.18. The method of claim 10 wherein said first and second antibodies andsaid taxane are administered concurrently.
 19. The method of claim 10wherein said first and second antibodies and said taxane areadministered consecutively, in any order.
 20. The method of claim 10wherein administration of the first antibody precedes administration ofthe second antibody and the taxane.
 21. The method of claim 16 whereinat least one of the pertuzumab and the trastuzumab is a naked antibody.22. The method of claim 16 wherein at least one of the pertuzumab andthe trastuzumab is an intact antibody.
 23. The method of claim 16wherein administration of the pertuzumab, trastuzumab and docetaxelresults in a synergistic effect.
 24. The method of claim 16 whereinadministration of the pertuzumab, trastuzumab and docetaxel extendssurvival of the human patient relative to treatment in the absence of atleast one of pertuzumab, trastuzumab and docetaxel.
 25. The method ofclaim 24 wherein progression free survival (PFS) is extended.
 26. Themethod of claim 24 wherein overall survival (OS) is extended.
 27. Themethod of claim 10 further comprising the administration of a furthertherapeutic agent selected from the group consisting of chemotherapeuticagent, a different HER antibody, antibody directed against a tumorassociated antigen, anti-hormonal compound, cardioprotectant, cytokine,EGFR-targeted drug, anti-angiogenic agent, tyrosine kinase inhibitor,COX inhibitor, non-steroidal anti-inflammatory drug, farnesyltransferase inhibitor, antibody that binds oncofetal protein CA 125,HER2 vaccine, HER targeting therapy, Raf or ras inhibitor, liposomaldoxorubicin, topotecan, taxane, dual tyrosine kinase inhibitor, TLK286,EMD-7200, a medicament that treats nausea, a medicament that prevents ortreats skin rash or standard acne therapy, a medicament that treats orprevents diarrhea, a body temperature-reducing medicament, and ahematopoietic growth factor.